<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:47:04Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10045040" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10045040</identifier>
        <datestamp>2023-03-29</datestamp>
        <setSpec>envhper</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Environ Health Perspect</journal-id>
              <journal-id journal-id-type="iso-abbrev">Environ Health Perspect</journal-id>
              <journal-id journal-id-type="publisher-id">EHP</journal-id>
              <journal-title-group>
                <journal-title>Environmental Health Perspectives</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0091-6765</issn>
              <issn pub-type="epub">1552-9924</issn>
              <publisher>
                <publisher-name>Environmental Health Perspectives</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10045040</article-id>
              <article-id pub-id-type="pmcid">PMC10045040</article-id>
              <article-id pub-id-type="pmc-uid">10045040</article-id>
              <article-id pub-id-type="pmid">36976258</article-id>
              <article-id pub-id-type="pmid">36976258</article-id>
              <article-id pub-id-type="publisher-id">EHP11270</article-id>
              <article-id pub-id-type="doi">10.1289/EHP11270</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>The Folic Acid and Creatine Trial: Treatment Effects of Supplementation on Arsenic Methylation Indices and Metabolite Concentrations in Blood in a Bangladeshi Population</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7241-4574</contrib-id>
                  <name>
                    <surname>Abuawad</surname>
                    <given-names>Ahlam K.</given-names>
                  </name>
                  <xref rid="a1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="fn1" ref-type="fn">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bozack</surname>
                    <given-names>Anne K.</given-names>
                  </name>
                  <xref rid="a1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="a2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="fn1" ref-type="fn">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Navas-Acien</surname>
                    <given-names>Ana</given-names>
                  </name>
                  <xref rid="a1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Goldsmith</surname>
                    <given-names>Jeff</given-names>
                  </name>
                  <xref rid="a3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Liu</surname>
                    <given-names>Xinhua</given-names>
                  </name>
                  <xref rid="a3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hall</surname>
                    <given-names>Megan N.</given-names>
                  </name>
                  <xref rid="a4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ilievski</surname>
                    <given-names>Vesna</given-names>
                  </name>
                  <xref rid="a1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lomax-Luu</surname>
                    <given-names>Angela M.</given-names>
                  </name>
                  <xref rid="a1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Parvez</surname>
                    <given-names>Faruque</given-names>
                  </name>
                  <xref rid="a1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shahriar</surname>
                    <given-names>Hasan</given-names>
                  </name>
                  <xref rid="a5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Uddin</surname>
                    <given-names>Mohammad N.</given-names>
                  </name>
                  <xref rid="a5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Islam</surname>
                    <given-names>Tariqul</given-names>
                  </name>
                  <xref rid="a5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Graziano</surname>
                    <given-names>Joseph H.</given-names>
                  </name>
                  <xref rid="a1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4169-1162</contrib-id>
                  <name>
                    <surname>Gamble</surname>
                    <given-names>Mary V.</given-names>
                  </name>
                  <xref rid="a1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <aff id="a1"><label><sup>1</sup></label>Department of Environmental Health Sciences, Mailman School of Public Health, <institution>Columbia University</institution>, New York, New York, <country>USA</country></aff>
                <aff id="a2"><label><sup>2</sup></label>Division of Environmental Health Sciences, School of Public Health, <institution>University of California, Berkeley</institution>, Berkeley, California, <country>USA</country></aff>
                <aff id="a3"><label><sup>3</sup></label>Department of Biostatistics, Mailman School of Public Health, <institution>Columbia University</institution>, New York, New York, <country>USA</country></aff>
                <aff id="a4"><label><sup>4</sup></label>Department of Epidemiology, Mailman School of Public Health, <institution>Columbia University</institution>, New York, New York, <country>USA</country></aff>
                <aff id="a5"><label><sup>5</sup></label><institution>Columbia University Arsenic Project in Bangladesh</institution>, Dhaka, <country>Bangladesh</country></aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1">Address correspondence to Mary V. Gamble, 722 W. 168th St., 1107E, New York, NY 10032 USA. Email: <email>mvg7@cumc.columbia.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>28</day>
                <month>3</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>3</month>
                <year>2023</year>
              </pub-date>
              <volume>131</volume>
              <issue>3</issue>
              <elocation-id>037015</elocation-id>
              <history>
                <date date-type="received">
                  <day>19</day>
                  <month>3</month>
                  <year>2022</year>
                </date>
                <date date-type="rev-recd">
                  <day>19</day>
                  <month>2</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>24</day>
                  <month>2</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <license>
                  <ali:license_ref>https://ehp.niehs.nih.gov/about-ehp/license</ali:license_ref>
                  <license-p><italic toggle="yes">EHP</italic> is an open-access journal published with support from the National Institute of Environmental Health Sciences, National Institutes of Health. All content is public domain unless otherwise noted.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="ehp11270.pdf"/>
              <abstract>
                <sec>
                  <title>Background:</title>
                  <p>Chronic arsenic (As) exposure is a global environmental health issue. Inorganic As (InAs) undergoes methylation to monomethyl (MMAs) and dimethyl-arsenical species (DMAs); full methylation to DMAs facilitates urinary excretion and is associated with reduced risk for As-related health outcomes. Nutritional factors, including folate and creatine, influence one-carbon metabolism, the biochemical pathway that provides methyl groups for As methylation.</p>
                </sec>
                <sec>
                  <title>Objective:</title>
                  <p>Our aim was to investigate the effects of supplementation with folic acid (FA), creatine, or the two combined on the concentrations of As metabolites and the primary methylation index (PMI: MMAs/InAs) and secondary methylation index (SMI: DMAs/MMAs) in blood in Bangladeshi adults having a wide range of folate status.</p>
                </sec>
                <sec>
                  <title>Methods:</title>
                  <p>In a randomized, double-blinded, placebo (PBO)-controlled trial, 622 participants were recruited independent of folate status and assigned to one of five treatment arms: <italic toggle="yes">a</italic>) PBO (<inline-formula><mml:math id="i1" display="inline" alttext="lowercase italic n equals 102"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>102</mml:mn></mml:mrow></mml:math></inline-formula>), <italic toggle="yes">b</italic>) <inline-formula><mml:math id="i2" display="inline" alttext="400 micrograms"><mml:mrow><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA/d (400FA; <inline-formula><mml:math id="i3" display="inline" alttext="uppercase italic n equals 153"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>153</mml:mn></mml:mrow></mml:math></inline-formula>), <italic toggle="yes">c</italic>) <inline-formula><mml:math id="i4" display="inline" alttext="800 micrograms"><mml:mrow><mml:mn>800</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA/d (800FA; <inline-formula><mml:math id="i5" display="inline" alttext="uppercase italic n equals 151"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>151</mml:mn></mml:mrow></mml:math></inline-formula>), <italic toggle="yes">d</italic>) <inline-formula><mml:math id="i6" display="inline" alttext="3 grams"><mml:mrow><mml:mn>3</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> creatine/d (creatine; <inline-formula><mml:math id="i7" display="inline" alttext="uppercase italic n equals 101"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>101</mml:mn></mml:mrow></mml:math></inline-formula>), or <italic toggle="yes">e</italic>) <inline-formula><mml:math id="i8" display="inline" alttext="3 grams creatine plus 400 micrograms of folic acid per day"><mml:mrow><mml:mn>3</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">g</mml:mi><mml:mtext> creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mtext> of FA</mml:mtext><mml:mo>/</mml:mo><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i9" display="inline" alttext="creatine plus 400 folic acid"><mml:mrow><mml:mtext>creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mtext>FA</mml:mtext></mml:mrow></mml:math></inline-formula>; <inline-formula><mml:math id="i10" display="inline" alttext="uppercase italic n equals 103"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>103</mml:mn></mml:mrow></mml:math></inline-formula>) for 12 wk. For the following 12 wk, half of the FA participants were randomly switched to the PBO while the other half continued FA supplementation. All participants received As-removal water filters at baseline. Blood As (bAs) metabolites were measured at weeks 0, 1, 12, and 24.</p>
                </sec>
                <sec>
                  <title>Results:</title>
                  <p>At baseline, 80.3% (<inline-formula><mml:math id="i11" display="inline" alttext="uppercase italic n equals 489"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>489</mml:mn></mml:mrow></mml:math></inline-formula>) of participants were folate sufficient (<inline-formula><mml:math id="i12" display="inline" alttext="greater than or equal to 9 nanomoles per liter"><mml:mrow><mml:mo>≥</mml:mo><mml:mn>9</mml:mn><mml:mtext> nmol</mml:mtext><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula> in plasma). In all groups, bAs metabolite concentrations decreased, likely due to filter use; for example, in the PBO group, blood concentrations of MMAs (bMMAs) (<inline-formula><mml:math id="i13" display="inline" alttext="geometric mean plus geometric standard deviation"><mml:mrow><mml:mtext>geometric mean</mml:mtext><mml:mo>±</mml:mo><mml:mtext>geometric standard deviation</mml:mtext></mml:mrow></mml:math></inline-formula>) decreased from <inline-formula><mml:math id="i14" display="inline" alttext="3.55 plus or minus 1.89 micrograms per liter"><mml:mrow><mml:mn>3.55</mml:mn><mml:mo>±</mml:mo><mml:mn>1.89</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula> at baseline to <inline-formula><mml:math id="i15" display="inline" alttext="2.73 plus or minus 1.74"><mml:mrow><mml:mn>2.73</mml:mn><mml:mo>±</mml:mo><mml:mn>1.74</mml:mn></mml:mrow></mml:math></inline-formula> at week 1. After 1 wk, the mean within-person increase in SMI for the <inline-formula><mml:math id="i16" display="inline" alttext="creatine plus 400 folic acid"><mml:mrow><mml:mtext>creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mtext>FA</mml:mtext></mml:mrow></mml:math></inline-formula> group was greater than that of the PBO group (<inline-formula><mml:math id="i17" display="inline" alttext="lowercase italic p equals 0.05"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>). The mean percentage decrease in bMMAs between baseline and week 12 was greater for all treatment groups compared with the PBO group [400FA: <inline-formula><mml:math id="i18" display="inline" alttext="negative 10.4"><mml:mrow><mml:mo>−</mml:mo><mml:mn>10.4</mml:mn></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i19" display="inline" alttext="negative 11.9"><mml:mrow><mml:mo>−</mml:mo><mml:mn>11.9</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i20" display="inline" alttext="negative 8.75"><mml:mrow><mml:mo>−</mml:mo><mml:mn>8.75</mml:mn></mml:mrow></mml:math></inline-formula>), 800FA: <inline-formula><mml:math id="i21" display="inline" alttext="negative 9.54"><mml:mrow><mml:mo>−</mml:mo><mml:mn>9.54</mml:mn></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i22" display="inline" alttext="negative 11.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>11.1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i23" display="inline" alttext="negative 7.97"><mml:mrow><mml:mo>−</mml:mo><mml:mn>7.97</mml:mn></mml:mrow></mml:math></inline-formula>), creatine: <inline-formula><mml:math id="i24" display="inline" alttext="negative 5.85"><mml:mrow><mml:mo>−</mml:mo><mml:mn>5.85</mml:mn></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i25" display="inline" alttext="negative 8.59"><mml:mrow><mml:mo>−</mml:mo><mml:mn>8.59</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i26" display="inline" alttext="negative 3.03"><mml:mrow><mml:mo>−</mml:mo><mml:mn>3.03</mml:mn></mml:mrow></mml:math></inline-formula>), <inline-formula><mml:math id="i27" display="inline" alttext="creatine plus 400 folic acid"><mml:mrow><mml:mtext>creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mtext>FA</mml:mtext></mml:mrow></mml:math></inline-formula>: <inline-formula><mml:math id="i28" display="inline" alttext="negative 8.44"><mml:mrow><mml:mo>−</mml:mo><mml:mn>8.44</mml:mn></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i29" display="inline" alttext="negative 9.95"><mml:mrow><mml:mo>−</mml:mo><mml:mn>9.95</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i30" display="inline" alttext="negative 6.90"><mml:mrow><mml:mo>−</mml:mo><mml:mn>6.90</mml:mn></mml:mrow></mml:math></inline-formula>), PBO: <inline-formula><mml:math id="i31" display="inline" alttext="negative 2.02"><mml:mrow><mml:mo>−</mml:mo><mml:mn>2.02</mml:mn></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i32" display="inline" alttext="negative 4.03"><mml:mrow><mml:mo>−</mml:mo><mml:mn>4.03</mml:mn></mml:mrow></mml:math></inline-formula>, 0.04)], and the percentage increase in blood DMAs (bDMAs) concentrations for the FA-treated groups significantly exceeded that of PBO [400FA: 12.8 (95% CI: 10.5, 15.2), 800FA: 11.3 (95% CI: 8.95, 13.8), <inline-formula><mml:math id="i33" display="inline" alttext="creatine plus 400 folic acid"><mml:mrow><mml:mtext>creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mtext>FA</mml:mtext></mml:mrow></mml:math></inline-formula>: 7.45 (95% CI: 5.23, 9.71), PBO: <inline-formula><mml:math id="i34" display="inline" alttext="negative 0.15"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.15</mml:mn></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i35" display="inline" alttext="negative 2.85"><mml:mrow><mml:mo>−</mml:mo><mml:mn>2.85</mml:mn></mml:mrow></mml:math></inline-formula>, 2.63)]. The mean decrease in PMI and increase in SMI in all FA groups significantly exceeded PBO (<inline-formula><mml:math id="i36" display="inline" alttext="lowercase italic p less than 0.05"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>). Data from week 24 showed evidence of a reversal of treatment effects on As metabolites from week 12 in those who switched from 800FA to PBO, with significant decreases in SMI [<inline-formula><mml:math id="i37" display="inline" alttext="negative 9.0 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>9.0</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i38" display="inline" alttext="negative 3.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>3.5</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i39" display="inline" alttext="negative 14.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>14.8</mml:mn></mml:mrow></mml:math></inline-formula>)] and bDMAs [<inline-formula><mml:math id="i40" display="inline" alttext="negative 5.9 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>5.9</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i41" display="inline" alttext="negative 1.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>1.8</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i42" display="inline" alttext="negative 10.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>10.2</mml:mn></mml:mrow></mml:math></inline-formula>)], whereas PMI and bMMAs concentrations continued to decline [<inline-formula><mml:math id="i43" display="inline" alttext="negative 7.16 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>7.16</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i44" display="inline" alttext="negative 0.48"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.48</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i45" display="inline" alttext="negative 14.3"><mml:mrow><mml:mo>−</mml:mo><mml:mn>14.3</mml:mn></mml:mrow></mml:math></inline-formula>) and <inline-formula><mml:math id="i46" display="inline" alttext="negative 3.1 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>3.1</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i47" display="inline" alttext="negative 0.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i48" display="inline" alttext="negative 6.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>6.2</mml:mn></mml:mrow></mml:math></inline-formula>), respectively] for those who remained on 800FA supplementation.</p>
                </sec>
                <sec>
                  <title>Conclusions:</title>
                  <p>FA supplementation lowered bMMAs and increased bDMAs in a sample of primarily folate-replete adults, whereas creatine supplementation lowered bMMAs. Evidence of the reversal of treatment effects on As metabolites following FA cessation suggests short-term benefits of supplementation and underscores the importance of long-term interventions, such as FA fortification. <ext-link xlink:href="https://doi.org/10.1289/EHP11270" ext-link-type="uri">https://doi.org/10.1289/EHP11270</ext-link></p>
                </sec>
              </abstract>
            </article-meta>
            <fn-group>
              <fn fn-type="other" specific-use="pdf-only">
                <p>Supplemental Material is available online (<ext-link xlink:href="https://doi.org/10.1289/EHP11270" ext-link-type="uri">https://doi.org/10.1289/EHP11270</ext-link>).</p>
              </fn>
              <fn fn-type="equal" id="fn1">
                <label>*</label>
                <p>These authors are joint first authors.</p>
              </fn>
              <fn fn-type="financial-disclosure">
                <p>The authors declare they have nothing to disclose.</p>
              </fn>
              <fn specific-use="pdf-only" fn-type="other">
                <p><bold>Note to readers with disabilities:</bold><italic toggle="yes">EHP</italic> strives to ensure that all journal content is accessible to all readers. However, some figures and Supplemental Material published in <italic toggle="yes">EHP</italic> articles may not conform to <ext-link xlink:href="http://ehp.niehs.nih.gov/accessibility/" ext-link-type="uri">508 standards</ext-link> due to the complexity of the information being presented. If you need assistance accessing journal content, please contact <email>ehpsubmissions@niehs.nih.gov</email>. Our staff will work with you to assess and meet your accessibility needs within 3 working days.</p>
              </fn>
            </fn-group>
          </front>
          <body>
            <sec id="s1">
              <title>Introduction</title>
              <p>Arsenic (As) contamination of groundwater is common in many regions of the world. At least <inline-formula><mml:math id="i49" display="inline" alttext="94 million"><mml:mrow><mml:mn>94</mml:mn><mml:mtext> million</mml:mtext></mml:mrow></mml:math></inline-formula> people worldwide are exposed to concentrations exceeding the World Health Organization (WHO) guideline of <inline-formula><mml:math id="i50" display="inline" alttext="10 micrograms per liter"><mml:mrow><mml:mn>10</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula> in groundwater.<sup><xref rid="c1" ref-type="bibr">1</xref>–<xref rid="c3" ref-type="bibr">3</xref></sup> In Bangladesh, where well water is used as an alternative to microbially contaminated surface water, <inline-formula><mml:math id="i51" display="inline" alttext="approximately 30 million"><mml:mrow><mml:mo>∼</mml:mo><mml:mn>30</mml:mn><mml:mtext> million</mml:mtext></mml:mrow></mml:math></inline-formula> people remain exposed to drinking water with high As concentrations (<inline-formula><mml:math id="i52" display="inline" alttext="greater than 10 micrograms per liter"><mml:mrow><mml:mo>&gt;</mml:mo><mml:mn>10</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula>).<sup><xref rid="c4" ref-type="bibr">4</xref></sup></p>
              <p>Arsenic exposure affects all organ systems, and chronic As exposure is associated with numerous adverse health effects, including cardiovascular disease, diabetes and diabetes-related outcomes, skin lesions (i.e., melanosis, leukomelanosis, and keratosis), impaired intellectual function, and cancers (e.g., bladder, lung, skin cancers).<sup><xref rid="c5" ref-type="bibr">5</xref>–<xref rid="c7" ref-type="bibr">7</xref></sup> Arsenic metabolism may modify disease risk. Ingested inorganic As (InAs) undergoes a series of reduction and oxidative methylation reactions. According to the Challenger pathway, arsenite (InAs<sup>III</sup>) is methylated to monomethylarsonic acid (MMAs<sup>V</sup>) by arsenic-3-methyltransferase (AS3MT) using <inline-formula><mml:math id="i53" display="inline" alttext="uppercase italic s"><mml:mi>S</mml:mi></mml:math></inline-formula>-adenosylmethionine (SAM) as the methyl donor. MMAs<sup>V</sup> is then reduced to MMAs<sup>III</sup> and methylated to form dimethylarsinic acid (DMAs<sup>V</sup>) (<xref rid="f1" ref-type="fig">Figure 1</xref>).<sup><xref rid="c9" ref-type="bibr">9</xref></sup> The complete methylation of InAs to DMAs is important because toxicological studies in human lung and bladder cells and hepatocytes have shown that MMAs<sup>III</sup> is the most cytotoxic and genotoxic As species.<sup><xref rid="c10" ref-type="bibr">10</xref>,<xref rid="c11" ref-type="bibr">11</xref></sup> It is difficult to distinguish between MMAs<sup>V</sup> and MMAs<sup>III</sup> in epidemiological studies owing to oxidation in biological samples; therefore, total MMAs (<inline-formula><mml:math id="i54" display="inline" alttext="monomethylarsonic acid begin superscript open parenthesis 3 plus 5 close parenthesis end superscript"><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mtext>MMAs</mml:mtext></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mtext>III</mml:mtext><mml:mo>+</mml:mo><mml:mi mathvariant="normal">V</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>) is reported. Among As-exposed populations, a higher proportion of <inline-formula><mml:math id="i55" display="inline" alttext="monomethylarsonic acids begin superscript open parenthesis 3 plus 5 close parenthesis end superscript"><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mtext>MMAs</mml:mtext></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mtext>III</mml:mtext><mml:mo>+</mml:mo><mml:mi mathvariant="normal">V</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> (and a lower proportion of DMAs) in urine has been associated with an increased risk for cancers (e.g., bladder, lung, skin cancers), skin lesions, peripheral vascular disease, and atherosclerosis.<sup><xref rid="c12" ref-type="bibr">12</xref>,<xref rid="c13" ref-type="bibr">13</xref></sup></p>
              <fig position="float" id="f1">
                <label>Figure 1.</label>
                <caption>
                  <p>Relative distribution of arsenic metabolites in blood and urine. Inorganic arsenic (InAs) in the form of arsenite (InAs<sup>III</sup>) is methylated to form monomethylarsonic acid (MMAs<sup>V</sup>) in a reaction that is catalyzed by arsenic (<inline-formula><mml:math id="i56" display="inline" alttext="plus 3 oxidation"><mml:mrow><mml:mo>+</mml:mo><mml:mn>3</mml:mn><mml:mtext> oxidation</mml:mtext></mml:mrow></mml:math></inline-formula> state) methyltransferase (AS3MT) using the methyl donor <inline-formula><mml:math id="i57" display="inline" alttext="uppercase italic s"><mml:mi>S</mml:mi></mml:math></inline-formula>-adenosylmethionine (SAM). MMAs<sup>V</sup> is then reduced to form methylarsonous acid (MMAs<sup>III</sup>), and a subsequent methylation yields dimethylarsinic acid (DMAs<sup>V</sup>) and <inline-formula><mml:math id="i58" display="inline" alttext="uppercase italic s"><mml:mi>S</mml:mi></mml:math></inline-formula>-adenosylhomocysteine (SAH). Total blood arsenic is composed of <inline-formula><mml:math id="i59" display="inline" alttext="approximately 25 percent"><mml:mrow><mml:mo>∼</mml:mo><mml:mn>25</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> InAs, 40% MMAs, and 35% DMAs, whereas total urine arsenic is composed of <inline-formula><mml:math id="i59a" display="inline" alttext="approximately 15 percent"><mml:mrow><mml:mo>∼</mml:mo><mml:mn>15</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> InAs, 15% MMAs, and 70% DMAs.<sup><xref rid="c8" ref-type="bibr">8</xref></sup></p>
                </caption>
                <alt-text>Figure 1 is an illustration, depicting the relative distribution of arsenic metabolites in blood and urine, where inorganic arsenic in the form of arsenite is methylated to form monomethylarsonic acid in a reaction that is catalyzed by arsenic methyltransferase and utilizes the methyl donor S-adenosylmethionine. The monomethylarsonic acid is then reduced to form methylarsonous acid, and a subsequent methylation yields dimethylarsinic acid and S-adenosylhomocysteine. The scale below titled “Arsenic metabolite distribution” displays the following information: In blood, inorganic arsenic is 25 percent; monomethyl-arsenicals are 40 percent; dimethyl-arsenicals are 35 percent. In urine, inorganic arsenic is 15 percent; monomethyl-arsenicals are 15 percent; dimethyl-arsenicals are 70 percent.</alt-text>
                <graphic xlink:href="ehp11270_f1" position="float"/>
              </fig>
              <p>One-carbon metabolism (OCM), the metabolic pathway that generates SAM, is influenced by nutrients, including folate and creatine. Folate, in the form of 5-methyltetrahydrofolate (5-mTHF), donates a methyl group to homocysteine to form methionine, which is activated by methionine adenosyltransferase to form SAM. An estimated 40% of SAM is consumed by the methylation of guanidinoacetate (GAA) to form creatine, an amino acid derivative that is found in tissues with high energy requirements, such as muscle cells.<sup><xref rid="c14" ref-type="bibr">14</xref></sup> Creatine synthesis is down-regulated by dietary intake of creatine, predominantly through the consumption of meat and by creatine supplementation.<sup><xref rid="c15" ref-type="bibr">15</xref></sup> Increased creatine consumption may increase SAM available for the methylation of As.</p>
              <p>In a previous randomized controlled trial (RCT), our group investigated the effect of folic acid (FA) supplementation on As methylation capacity among folate-deficient Bangladeshi adults (plasma folate concentrations <inline-formula><mml:math id="i60" display="inline" alttext="less than 9 nanomoles per liter"><mml:mrow><mml:mo>&lt;</mml:mo><mml:mn>9</mml:mn><mml:mtext> nmol</mml:mtext><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula>) exposed to As through drinking water. Following 12 wk of treatment, the proportion of DMAs (%DMAs) in urine increased while %InAs and %MMAs in urine, as well as total blood As (bAs) and blood MMAs (bMMAs) concentrations decreased among participants receiving <inline-formula><mml:math id="i61" display="inline" alttext="400 micrograms"><mml:mrow><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA/d compared with the placebo (PBO) group.<sup><xref rid="c8" ref-type="bibr">8</xref>,<xref rid="c16" ref-type="bibr">16</xref></sup></p>
              <p>More recently, in the Folic Acid and Creatine Trial (FACT), we examined the independent and joint effects of FA and creatine treatment among adults recruited independent of folate status in Bangladesh, a country without FA fortification of food. The <italic toggle="yes">a priori</italic> primary outcome was change in total bAs concentrations at 12 wk. Among participants receiving <inline-formula><mml:math id="i62" display="inline" alttext="800 micrograms"><mml:mrow><mml:mn>800</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA/d, there was a greater decrease in total bAs concentrations [percentage change in geometric mean (GM) of <inline-formula><mml:math id="i63" display="inline" alttext="negative 17.8 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>17.8</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula>] compared with PBO (<inline-formula><mml:math id="i64" display="inline" alttext="negative 9.5 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>9.5</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula>) (<inline-formula><mml:math id="i65" display="inline" alttext="lowercase italic p less than 0.05"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>).<sup><xref rid="c17" ref-type="bibr">17</xref></sup> Secondary outcomes included bAs metabolite concentrations (recently measured and reported here) and the proportions of As metabolites in urine (reported by Bozack et al.<sup><xref rid="c18" ref-type="bibr">18</xref></sup>). Among participants receiving <inline-formula><mml:math id="i66" display="inline" alttext="400 micrograms"><mml:mrow><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA, <inline-formula><mml:math id="i67" display="inline" alttext="800 micrograms"><mml:mrow><mml:mn>800</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA, or <inline-formula><mml:math id="i68" display="inline" alttext="400 micrograms"><mml:mrow><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula>
<inline-formula><mml:math id="i69" display="inline" alttext="folic acid plus creatine"><mml:mrow><mml:mtext>FA</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mtext>creatine</mml:mtext></mml:mrow></mml:math></inline-formula> daily, there were significantly greater mean decreases in urine %InAs and %MMAs [change in <inline-formula><mml:math id="i70" display="inline" alttext="log open parenthesis percent of inorganic arsenic close parenthesis equals negative 0.09"><mml:mrow><mml:mi mathvariant="normal">log</mml:mi><mml:mtext> </mml:mtext><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>%</mml:mo><mml:mtext>InAs</mml:mtext></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mn>0.09</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i71" display="inline" alttext="negative 0.14"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.14</mml:mn></mml:mrow></mml:math></inline-formula>, and <inline-formula><mml:math id="i72" display="inline" alttext="negative 0.11"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.11</mml:mn></mml:mrow></mml:math></inline-formula> for each treatment group, respectively; change in <inline-formula><mml:math id="i73" display="inline" alttext="percent of monomethylarsonic acids equals negative 1.80"><mml:mrow><mml:mo>%</mml:mo><mml:mtext>MMAs</mml:mtext><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mn>1.80</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i74" display="inline" alttext="negative 2.60"><mml:mrow><mml:mo>−</mml:mo><mml:mn>2.60</mml:mn></mml:mrow></mml:math></inline-formula>, and <inline-formula><mml:math id="i75" display="inline" alttext="negative 1.85"><mml:mrow><mml:mo>−</mml:mo><mml:mn>1.85</mml:mn></mml:mrow></mml:math></inline-formula>, respectively] compared with PBO [changes in log (%InAs) and <inline-formula><mml:math id="i76" display="inline" alttext="percent of monomethylarsonic acids equals 0.05"><mml:mrow><mml:mo>%</mml:mo><mml:mtext>MMAs</mml:mtext><mml:mo>=</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula> and 0.15, respectively] (<inline-formula><mml:math id="i77" display="inline" alttext="lowercase italic p less than 0.05"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>). In addition, participants receiving <inline-formula><mml:math id="i78" display="inline" alttext="400 micrograms"><mml:mrow><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA, <inline-formula><mml:math id="i79" display="inline" alttext="800 micrograms"><mml:mrow><mml:mn>800</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA, or <inline-formula><mml:math id="i80" display="inline" alttext="400 micrograms"><mml:mrow><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula>
<inline-formula><mml:math id="i81" display="inline" alttext="folic acid plus creatine"><mml:mrow><mml:mtext>FA</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mtext>creatine</mml:mtext></mml:mrow></mml:math></inline-formula> daily had a greater mean increase in %DMAs (3.25, 4.57, and 3.11, respectively) compared with PBO (<inline-formula><mml:math id="i82" display="inline" alttext="negative 1.17"><mml:mrow><mml:mo>−</mml:mo><mml:mn>1.17</mml:mn></mml:mrow></mml:math></inline-formula>) (<inline-formula><mml:math id="i83" display="inline" alttext="lowercase italic p less than 0.05"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>).<sup><xref rid="c18" ref-type="bibr">18</xref></sup> The decrease in urinary %MMAs among participants receiving <inline-formula><mml:math id="i84" display="inline" alttext="3 grams"><mml:mrow><mml:mn>3</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> creatine/d at week 1 (<inline-formula><mml:math id="i85" display="inline" alttext="negative 0.90"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.90</mml:mn></mml:mrow></mml:math></inline-formula>) and week 12 (<inline-formula><mml:math id="i86" display="inline" alttext="negative 1.13"><mml:mrow><mml:mo>−</mml:mo><mml:mn>1.13</mml:mn></mml:mrow></mml:math></inline-formula>) also exceeded that of the PBO group (change in %MMAs, week <inline-formula><mml:math id="i87" display="inline" alttext="1 equals negative 0.62"><mml:mrow><mml:mn>1</mml:mn><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mn>0.62</mml:mn></mml:mrow></mml:math></inline-formula>) (<inline-formula><mml:math id="i88" display="inline" alttext="lowercase italic p less than 0.05"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>).<sup><xref rid="c18" ref-type="bibr">18</xref></sup></p>
              <p>Although the relative distribution of As metabolite proportions in urine is an informative indicator of As methylation capacity, the concentrations of As metabolites in blood may better reflect As exposure to tissues. In addition, as a biomarker of exposure, bAs is not complicated by adjustment for dilution, as urinary As is, or—as compared with water As—by difficulties associated with estimating As consumption through water or dietary sources.</p>
              <p>The present study uses newly available bAs metabolite data from FACT to investigate the effect of FA and creatine supplementation on As metabolites in blood. We report the effects of supplementation on the bAs primary methylation index (PMI: MMAs/InAs) and the secondary methylation index (SMI: DMAs/MMAs), as well as metabolite concentrations: blood InAs (bInAs), bMMAs, and blood DMAs (bDMAs), in a population of Bangladeshi adults having a wide range of folate nutritional status.</p>
            </sec>
            <sec id="s2">
              <title>Methods</title>
              <sec id="s2.1">
                <title>Study Population and Design</title>
                <p>FACT was conducted in Araihazar, Bangladesh, and has previously been described in detail.<sup><xref rid="c17" ref-type="bibr">17</xref></sup> FACT participants were recruited from the Health Effects of Arsenic Longitudinal Study (HEALS), a prospective cohort that originally comprised 11,746 adults living in a <inline-formula><mml:math id="i89" display="inline" alttext="25 kilometer squared"><mml:mrow><mml:mn>25</mml:mn><mml:msup><mml:mrow><mml:mtext>-km</mml:mtext></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> area of Araihazar, Bangladesh, recruited in 2000.<sup><xref rid="c19" ref-type="bibr">19</xref></sup> HEALS was subsequently expanded to include <inline-formula><mml:math id="i90" display="inline" alttext="more than 35,000"><mml:mrow><mml:mo>&gt;</mml:mo><mml:mn>35,000</mml:mn></mml:mrow></mml:math></inline-formula> participants.<sup><xref rid="c20" ref-type="bibr">20</xref></sup> Married adults were eligible for enrollment in HEALS if they had resided in the study area for <inline-formula><mml:math id="i91" display="inline" alttext="greater than or equal to 5"><mml:mrow><mml:mo>≥</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:math></inline-formula> y and had primarily obtained their drinking water from one of the study wells for <inline-formula><mml:math id="i92" display="inline" alttext="greater than or equal to 3"><mml:mrow><mml:mo>≥</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:math></inline-formula> y. Between December 2009 and May 2011, a random subset of 622 participants were recruited from the HEALS cohort to participate in FACT. Five trained teams consisting of one interviewer and one physician recruited participants through house-to-house visits. Male and female participants were eligible for FACT if, upon medical examination, they were 20–65 years of age and had been drinking water from a household well with water As concentrations <inline-formula><mml:math id="i93" display="inline" alttext="greater than 50 micrograms per liter"><mml:mrow><mml:mo>&gt;</mml:mo><mml:mn>50</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula> for <inline-formula><mml:math id="i94" display="inline" alttext="greater than or equal to 1"><mml:mrow><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> y. Medical conditions were determined by a study physician who conducted a thorough medical examination at the screening visit. This examination included assessment of current and past medications, physical exam, self-report, and review of medical records. Individuals were excluded if they were pregnant, taking nutritional supplements, had protein in their urine, renal diseases, diabetes, or other health problems, such as gastrointestinal issues.</p>
                <p>FACT participants were randomly assigned to one of the following treatment groups: <italic toggle="yes">a</italic>) PBO (<inline-formula><mml:math id="i95" display="inline" alttext="uppercase italic n equals 104"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>104</mml:mn></mml:mrow></mml:math></inline-formula>), <italic toggle="yes">b</italic>) <inline-formula><mml:math id="i96" display="inline" alttext="400 micrograms"><mml:mrow><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA/d (referred to hereafter as 400FA; <inline-formula><mml:math id="i97" display="inline" alttext="uppercase italic n equals 156"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>156</mml:mn></mml:mrow></mml:math></inline-formula>), <italic toggle="yes">c</italic>) <inline-formula><mml:math id="i98" display="inline" alttext="800 micrograms"><mml:mrow><mml:mn>800</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA/d (800FA; <inline-formula><mml:math id="i99" display="inline" alttext="uppercase italic n equals 154"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>154</mml:mn></mml:mrow></mml:math></inline-formula>), <italic toggle="yes">d</italic>) <inline-formula><mml:math id="i100" display="inline" alttext="3 grams"><mml:mrow><mml:mn>3</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> creatine/d (creatine; <inline-formula><mml:math id="i101" display="inline" alttext="uppercase italic n equals 104"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>104</mml:mn></mml:mrow></mml:math></inline-formula>), and <italic toggle="yes">e</italic>) <inline-formula><mml:math id="i102" display="inline" alttext="3 grams"><mml:mrow><mml:mn>3</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> creatine and <inline-formula><mml:math id="i103" display="inline" alttext="400 micrograms"><mml:mrow><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA/d (<inline-formula><mml:math id="i104" display="inline" alttext="creatine plus 400 folic acid"><mml:mrow><mml:mtext>creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mtext>FA</mml:mtext></mml:mrow></mml:math></inline-formula>; <inline-formula><mml:math id="i105" display="inline" alttext="uppercase italic n equals 104"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>104</mml:mn></mml:mrow></mml:math></inline-formula>). The dose of <inline-formula><mml:math id="i106" display="inline" alttext="400 micrograms"><mml:mrow><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA/d was selected because it is the U.S. recommended dietary allowance (RDA)<sup><xref rid="c21" ref-type="bibr">21</xref></sup>; the dose of <inline-formula><mml:math id="i107" display="inline" alttext="800 micrograms"><mml:mrow><mml:mn>800</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA/d was selected to evaluate whether a higher dose would be more effective; and the dose of <inline-formula><mml:math id="i108" display="inline" alttext="3 grams"><mml:mrow><mml:mn>3</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> creatine/d was selected to exceed the average daily creatine loss for a <inline-formula><mml:math id="i109" display="inline" alttext="70 kilogram"><mml:mrow><mml:mn>70</mml:mn><mml:mtext>-kg</mml:mtext></mml:mrow></mml:math></inline-formula> male individual (<inline-formula><mml:math id="i110" display="inline" alttext="approximately 1.9 grams per day"><mml:mrow><mml:mo>∼</mml:mo><mml:mn>1.9</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:math></inline-formula>) as estimated by Brosnan et al., that is, it was a dose predicted to down-regulate endogenous creatine biosynthesis.<sup><xref rid="c14" ref-type="bibr">14</xref></sup> To reduce bias and ensure a balance of male and female participants in each treatment arm, male and female participants were randomized separately in blocks. By blocks, treatment groups were assigned in the ratio of 1 (PBO):1.5 (400FA):1.5 (800FA):1 (creatine):1 (<inline-formula><mml:math id="i111" display="inline" alttext="creatine plus 400 folic acid"><mml:mrow><mml:mtext>creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mtext>FA</mml:mtext></mml:mrow></mml:math></inline-formula>). Random permutation was used to assign treatment groups. With the exception of the data management specialists who assigned treatment groups, all participants, field staff, village health workers, laboratory technicians, and investigators were blinded to the treatment for the duration of the study.</p>
                <p>The study included two phases (<xref rid="f2" ref-type="fig">Figure 2</xref>). In the first 12-wk phase, participants received supplementation according to treatment group assignments, and in the second 12-wk phase, half of the participants in the 400FA and 800FA groups were randomly switched to PBO (400FA/PBO: <inline-formula><mml:math id="i112" display="inline" alttext="uppercase italic n equals 76"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>76</mml:mn></mml:mrow></mml:math></inline-formula> and 800FA/PBO: <inline-formula><mml:math id="i113" display="inline" alttext="uppercase italic n equals 74"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>74</mml:mn></mml:mrow></mml:math></inline-formula>) and half continued FA supplementation (400FA/FA: <inline-formula><mml:math id="i114" display="inline" alttext="uppercase italic n equals 77"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>77</mml:mn></mml:mrow></mml:math></inline-formula>; 800FA/FA: <inline-formula><mml:math id="i115" display="inline" alttext="uppercase italic n equals 77"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>77</mml:mn></mml:mrow></mml:math></inline-formula>) to assess the potential reversal of treatment effects on As metabolites following cessation of FA supplementation. During the second phase, all participants in the PBO, creatine, and <inline-formula><mml:math id="i116" display="inline" alttext="creatine plus 400 folic acid"><mml:mrow><mml:mtext>creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mtext>FA</mml:mtext></mml:mrow></mml:math></inline-formula> groups received PBO to maintain the study blind.</p>
                <fig position="float" id="f2">
                  <label>Figure 2.</label>
                  <caption>
                    <p>Folic Acid and Creatine Trial (FACT) study design overview. The PBO, <inline-formula><mml:math id="i117" display="inline" alttext="400 micrograms"><mml:mrow><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> of FA/d (400FA), <inline-formula><mml:math id="i118" display="inline" alttext="800 micrograms"><mml:mrow><mml:mn>800</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> of FA/d (800FA), <inline-formula><mml:math id="i119" display="inline" alttext="3 grams"><mml:mrow><mml:mn>3</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> creatine (creatine), and <inline-formula><mml:math id="i120" display="inline" alttext="3 grams creatine plus 400 micrograms of folic acid per day"><mml:mrow><mml:mn>3</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">g</mml:mi><mml:mtext> creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mtext> of FA</mml:mtext><mml:mo>/</mml:mo><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i121" display="inline" alttext="creatine plus 400 folic acid"><mml:mrow><mml:mtext>creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mtext>FA</mml:mtext></mml:mrow></mml:math></inline-formula>) are shown in brown, green, blue, orange, and purple, respectively. All five treatments were administered daily, with participants switching to PBO at 12 wk as indicated with a lighter color. Modified from Peters et al.<sup><xref rid="c17" ref-type="bibr">17</xref></sup> Note: FA, folic acid; PBO, placebo.</p>
                  </caption>
                  <alt-text> Figure 2 shows a timeline and an illustration. The timeline depicts weeks: 0 to 12 weeks is the first phase, and 13 to 24 weeks is the second phase. The illustration depicts the Folic Acid and Creatine Trial study design and displays the treatment groups with the number of participants per group. 102 participants received placebo for both phases; 77 participants received 400 micrograms of folic acid, of which 76 switched to placebo for the second phase; 151 participants received 800 micrograms of folic acid, of which 74 switched to placebo for the second phase; 101 participants received 3 grams of creatine, all of which were switched to placebo for the second phase; 103 participants received 3 grams creatine plus 400 micrograms folic acid, all of which were switched to placebo for the second phase.</alt-text>
                  <graphic xlink:href="ehp11270_f2" position="float"/>
                </fig>
              </sec>
              <sec id="s2.2">
                <title>Ethics</title>
                <p>The FACT protocol was approved by the institutional review board at Columbia University and the Bangladesh Medical Research Council. Informed consent was obtained by staff physicians in Bangladesh.</p>
              </sec>
              <sec id="s2.3">
                <title>Fieldwork and Study Follow-Up</title>
                <p>Fieldwork was conducted by the five trained teams, each comprising one interviewer and one physician. Sociodemographic characteristics were obtained at enrollment by field staff–administered questionnaires designed specifically for this study. During home visits, blood samples were collected at baseline and at weeks 1, 12, and 24.</p>
                <p>At the beginning of the trial, participants received READ-F As-removal water filters (Brota Services International) and were encouraged to use the filters for all drinking and cooking water. Efficacy of the filters was tested in the field during home visits using the Hach EZ kit (Hach Company); filters were repaired or replaced if As water concentrations exceeded <inline-formula><mml:math id="i122" display="inline" alttext="10 micrograms per liter"><mml:mrow><mml:mn>10</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula> or if participants reported failure of the filter<sup><xref rid="c22" ref-type="bibr">22</xref></sup> (<inline-formula><mml:math id="i123" display="inline" alttext="approximately 50"><mml:mrow><mml:mo>∼</mml:mo><mml:mn>50</mml:mn></mml:mrow></mml:math></inline-formula> of the 622 filters failed during the trial). Arsenic concentrations were also measured by laboratory analysis in a random subset of filtered water collected at baseline and at weeks 12 and 24 (described below). Total urinary As concentrations throughout the study were used as a proxy of water filter use. In addition, water filter use 1 y after FACT ended was measured by a follow-up survey, as previously reported by Sanchez et al.<sup><xref rid="c22" ref-type="bibr">22</xref></sup></p>
                <p>In the first phase of the trial, all participants received two pill bottles containing <italic toggle="yes">a</italic>) FA or matched PBO pills and <italic toggle="yes">b</italic>) creatine or matched PBO pills. In the second phase, all participants received one pill bottle containing FA or matched PBO pills. Village health workers performed daily home visits to ask about compliance or observe participants taking pills. Compliance was assessed using pill counts and circulating folate concentrations as follows: <italic toggle="yes">a</italic>) the percentage of study pills taken, and <italic toggle="yes">b</italic>) changes in red blood cell and plasma folate concentrations as reported in changes in GMs over time.<sup><xref rid="c17" ref-type="bibr">17</xref></sup></p>
              </sec>
              <sec id="s2.4">
                <title>Sample Handling and Laboratory Measures</title>
                <p>Sample handling and laboratory methods have been described in detail.<sup><xref rid="c17" ref-type="bibr">17</xref></sup> Briefly, venous blood was collected in vacutainer tubes with ethylenediaminetetraacetic acid during field visits, stored in IsoRack cool packs (Brinkmann Instruments) at 4°C, and transported to our Araihazar field clinic within 4 h. Plasma was separated by centrifugation at <inline-formula><mml:math id="i124" display="inline" alttext="1,350 times centrifugal force"><mml:mrow><mml:mn>1,350</mml:mn><mml:mo>×</mml:mo><mml:mi>g</mml:mi></mml:mrow></mml:math></inline-formula> for 10 min at 25°C. Whole blood and plasma samples were stored at <inline-formula><mml:math id="i125" display="inline" alttext="negative 80 degrees Celsius"><mml:mrow><mml:mo>−</mml:mo><mml:mn>80</mml:mn><mml:mo>°</mml:mo><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:math></inline-formula> before shipment to Columbia University on dry ice.</p>
                <p>Total bAs was measured using a PerkinElmer Elan DRC II inductively coupled plasma mass spectrometer (ICP-MS) with an AS <inline-formula><mml:math id="i126" display="inline" alttext="93 plus autosampler"><mml:mrow><mml:mn>93</mml:mn><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mtext>autosampler</mml:mtext></mml:mrow></mml:math></inline-formula> [intra- and interassay coefficient of variations (CVs): 2.7% and 5.7%, respectively]. As<sup>III</sup>, arsenate (As<sup>V</sup>), MMAs, and DMAs were measured in blood and urine using high-performance liquid chromatography (HPLC) coupled to dynamic reaction cell ICP-MS, as previously described.<sup><xref rid="c23" ref-type="bibr">23</xref>,<xref rid="c24" ref-type="bibr">24</xref></sup> This method cannot differentiate between reduced and oxidized forms of MMAs and DMAs. Although this method can separate As<sup>V</sup> from As<sup>III</sup>, samples can oxidize during sample processing; therefore, As<sup>V</sup> and As<sup>III</sup> were added and reported as a single variable reflecting total InAs. The limit of detection (LOD) and interassay CVs were, respectively, <inline-formula><mml:math id="i127" display="inline" alttext="0.11 microgram per liter"><mml:mrow><mml:mn>0.11</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula> and 15.9% for <inline-formula><mml:math id="i128" display="inline" alttext="arsenobetaine plus arsenocholine"><mml:mrow><mml:mtext>arsenobetaine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mtext>arsenocholine</mml:mtext></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i129" display="inline" alttext="0.22 microgram per liter"><mml:mrow><mml:mn>0.22</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula> and 4.4% for As<sup>III</sup> and As<sup>V</sup>, <inline-formula><mml:math id="i130" display="inline" alttext="0.22 microgram per liter"><mml:mrow><mml:mn>0.22</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula> and 4.4% for MMAs, and <inline-formula><mml:math id="i131" display="inline" alttext="0.22 microgram per liter"><mml:mrow><mml:mn>0.22</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula> and 4.7% for DMAs.</p>
                <p>Plasma folate and vitamin <inline-formula><mml:math id="i132" display="inline" alttext="uppercase b begin subscript 12 end subscript"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> were analyzed using a radio protein-binding assay according to the manufacturer’s instructions (SimulTRAC-SNB; MP Biomedicals). Intra- and interassay CVs for plasma folate were 5% and 13%, respectively, and for vitamin <inline-formula><mml:math id="i133" display="inline" alttext="uppercase b begin subscript 12 end subscript"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> were 6% and 17%, respectively. Plasma total homocysteine (tHcy) concentrations were measured by HPLC with fluorescence detection according to method described by Pfeiffer et al.<sup><xref rid="c25" ref-type="bibr">25</xref></sup> Separation was achieved with a <inline-formula><mml:math id="i134" display="inline" alttext="150 by 3.2 millimeter"><mml:mrow><mml:mn>150</mml:mn><mml:mo>×</mml:mo><mml:mn>3.2</mml:mn><mml:mtext>-</mml:mtext><mml:mi mathvariant="normal">mm</mml:mi></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i135" display="inline" alttext="5 micrometer"><mml:mrow><mml:mn>5</mml:mn><mml:mtext>-</mml:mtext><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:mrow></mml:math></inline-formula> Prodigy ODS2 analytic column (Phenomenex). Fluorescence was detected with a Waters 474 fluorescence detector (Waters Corporation) with excitation at <inline-formula><mml:math id="i136" display="inline" alttext="385 millimeters"><mml:mrow><mml:mn>385</mml:mn><mml:mtext> nm</mml:mtext></mml:mrow></mml:math></inline-formula> and emission at <inline-formula><mml:math id="i137" display="inline" alttext="515 nanometers"><mml:mrow><mml:mn>515</mml:mn><mml:mtext> nm</mml:mtext></mml:mrow></mml:math></inline-formula>. <sc>l</sc>-Homocysteine and <sc>l</sc>-cysteine were used as external calibrators.<sup><xref rid="c25" ref-type="bibr">25</xref></sup> The intra- and interassay CVs for tHcy were 5% and 7%, respectively.</p>
                <p>Baseline water As concentrations were measured in nonfiltered water samples collected in polyethylene scintillation vials. Samples were acidified to 1% using high-purity Optima HCl (Fisher Scientific) for 48 h, diluted 1:10, and analyzed with high-resolution ICP-MS.<sup><xref rid="c26" ref-type="bibr">26</xref></sup> No samples were below the LOD of <inline-formula><mml:math id="i138" display="inline" alttext="less than 0.2 microgram per liter"><mml:mrow><mml:mo>&lt;</mml:mo><mml:mn>0.2</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula>, and the intra- and interassay CVs were 2% and 2.6%, respectively.</p>
              </sec>
              <sec id="s2.5">
                <title>Study Sample</title>
                <p>A total of 622 participants were recruited. Six participants discontinued the trial owing to adverse events [PBO group (1 participant): abdominal cramps; 400FA group (1 participant): hypertension; 800FA group (3 participants): abdominal cramps, severe vertigo, bilateral hydronephrosis; creatine group (1 participant): severe vertigo] and 3 participants discontinued owing to pregnancy (400FA, creatine, and <inline-formula><mml:math id="i139" display="inline" alttext="creatine plus 400 folic acid"><mml:mrow><mml:mtext>creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mtext>FA</mml:mtext></mml:mrow></mml:math></inline-formula> groups). Two participants dropped out of the trial (PBO and 400FA groups), and 1 participant was excluded from this analysis owing to a missing blood sample. A total of 609 participants completed the study and were used for the present analyses (PBO: <inline-formula><mml:math id="i140" display="inline" alttext="uppercase italic n equals 102"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>102</mml:mn></mml:mrow></mml:math></inline-formula>, 400FA: <inline-formula><mml:math id="i141" display="inline" alttext="uppercase italic n equals 153"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>153</mml:mn></mml:mrow></mml:math></inline-formula>, 800FA: <inline-formula><mml:math id="i142" display="inline" alttext="uppercase italic n equals 150"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>150</mml:mn></mml:mrow></mml:math></inline-formula>, creatine: <inline-formula><mml:math id="i143" display="inline" alttext="uppercase italic n equals 101"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>101</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i144" display="inline" alttext="creatine plus 400 folic acid"><mml:mrow><mml:mtext>creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mtext>FA</mml:mtext></mml:mrow></mml:math></inline-formula>: <inline-formula><mml:math id="i145" display="inline" alttext="uppercase italic n equals 103"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>103</mml:mn></mml:mrow></mml:math></inline-formula>).</p>
              </sec>
              <sec id="s2.6">
                <title>Statistical Methods</title>
                <p>Primary and secondary bAs methylation indices were calculated as bMMAs/bInAs concentrations and bDMAs/bMMAs concentrations, respectively. Baseline summary statistics were calculated for participant sociodemographic data, baseline As methylation indices and metabolites, and nutritional parameters using GMs and geometric standard deviations (GSDs) for continuous variables and frequencies for categorical variables. GMs are commonly used in analyses involving environmental chemicals and toxicants, such as metals or metalloids that are measured in blood and urine, because they provide a more accurate measure of the central tendency of lognormally distributed variables, such as bAs metabolites, as compared with arithmetic means.<sup><xref rid="c27" ref-type="bibr">27</xref></sup> Differences between treatment groups at baseline were detected using the Kruskall–Wallis test for continuous variables and chi-square test for categorical variables. Because the distributions of bAs methylation indices and metabolites were right skewed, these variables were natural log-transformed to meet model assumptions, reduce the impact of extreme values, and improve model fitting.</p>
                <p>Linear models with repeated measures were used to examine treatment effects on bAs methylation indices and metabolite concentrations in the first 12-wk phase and the potential reversal of treatment effects on As metabolites following FA cessation during phase 2 (weeks 12–24). Model parameters were estimated using generalized estimating equations with an exchangeable correlation structure to account for within-person correlation in repeated measures over time; robust standard errors were used for statistical inference. The models for phase 1 of the RCT included the variables of baseline total bAs, treatment group for the five arms, time (baseline, week 1, and week 12), and group-by-time interactions. Coefficients of interaction terms indicate differences between each treatment group and the PBO group in the mean within-person change from baseline. A Wald test on the coefficients that define group-by-time interactions was used to detect differences in the mean within-person change between specific treatment groups. In addition, to explore potential sex-differences, models examining the treatment effects on bAs methylation indices and metabolite concentrations during phase 1 were further stratified by sex. Effect modification was also assessed using models including group-by-time-by-sex interaction terms. The models for phase 2 of the RCT (effect of FA cessation) included variables for baseline total bAs, time (baseline, week 12, and week 24), treatment groups (two FA doses over 24 wk and two FA doses switched to PBO in the second 12 wk), and interactions of group-by-time. Percentage change in GM over a specific time interval for each treatment group was derived from the estimated model parameters with a 95% CI. All analyses were performed using R (version 3.6.3; R Development Core Team).</p>
              </sec>
            </sec>
            <sec id="s3">
              <title>Results</title>
              <p>By design, approximately half of participants were male (50.2%, <inline-formula><mml:math id="i146" display="inline" alttext="uppercase italic n equals 306"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>306</mml:mn></mml:mrow></mml:math></inline-formula>). The age (<inline-formula><mml:math id="i147" display="inline" alttext="geometric mean plus or minus geometric standard deviation"><mml:mrow><mml:mtext>GM</mml:mtext><mml:mo>±</mml:mo><mml:mtext>GSD</mml:mtext></mml:mrow></mml:math></inline-formula>) of participants ranged from 24 to 55 y (<inline-formula><mml:math id="i148" display="inline" alttext="37.5 plus or minus 1.2"><mml:mrow><mml:mn>37.5</mml:mn><mml:mo>±</mml:mo><mml:mn>1.2</mml:mn></mml:mrow></mml:math></inline-formula> y). The prevalence of folate deficiency (<inline-formula><mml:math id="i149" display="inline" alttext="less than 9 nanomoles per liter"><mml:mrow><mml:mo>&lt;</mml:mo><mml:mn>9</mml:mn><mml:mtext> nmol</mml:mtext><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula> in plasma) was 19.7% (<inline-formula><mml:math id="i150" display="inline" alttext="uppercase italic n equals 120"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>120</mml:mn></mml:mrow></mml:math></inline-formula>) in this study population. In addition, 38.8% (<inline-formula><mml:math id="i151" display="inline" alttext="uppercase italic n equals 236"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>236</mml:mn></mml:mrow></mml:math></inline-formula>) of participants had hyperhomocysteinemia (plasma homocysteine <inline-formula><mml:math id="i152" display="inline" alttext="greater than or equal to 13 micromoles per liter"><mml:mrow><mml:mo>≥</mml:mo><mml:mn>13</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mtext>mol</mml:mtext><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula>) and 24% (<inline-formula><mml:math id="i153" display="inline" alttext="uppercase italic n equals 146"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>146</mml:mn></mml:mrow></mml:math></inline-formula>) were <inline-formula><mml:math id="i154" display="inline" alttext="uppercase b begin subscript 12 end subscript"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> deficient (<inline-formula><mml:math id="i155" display="inline" alttext="less than 151 picomoles per liter"><mml:mrow><mml:mo>&lt;</mml:mo><mml:mn>151</mml:mn><mml:mtext> pmol</mml:mtext><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula> in plasma). GM baseline well water As concentrations across treatment groups ranged from <inline-formula><mml:math id="i156" display="inline" alttext="119 to 128 micrograms per liter"><mml:mrow><mml:mn>119</mml:mn><mml:mtext> to </mml:mtext><mml:mn>128</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula>, that is, they were <inline-formula><mml:math id="i157" display="inline" alttext="approximately 12 to 15"><mml:mrow><mml:mo>∼</mml:mo><mml:mn>12</mml:mn><mml:mo>–</mml:mo><mml:mn>15</mml:mn></mml:mrow></mml:math></inline-formula> times the WHO-recommended limit of <inline-formula><mml:math id="i158" display="inline" alttext="10 micrograms per liter"><mml:mrow><mml:mn>10</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula><sup><xref rid="c3" ref-type="bibr">3</xref></sup> but were not statistically different across treatment groups (<inline-formula><mml:math id="i159" display="inline" alttext="lowercase italic p equals 0.95"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.95</mml:mn></mml:mrow></mml:math></inline-formula>). There were no significant differences in participant characteristics between treatment groups at baseline (<inline-formula><mml:math id="i160" display="inline" alttext="lowercase italic p greater than 0.05"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>) (<xref rid="t1" ref-type="table">Table 1</xref>).</p>
              <table-wrap position="float" id="t1">
                <label>Table 1</label>
                <caption>
                  <p>Folic Acid and Creatine Trial study participant characteristics [<inline-formula><mml:math id="i161" display="inline" alttext="geometric mean plus or minus geometric standard deviation"><mml:mrow><mml:mtext>GM</mml:mtext><mml:mspace width="0.3em"/><mml:mo>±</mml:mo><mml:mspace width="0.3em"/><mml:mtext>GSD</mml:mtext></mml:mrow></mml:math></inline-formula> or <inline-formula><mml:math id="i162" display="inline" alttext="uppercase italic n"><mml:mi>n</mml:mi></mml:math></inline-formula> (%)] at baseline by treatment group.</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <colgroup span="1">
                    <col align="left" valign="top" span="1"/>
                    <col align="left" valign="top" span="1"/>
                    <col align="left" valign="top" span="1"/>
                    <col align="left" valign="top" span="1"/>
                    <col align="left" valign="top" span="1"/>
                    <col align="left" valign="top" span="1"/>
                    <col align="left" valign="top" span="1"/>
                  </colgroup>
                  <thead>
                    <tr>
                      <th align="left" id="t1c1" scope="col" colspan="1" rowspan="1">Characteristic</th>
                      <th align="center" id="t1c2" scope="col" colspan="1" rowspan="1">PBO (<inline-formula><mml:math id="i163" display="inline" alttext="uppercase italic n equals 102"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>102</mml:mn></mml:mrow></mml:math></inline-formula>)</th>
                      <th align="center" id="t1c3" scope="col" colspan="1" rowspan="1">400FA (<inline-formula><mml:math id="i164" display="inline" alttext="uppercase italic n equals 153"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>153</mml:mn></mml:mrow></mml:math></inline-formula>)</th>
                      <th align="center" id="t1c4" scope="col" colspan="1" rowspan="1">800FA (<inline-formula><mml:math id="i165" display="inline" alttext="uppercase italic n equals 150"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>150</mml:mn></mml:mrow></mml:math></inline-formula>)</th>
                      <th align="center" id="t1c5" scope="col" colspan="1" rowspan="1">Creatine (<inline-formula><mml:math id="i166" display="inline" alttext="uppercase italic n equals 101"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>101</mml:mn></mml:mrow></mml:math></inline-formula>)</th>
                      <th align="center" id="t1c6" scope="col" colspan="1" rowspan="1"><inline-formula><mml:math id="i167" display="inline" alttext="creatine plus 400 folic acid"><mml:mrow><mml:mtext>Creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mtext>FA</mml:mtext></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i168" display="inline" alttext="uppercase italic n equals 103"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>103</mml:mn></mml:mrow></mml:math></inline-formula>)</th>
                      <th align="center" id="t1c7" scope="col" colspan="1" rowspan="1"><inline-formula><mml:math id="i169" display="inline" alttext="lowercase italic p"><mml:mi>p</mml:mi></mml:math></inline-formula>-Value<xref rid="TF2" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></th>
                    </tr>
                  </thead>
                  <tbody valign="top">
                    <tr>
                      <td align="left" id="t1c8" scope="row" headers="t1c1" colspan="1" rowspan="1">Age (y)</td>
                      <td align="char" char="plusmn" headers="t1c2 t1c8" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i170" display="inline" alttext="37.3 plus or minus 1.2">
                            <mml:mrow>
                              <mml:mn>37.3</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c3 t1c8" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i171" display="inline" alttext="38.2 plus or minus 1.2">
                            <mml:mrow>
                              <mml:mn>38.2</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c4 t1c8" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i172" display="inline" alttext="37.3 plus or minus 1.3">
                            <mml:mrow>
                              <mml:mn>37.3</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.3</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c5 t1c8" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i173" display="inline" alttext="37.4 plus or minus 1.3">
                            <mml:mrow>
                              <mml:mn>37.4</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.3</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c6 t1c8" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i174" display="inline" alttext="37.2 plus or minus 1.2">
                            <mml:mrow>
                              <mml:mn>37.2</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="." headers="t1c7 t1c8" colspan="1" rowspan="1">0.85</td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c9" scope="row" headers="t1c1" colspan="1" rowspan="1">Sex (<inline-formula><mml:math id="i175" display="inline" alttext="uppercase italic n"><mml:mi>n</mml:mi></mml:math></inline-formula>)</td>
                      <td align="center" headers="t1c2 t1c9" colspan="1" rowspan="1"/>
                      <td align="center" headers="t1c3 t1c9" colspan="1" rowspan="1"/>
                      <td align="center" headers="t1c4 t1c9" colspan="1" rowspan="1"/>
                      <td align="center" headers="t1c5 t1c9" colspan="1" rowspan="1"/>
                      <td align="center" headers="t1c6 t1c9" colspan="1" rowspan="1"/>
                      <td align="center" char="." headers="t1c7 t1c9" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i176" display="inline" alttext="greater than 0.99">
                            <mml:mrow>
                              <mml:mo>&gt;</mml:mo>
                              <mml:mn>0.99</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c10" scope="row" headers="t1c1" colspan="1" rowspan="1"> Female</td>
                      <td align="char" char="(" headers="t1c2 t1c10" colspan="1" rowspan="1">51 (50.0)</td>
                      <td align="char" char="(" headers="t1c3 t1c10" colspan="1" rowspan="1">76 (49.7)</td>
                      <td align="char" char="(" headers="t1c4 t1c10" colspan="1" rowspan="1">75 (50.0)</td>
                      <td align="char" char="(" headers="t1c5 t1c10" colspan="1" rowspan="1">50 (49.5)</td>
                      <td align="char" char="(" headers="t1c6 t1c10" colspan="1" rowspan="1">51 (49.5)</td>
                      <td align="center" headers="t1c7 t1c10" colspan="1" rowspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" id="t1c11" scope="row" headers="t1c1" colspan="1" rowspan="1"> Male</td>
                      <td align="char" char="(" headers="t1c2 t1c11" colspan="1" rowspan="1">51 (50.0)</td>
                      <td align="char" char="(" headers="t1c3 t1c11" colspan="1" rowspan="1">77 (50.3)</td>
                      <td align="char" char="(" headers="t1c4 t1c11" colspan="1" rowspan="1">75 (50.0)</td>
                      <td align="char" char="(" headers="t1c5 t1c11" colspan="1" rowspan="1">51 (50.5)</td>
                      <td align="char" char="(" headers="t1c6 t1c11" colspan="1" rowspan="1">52 (50.5)</td>
                      <td align="center" headers="t1c7 t1c11" colspan="1" rowspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" id="t1c12" scope="row" headers="t1c1" colspan="1" rowspan="1">Smoking status (<inline-formula><mml:math id="i177" display="inline" alttext="uppercase italic n"><mml:mi>n</mml:mi></mml:math></inline-formula>)<xref rid="TF3" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td>
                      <td align="center" headers="t1c2 t1c12" colspan="1" rowspan="1"/>
                      <td align="center" headers="t1c3 t1c12" colspan="1" rowspan="1"/>
                      <td align="center" headers="t1c4 t1c12" colspan="1" rowspan="1"/>
                      <td align="center" headers="t1c5 t1c12" colspan="1" rowspan="1"/>
                      <td align="center" headers="t1c6 t1c12" colspan="1" rowspan="1"/>
                      <td align="char" char="." headers="t1c7 t1c12" colspan="1" rowspan="1">0.69</td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c13" scope="row" headers="t1c1" colspan="1" rowspan="1"> Never</td>
                      <td align="char" char="(" headers="t1c2 t1c13" colspan="1" rowspan="1">77 (75.5)</td>
                      <td align="char" char="(" headers="t1c3 t1c13" colspan="1" rowspan="1">115 (75.2)</td>
                      <td align="char" char="(" headers="t1c4 t1c13" colspan="1" rowspan="1">106 (70.7)</td>
                      <td align="char" char="(" headers="t1c5 t1c13" colspan="1" rowspan="1">72 (71.3)</td>
                      <td align="char" char="(" headers="t1c6 t1c13" colspan="1" rowspan="1">72 (69.9)</td>
                      <td align="center" headers="t1c7 t1c13" colspan="1" rowspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" id="t1c14" scope="row" headers="t1c1" colspan="1" rowspan="1"> Ever</td>
                      <td align="char" char="(" headers="t1c2 t1c14" colspan="1" rowspan="1">25 (24.5)</td>
                      <td align="char" char="(" headers="t1c3 t1c14" colspan="1" rowspan="1">36 (23.5)</td>
                      <td align="char" char="(" headers="t1c4 t1c14" colspan="1" rowspan="1">44 (29.3)</td>
                      <td align="char" char="(" headers="t1c5 t1c14" colspan="1" rowspan="1">29 (28.7)</td>
                      <td align="char" char="(" headers="t1c6 t1c14" colspan="1" rowspan="1">31 (30.1)</td>
                      <td align="center" headers="t1c7 t1c14" colspan="1" rowspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" id="t1c15" scope="row" headers="t1c1" colspan="1" rowspan="1">Betel nut use (<inline-formula><mml:math id="i178" display="inline" alttext="uppercase italic n"><mml:mi>n</mml:mi></mml:math></inline-formula>)<xref rid="TF3" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td>
                      <td align="center" headers="t1c2 t1c15" colspan="1" rowspan="1"/>
                      <td align="center" headers="t1c3 t1c15" colspan="1" rowspan="1"/>
                      <td align="center" headers="t1c4 t1c15" colspan="1" rowspan="1"/>
                      <td align="center" headers="t1c5 t1c15" colspan="1" rowspan="1"/>
                      <td align="center" headers="t1c6 t1c15" colspan="1" rowspan="1"/>
                      <td align="char" char="." headers="t1c7 t1c15" colspan="1" rowspan="1">0.76</td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c16" scope="row" headers="t1c1" colspan="1" rowspan="1"> Never</td>
                      <td align="char" char="(" headers="t1c2 t1c16" colspan="1" rowspan="1">73 (71.6)</td>
                      <td align="char" char="(" headers="t1c3 t1c16" colspan="1" rowspan="1">115 (75.2)</td>
                      <td align="char" char="(" headers="t1c4 t1c16" colspan="1" rowspan="1">113 (75.3)</td>
                      <td align="char" char="(" headers="t1c5 t1c16" colspan="1" rowspan="1">76 (75.2)</td>
                      <td align="char" char="(" headers="t1c6 t1c16" colspan="1" rowspan="1">82 (79.6)</td>
                      <td align="center" headers="t1c7 t1c16" colspan="1" rowspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" id="t1c17" scope="row" headers="t1c1" colspan="1" rowspan="1"> Ever</td>
                      <td align="char" char="(" headers="t1c2 t1c17" colspan="1" rowspan="1">29 (28.4)</td>
                      <td align="char" char="(" headers="t1c3 t1c17" colspan="1" rowspan="1">36 (23.5)</td>
                      <td align="char" char="(" headers="t1c4 t1c17" colspan="1" rowspan="1">37 (24.7)</td>
                      <td align="char" char="(" headers="t1c5 t1c17" colspan="1" rowspan="1">25 (24.8)</td>
                      <td align="char" char="(" headers="t1c6 t1c17" colspan="1" rowspan="1">21 (20.4)</td>
                      <td align="center" headers="t1c7 t1c17" colspan="1" rowspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" id="t1c18" scope="row" headers="t1c1" colspan="1" rowspan="1">Land ownership (<inline-formula><mml:math id="i179" display="inline" alttext="uppercase italic n"><mml:mi>n</mml:mi></mml:math></inline-formula>)<xref rid="TF4" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref></td>
                      <td align="center" headers="t1c2 t1c18" colspan="1" rowspan="1"/>
                      <td align="center" headers="t1c3 t1c18" colspan="1" rowspan="1"/>
                      <td align="center" headers="t1c4 t1c18" colspan="1" rowspan="1"/>
                      <td align="center" headers="t1c5 t1c18" colspan="1" rowspan="1"/>
                      <td align="center" headers="t1c6 t1c18" colspan="1" rowspan="1"/>
                      <td align="char" char="." headers="t1c7 t1c18" colspan="1" rowspan="1">0.85</td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c19" scope="row" headers="t1c1" colspan="1" rowspan="1"> Does not own land</td>
                      <td align="char" char="(" headers="t1c2 t1c19" colspan="1" rowspan="1">55 (53.9)</td>
                      <td align="char" char="(" headers="t1c3 t1c19" colspan="1" rowspan="1">76 (49.7)</td>
                      <td align="char" char="(" headers="t1c4 t1c19" colspan="1" rowspan="1">78 (52.0)</td>
                      <td align="char" char="(" headers="t1c5 t1c19" colspan="1" rowspan="1">53 (52.5)</td>
                      <td align="char" char="(" headers="t1c6 t1c19" colspan="1" rowspan="1">58 (56.3)</td>
                      <td align="center" headers="t1c7 t1c19" colspan="1" rowspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" id="t1c20" scope="row" headers="t1c1" colspan="1" rowspan="1"> Owns land</td>
                      <td align="char" char="(" headers="t1c2 t1c20" colspan="1" rowspan="1">47 (46.1)</td>
                      <td align="char" char="(" headers="t1c3 t1c20" colspan="1" rowspan="1">77 (50.3)</td>
                      <td align="char" char="(" headers="t1c4 t1c20" colspan="1" rowspan="1">72 (48.0)</td>
                      <td align="char" char="(" headers="t1c5 t1c20" colspan="1" rowspan="1">48 (47.5)</td>
                      <td align="char" char="(" headers="t1c6 t1c20" colspan="1" rowspan="1">44 (42.7)</td>
                      <td align="center" headers="t1c7 t1c20" colspan="1" rowspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" id="t1c21" scope="row" headers="t1c1" colspan="1" rowspan="1">Body mass index (<inline-formula><mml:math id="i180" display="inline" alttext="kilograms per meter squared"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">kg</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>)<xref rid="TF5" ref-type="table-fn"><sup><italic toggle="yes">d</italic></sup></xref></td>
                      <td align="char" char="plusmn" headers="t1c2 t1c21" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i181" display="inline" alttext="20.2 plus or minus 1.2">
                            <mml:mrow>
                              <mml:mn>20.2</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c3 t1c21" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i182" display="inline" alttext="19.4 plus or minus 1.1">
                            <mml:mrow>
                              <mml:mn>19.4</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.1</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c4 t1c21" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i183" display="inline" alttext="19.7 plus or minus 1.1">
                            <mml:mrow>
                              <mml:mn>19.7</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.1</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c5 t1c21" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i184" display="inline" alttext="19.8 plus or minus 1.2">
                            <mml:mrow>
                              <mml:mn>19.8</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c6 t1c21" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i185" display="inline" alttext="19.3 plus or minus 1.1">
                            <mml:mrow>
                              <mml:mn>19.3</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.1</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="." headers="t1c7 t1c21" colspan="1" rowspan="1">0.30</td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c22" scope="row" headers="t1c1" colspan="1" rowspan="1">Water arsenic (<inline-formula><mml:math id="i186" display="inline" alttext="micrograms per liter"><mml:mrow><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula>)</td>
                      <td align="char" char="plusmn" headers="t1c2 t1c22" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i187" display="inline" alttext="123 plus or minus 2">
                            <mml:mrow>
                              <mml:mn>123</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c3 t1c22" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i188" display="inline" alttext="119 plus or minus 2">
                            <mml:mrow>
                              <mml:mn>119</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c4 t1c22" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i189" display="inline" alttext="119 plus or minus 2">
                            <mml:mrow>
                              <mml:mn>119</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c5 t1c22" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i190" display="inline" alttext="125 plus or minus 2">
                            <mml:mrow>
                              <mml:mn>125</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c6 t1c22" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i191" display="inline" alttext="128 plus or minus 2">
                            <mml:mrow>
                              <mml:mn>128</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="." headers="t1c7 t1c22" colspan="1" rowspan="1">0.95</td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c23" scope="row" headers="t1c1" colspan="1" rowspan="1">Urinary arsenic (<inline-formula><mml:math id="i192" display="inline" alttext="micrograms per liter"><mml:mrow><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula>)</td>
                      <td align="char" char="plusmn" headers="t1c2 t1c23" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i193" display="inline" alttext="86.2 plus or minus 2.4">
                            <mml:mrow>
                              <mml:mn>86.2</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>2.4</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c3 t1c23" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i194" display="inline" alttext="98.6 plus or minus 2.5">
                            <mml:mrow>
                              <mml:mn>98.6</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>2.5</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c4 t1c23" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i195" display="inline" alttext="97.2 plus or minus 2.4">
                            <mml:mrow>
                              <mml:mn>97.2</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>2.4</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c5 t1c23" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i196" display="inline" alttext="110.0 plus or minus 2.5">
                            <mml:mrow>
                              <mml:mn>110.0</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>2.5</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c6 t1c23" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i197" display="inline" alttext="117.0 plus or minus 2.3">
                            <mml:mrow>
                              <mml:mn>117.0</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>2.3</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="." headers="t1c7 t1c23" colspan="1" rowspan="1">0.38</td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c24" scope="row" headers="t1c1" colspan="1" rowspan="1">Blood arsenic<xref rid="TF6" ref-type="table-fn"><sup><italic toggle="yes">e</italic></sup></xref></td>
                      <td align="char" char="plusmn" headers="t1c2 t1c24" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i198" display="inline" alttext="8.0 3 plus or minus1.80">
                            <mml:mrow>
                              <mml:mn>8.03</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.80</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c3 t1c24" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i199" display="inline" alttext="8.26 plus or minus 1.88">
                            <mml:mrow>
                              <mml:mn>8.26</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.88</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c4 t1c24" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i200" display="inline" alttext="8.37 plus or minus 1.72">
                            <mml:mrow>
                              <mml:mn>8.37</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.72</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c5 t1c24" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i201" display="inline" alttext="8.24 plus or minus 1.85">
                            <mml:mrow>
                              <mml:mn>8.24</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.85</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c6 t1c24" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i202" display="inline" alttext="8.76 plus or minus 1.68">
                            <mml:mrow>
                              <mml:mn>8.76</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.68</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="." headers="t1c7 t1c24" colspan="1" rowspan="1">0.64</td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c25" scope="row" headers="t1c1" colspan="1" rowspan="1"> PMI<xref rid="TF6" ref-type="table-fn"><sup><italic toggle="yes">e</italic></sup></xref></td>
                      <td align="char" char="plusmn" headers="t1c2 t1c25" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i203" display="inline" alttext="1.61 plus or minus 1.27">
                            <mml:mrow>
                              <mml:mn>1.61</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.27</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c3 t1c25" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i204" display="inline" alttext="1.65 plus or minus 1.20">
                            <mml:mrow>
                              <mml:mn>1.65</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.20</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c4 t1c25" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i205" display="inline" alttext="1.63 plus or minus 1.20">
                            <mml:mrow>
                              <mml:mn>1.63</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.20</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c5 t1c25" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i206" display="inline" alttext="1.63 plus or minus 1.20">
                            <mml:mrow>
                              <mml:mn>1.63</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.20</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c6 t1c25" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i207" display="inline" alttext="1.70 plus or minus 1.19">
                            <mml:mrow>
                              <mml:mn>1.70</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.19</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="." headers="t1c7 t1c25" colspan="1" rowspan="1">0.56</td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c26" scope="row" headers="t1c1" colspan="1" rowspan="1"> SMI<xref rid="TF6" ref-type="table-fn"><sup><italic toggle="yes">e</italic></sup></xref></td>
                      <td align="center" headers="t1c2 t1c26" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i208" display="inline" alttext="0.62 plus or minus 1.29">
                            <mml:mrow>
                              <mml:mn>0.62</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.29</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c3 t1c26" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i209" display="inline" alttext="0.63 plus or minus 1.29">
                            <mml:mrow>
                              <mml:mn>0.63</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.29</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c4 t1c26" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i210" display="inline" alttext="0.65 plus or minus 1.31">
                            <mml:mrow>
                              <mml:mn>0.65</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.31</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c5 t1c26" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i211" display="inline" alttext="0.63 plus or minus 1.29">
                            <mml:mrow>
                              <mml:mn>0.63</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.29</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c6 t1c26" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i212" display="inline" alttext="0.66 plus or minus 1.30">
                            <mml:mrow>
                              <mml:mn>0.66</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.30</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="." headers="t1c7 t1c26" colspan="1" rowspan="1">0.29</td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c27" scope="row" headers="t1c1" colspan="1" rowspan="1"> InAs (<inline-formula><mml:math id="i213" display="inline" alttext="micrograms per liter"><mml:mrow><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula>)<xref rid="TF6" ref-type="table-fn"><sup><italic toggle="yes">e</italic></sup></xref></td>
                      <td align="char" char="plusmn" headers="t1c2 t1c27" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i214" display="inline" alttext="2.20 plus or minus 1.75">
                            <mml:mrow>
                              <mml:mn>2.20</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.75</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c3 t1c27" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i215" display="inline" alttext="2.22 plus or minus 1.79">
                            <mml:mrow>
                              <mml:mn>2.22</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.79</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c4 t1c27" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i216" display="inline" alttext="2.25 plus or minus 1.65">
                            <mml:mrow>
                              <mml:mn>2.25</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.65</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c5 t1c27" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i217" display="inline" alttext="2.24 plus or minus 1.85">
                            <mml:mrow>
                              <mml:mn>2.24</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.85</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c6 t1c27" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i218" display="inline" alttext="2.27 plus or minus 1.65">
                            <mml:mrow>
                              <mml:mn>2.27</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.65</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="." headers="t1c7 t1c27" colspan="1" rowspan="1">0.86</td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c28" scope="row" headers="t1c1" colspan="1" rowspan="1"> MMAs (<inline-formula><mml:math id="i219" display="inline" alttext="micrograms per liter"><mml:mrow><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula>)<xref rid="TF6" ref-type="table-fn"><sup><italic toggle="yes">e</italic></sup></xref></td>
                      <td align="char" char="plusmn" headers="t1c2 t1c28" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i220" display="inline" alttext="3.55 plus or minus 1.89">
                            <mml:mrow>
                              <mml:mn>3.55</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.89</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c3 t1c28" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i221" display="inline" alttext="3.67 plus or minus 1.97">
                            <mml:mrow>
                              <mml:mn>3.67</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.97</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c4 t1c28" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i222" display="inline" alttext="3.67 plus or minus 1.82">
                            <mml:mrow>
                              <mml:mn>3.67</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.82</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c5 t1c28" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i223" display="inline" alttext="3.64 plus or minus 1.93">
                            <mml:mrow>
                              <mml:mn>3.64</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.93</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c6 t1c28" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i224" display="inline" alttext="3.85 plus or minus 1.73">
                            <mml:mrow>
                              <mml:mn>3.85</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.73</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="." headers="t1c7 t1c28" colspan="1" rowspan="1">0.79</td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c29" scope="row" headers="t1c1" colspan="1" rowspan="1"> DMAs (<inline-formula><mml:math id="i225" display="inline" alttext="micrograms per liter"><mml:mrow><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula>)<xref rid="TF6" ref-type="table-fn"><sup><italic toggle="yes">e</italic></sup></xref></td>
                      <td align="char" char="plusmn" headers="t1c2 t1c29" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i226" display="inline" alttext="2.19 plus or minus 1.83">
                            <mml:mrow>
                              <mml:mn>2.19</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.83</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c3 t1c29" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i227" display="inline" alttext="2.30 plus or minus 1.93">
                            <mml:mrow>
                              <mml:mn>2.30</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.93</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c4 t1c29" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i228" display="inline" alttext="2.38 plus or minus 1.75">
                            <mml:mrow>
                              <mml:mn>2.38</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.75</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c5 t1c29" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i229" display="inline" alttext="2.29 plus or minus 1.83">
                            <mml:mrow>
                              <mml:mn>2.29</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.83</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c6 t1c29" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i230" display="inline" alttext="2.56 plus or minus 1.73">
                            <mml:mrow>
                              <mml:mn>2.56</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.73</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="." headers="t1c7 t1c29" colspan="1" rowspan="1">0.37</td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c30" scope="row" headers="t1c1" colspan="1" rowspan="1"> %InAs<xref rid="TF6" ref-type="table-fn"><sup><italic toggle="yes">e</italic></sup></xref></td>
                      <td align="char" char="plusmn" headers="t1c2 t1c30" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i231" display="inline" alttext="27.5 plus or minus 1.2">
                            <mml:mrow>
                              <mml:mn>27.5</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c3 t1c30" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i232" display="inline" alttext="26.9 plus or minus 1.2">
                            <mml:mrow>
                              <mml:mn>26.9</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c4 t1c30" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i233" display="inline" alttext="26.9 plus or minus 1.1">
                            <mml:mrow>
                              <mml:mn>26.9</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.1</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c5 t1c30" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i234" display="inline" alttext="27.1 plus or minus 1.1">
                            <mml:mrow>
                              <mml:mn>27.1</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.1</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c6 t1c30" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i235" display="inline" alttext="25.9 plus or minus 1.1">
                            <mml:mrow>
                              <mml:mn>25.9</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.1</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="." headers="t1c7 t1c30" colspan="1" rowspan="1">0.05</td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c31" scope="row" headers="t1c1" colspan="1" rowspan="1"> %MMAs<xref rid="TF6" ref-type="table-fn"><sup><italic toggle="yes">e</italic></sup></xref></td>
                      <td align="char" char="plusmn" headers="t1c2 t1c31" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i236" display="inline" alttext="44.2 plus or minus 1.1">
                            <mml:mrow>
                              <mml:mn>44.2</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.1</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c3 t1c31" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i237" display="inline" alttext="44.3 plus or minus 1.1">
                            <mml:mrow>
                              <mml:mn>44.3</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.1</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c4 t1c31" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i238" display="inline" alttext="43.8 plus or minus 1.1">
                            <mml:mrow>
                              <mml:mn>43.8</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.1</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c5 t1c31" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i239" display="inline" alttext="44.2 plus or minus 1.1">
                            <mml:mrow>
                              <mml:mn>44.2</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.1</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c6 t1c31" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i240" display="inline" alttext="44.0 plus or minus 1.1">
                            <mml:mrow>
                              <mml:mn>44.0</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.1</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="." headers="t1c7 t1c31" colspan="1" rowspan="1">0.75</td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c32" scope="row" headers="t1c1" colspan="1" rowspan="1"> %DMAs<xref rid="TF6" ref-type="table-fn"><sup><italic toggle="yes">e</italic></sup></xref></td>
                      <td align="char" char="plusmn" headers="t1c2 t1c32" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i241" display="inline" alttext="27.2 plus or minus 1.2">
                            <mml:mrow>
                              <mml:mn>27.2</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c3 t1c32" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i242" display="inline" alttext="27.8 plus or minus 1.2">
                            <mml:mrow>
                              <mml:mn>27.8</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c4 t1c32" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i243" display="inline" alttext="28.4 plus or minus 1.2">
                            <mml:mrow>
                              <mml:mn>28.4</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c5 t1c32" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i244" display="inline" alttext="27.8 plus or minus 1.2">
                            <mml:mrow>
                              <mml:mn>27.8</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c6 t1c32" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i245" display="inline" alttext="29.2 plus or minus 1.2">
                            <mml:mrow>
                              <mml:mn>29.2</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="." headers="t1c7 t1c32" colspan="1" rowspan="1">0.08</td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c33" scope="row" headers="t1c1" colspan="1" rowspan="1">Urinary creatinine (mg/dL)</td>
                      <td align="char" char="plusmn" headers="t1c2 t1c33" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i246" display="inline" alttext="38.6 plus or minus 2.1">
                            <mml:mrow>
                              <mml:mn>38.6</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>2.1</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c3 t1c33" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i247" display="inline" alttext="43.7 plus or minus 2.2">
                            <mml:mrow>
                              <mml:mn>43.7</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>2.2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c4 t1c33" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i248" display="inline" alttext="40.9 plus or minus 2.2">
                            <mml:mrow>
                              <mml:mn>40.9</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>2.2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c5 t1c33" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i249" display="inline" alttext="46.2 plus or minus 2.0">
                            <mml:mrow>
                              <mml:mn>46.2</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>2.0</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c6 t1c33" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i250" display="inline" alttext="47.5 plus or minus 2.2">
                            <mml:mrow>
                              <mml:mn>47.5</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>2.2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="." headers="t1c7 t1c33" colspan="1" rowspan="1">0.35</td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c34" scope="row" headers="t1c1" colspan="1" rowspan="1">Red blood cell folate (nmol/L)<xref rid="TF7" ref-type="table-fn"><sup><italic toggle="yes">f</italic></sup></xref></td>
                      <td align="char" char="plusmn" headers="t1c2 t1c34" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i251" display="inline" alttext="451 plus or minus 1">
                            <mml:mrow>
                              <mml:mn>451</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c3 t1c34" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i252" display="inline" alttext="448 plus or minus 2">
                            <mml:mrow>
                              <mml:mn>448</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c4 t1c34" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i253" display="inline" alttext="468 plus or minus 1">
                            <mml:mrow>
                              <mml:mn>468</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="center" headers="t1c5 t1c34" colspan="1" rowspan="1">NA</td>
                      <td align="center" headers="t1c6 t1c34" colspan="1" rowspan="1">NA</td>
                      <td align="char" char="." headers="t1c7 t1c34" colspan="1" rowspan="1">0.63</td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c35" scope="row" headers="t1c1" colspan="1" rowspan="1">Plasma folate (nmol/L)</td>
                      <td align="char" char="plusmn" headers="t1c2 t1c35" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i254" display="inline" alttext="13.6 plus or minus 1.8">
                            <mml:mrow>
                              <mml:mn>13.6</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.8</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c3 t1c35" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i255" display="inline" alttext="13.5 plus or minus 1.9">
                            <mml:mrow>
                              <mml:mn>13.5</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.9</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c4 t1c35" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i256" display="inline" alttext="14.5 plus or minus 1.8">
                            <mml:mrow>
                              <mml:mn>14.5</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.8</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c5 t1c35" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i257" display="inline" alttext="14.4 plus or minus 1.6">
                            <mml:mrow>
                              <mml:mn>14.4</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.6</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c6 t1c35" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i258" display="inline" alttext="13.3 plus or minus 1.7">
                            <mml:mrow>
                              <mml:mn>13.3</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.7</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="." headers="t1c7 t1c35" colspan="1" rowspan="1">0.66</td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c36" scope="row" headers="t1c1" colspan="1" rowspan="1">Folate deficient (<inline-formula><mml:math id="i259" display="inline" alttext="less than 9 nanomoles per liter"><mml:mrow><mml:mo>&lt;</mml:mo><mml:mn>9</mml:mn><mml:mtext> nmol</mml:mtext><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula> in plasma) (<inline-formula><mml:math id="i260" display="inline" alttext="uppercase italic n"><mml:mi>n</mml:mi></mml:math></inline-formula>)</td>
                      <td align="char" char="(" headers="t1c2 t1c36" colspan="1" rowspan="1">22 (21.6)</td>
                      <td align="char" char="(" headers="t1c3 t1c36" colspan="1" rowspan="1">36 (23.5)</td>
                      <td align="char" char="(" headers="t1c4 t1c36" colspan="1" rowspan="1">27 (18.0)</td>
                      <td align="char" char="(" headers="t1c5 t1c36" colspan="1" rowspan="1">14 (13.9)</td>
                      <td align="char" char="(" headers="t1c6 t1c36" colspan="1" rowspan="1">21 (20.4)</td>
                      <td align="char" char="." headers="t1c7 t1c36" colspan="1" rowspan="1">0.39</td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c37" scope="row" headers="t1c1" colspan="1" rowspan="1">Plasma homocysteine (<inline-formula><mml:math id="i261" display="inline" alttext="micromoles per liter"><mml:mrow><mml:mi mathvariant="normal">μ</mml:mi><mml:mtext>mol</mml:mtext><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula>)</td>
                      <td align="char" char="plusmn" headers="t1c2 t1c37" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i262" display="inline" alttext="12.2 plus or minus 1.6">
                            <mml:mrow>
                              <mml:mn>12.2</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.6</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c3 t1c37" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i263" display="inline" alttext="11.9 plus or minus 1.6">
                            <mml:mrow>
                              <mml:mn>11.9</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.6</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c4 t1c37" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i264" display="inline" alttext="11.9 plus or minus 1.6">
                            <mml:mrow>
                              <mml:mn>11.9</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.6</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c5 t1c37" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i265" display="inline" alttext="11.4 plus or minus 1.5">
                            <mml:mrow>
                              <mml:mn>11.4</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.5</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c6 t1c37" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i266" display="inline" alttext="11.8 plus or minus 1.5">
                            <mml:mrow>
                              <mml:mn>11.8</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>1.5</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="." headers="t1c7 t1c37" colspan="1" rowspan="1">0.90</td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c38" scope="row" headers="t1c1" colspan="1" rowspan="1">Hyperhomocysteinemia (<inline-formula><mml:math id="i267" display="inline" alttext="greater than or equal to 13 micromoles per liter"><mml:mrow><mml:mo>≥</mml:mo><mml:mn>13</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mtext>mol</mml:mtext><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula>) (<inline-formula><mml:math id="i268" display="inline" alttext="uppercase italic n"><mml:mi>n</mml:mi></mml:math></inline-formula>)</td>
                      <td align="char" char="(" headers="t1c2 t1c38" colspan="1" rowspan="1">43 (42.2)</td>
                      <td align="char" char="(" headers="t1c3 t1c38" colspan="1" rowspan="1">56 (36.6)</td>
                      <td align="char" char="(" headers="t1c4 t1c38" colspan="1" rowspan="1">59 (39.3)</td>
                      <td align="char" char="(" headers="t1c5 t1c38" colspan="1" rowspan="1">39 (38.6)</td>
                      <td align="char" char="(" headers="t1c6 t1c38" colspan="1" rowspan="1">39 (37.9)</td>
                      <td align="char" char="." headers="t1c7 t1c38" colspan="1" rowspan="1">0.93</td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c39" scope="row" headers="t1c1" colspan="1" rowspan="1">Plasma vitamin <inline-formula><mml:math id="i269" display="inline" alttext="uppercase b begin subscript 12 end subscript"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> (pmol/L)</td>
                      <td align="char" char="plusmn" headers="t1c2 t1c39" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i270" display="inline" alttext="204 plus or minus 2">
                            <mml:mrow>
                              <mml:mn>204</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c3 t1c39" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i271" display="inline" alttext="216 plus or minus 2">
                            <mml:mrow>
                              <mml:mn>216</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c4 t1c39" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i272" display="inline" alttext="214 plus or minus 2">
                            <mml:mrow>
                              <mml:mn>214</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c5 t1c39" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i273" display="inline" alttext="224 plus or minus 2">
                            <mml:mrow>
                              <mml:mn>224</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="plusmn" headers="t1c6 t1c39" colspan="1" rowspan="1">
                        <inline-formula>
                          <mml:math id="i274" display="inline" alttext="210 plus or minus 2">
                            <mml:mrow>
                              <mml:mn>210</mml:mn>
                              <mml:mo>±</mml:mo>
                              <mml:mn>2</mml:mn>
                            </mml:mrow>
                          </mml:math>
                        </inline-formula>
                      </td>
                      <td align="char" char="." headers="t1c7 t1c39" colspan="1" rowspan="1">0.82</td>
                    </tr>
                    <tr>
                      <td align="left" id="t1c40" scope="row" headers="t1c1" colspan="1" rowspan="1">Vitamin <inline-formula><mml:math id="i275" display="inline" alttext="uppercase b begin subscript 12 end subscript"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> deficient (<inline-formula><mml:math id="i276" display="inline" alttext="less than 151 picomoles per liter"><mml:mrow><mml:mo>&lt;</mml:mo><mml:mn>151</mml:mn><mml:mtext> pmol</mml:mtext><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula>) (<inline-formula><mml:math id="i277" display="inline" alttext="uppercase italic n"><mml:mi>n</mml:mi></mml:math></inline-formula>)</td>
                      <td align="char" char="(" headers="t1c2 t1c40" colspan="1" rowspan="1">25 (24.5)</td>
                      <td align="char" char="(" headers="t1c3 t1c40" colspan="1" rowspan="1">37 (24.2)</td>
                      <td align="char" char="(" headers="t1c4 t1c40" colspan="1" rowspan="1">39 (26.0)</td>
                      <td align="char" char="(" headers="t1c5 t1c40" colspan="1" rowspan="1">20 (19.8)</td>
                      <td align="char" char="(" headers="t1c6 t1c40" colspan="1" rowspan="1">25 (24.3)</td>
                      <td align="char" char="." headers="t1c7 t1c40" colspan="1" rowspan="1">0.86</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="TF1">
                    <p>Note: %, percentage; 400FA, <inline-formula><mml:math id="i278" display="inline" alttext="400 micrograms"><mml:mrow><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA/d; 800FA, <inline-formula><mml:math id="i279" display="inline" alttext="800 micrograms"><mml:mrow><mml:mn>800</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA/d; creatine, <inline-formula><mml:math id="i280" display="inline" alttext="3 grams"><mml:mrow><mml:mn>3</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> creatine/d; <inline-formula><mml:math id="i281" display="inline" alttext="creatine plus 400 folic acid"><mml:mrow><mml:mtext>creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mtext>FA</mml:mtext></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i282" display="inline" alttext="3 grams"><mml:mrow><mml:mn>3</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> creatine and <inline-formula><mml:math id="i283" display="inline" alttext="400 micrograms"><mml:mrow><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA/d; DMAs, dimethyl-arsenical species; FA, folic acid; GM, geometric mean; GSD, geometric standard deviation; InAs, inorganic arsenic; MMAs, monomethyl-arsenical species; NA, not available/not measured for creatine and <inline-formula><mml:math id="i284" display="inline" alttext="creatine plus 400 folic acid"><mml:mrow><mml:mtext>creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mtext> FA</mml:mtext></mml:mrow></mml:math></inline-formula> groups; PBO, placebo; PMI, primary methylation index; SMI, secondary methylation index.</p>
                  </fn>
                  <fn id="TF2">
                    <label>
                      <sup>
                        <italic toggle="yes">a</italic>
                      </sup>
                    </label>
                    <p>Kruskal–Wallis test for continuous variables and chi-square test for categorical variables.</p>
                  </fn>
                  <fn id="TF3">
                    <label>
                      <sup>
                        <italic toggle="yes">b</italic>
                      </sup>
                    </label>
                    <p>400FA: <inline-formula><mml:math id="i285" display="inline" alttext="uppercase italic n equals 151"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>151</mml:mn></mml:mrow></mml:math></inline-formula>.</p>
                  </fn>
                  <fn id="TF4">
                    <label>
                      <sup>
                        <italic toggle="yes">c</italic>
                      </sup>
                    </label>
                    <p><inline-formula><mml:math id="i286" display="inline" alttext="creatine plus 400 folic acid"><mml:mrow><mml:mtext>Creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mtext>FA</mml:mtext></mml:mrow></mml:math></inline-formula>: <inline-formula><mml:math id="i287" display="inline" alttext="uppercase italic n equals 102"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>102</mml:mn></mml:mrow></mml:math></inline-formula>.</p>
                  </fn>
                  <fn id="TF5">
                    <label>
                      <sup>
                        <italic toggle="yes">d</italic>
                      </sup>
                    </label>
                    <p>PBO: <inline-formula><mml:math id="i288" display="inline" alttext="uppercase italic n equals 101"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>101</mml:mn></mml:mrow></mml:math></inline-formula>; 400FA:<inline-formula><mml:math id="i289" display="inline" alttext=" [uppercase italic n equals 150"><mml:mrow><mml:mtext> </mml:mtext><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>150</mml:mn></mml:mrow></mml:math></inline-formula>; 800FA: <inline-formula><mml:math id="i290" display="inline" alttext="uppercase italic n equals 147"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>147</mml:mn></mml:mrow></mml:math></inline-formula>; creatine: <inline-formula><mml:math id="i291" display="inline" alttext="uppercase italic n equals 98"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>98</mml:mn></mml:mrow></mml:math></inline-formula>; <inline-formula><mml:math id="i292" display="inline" alttext="creatine plus 400 folic acid"><mml:mrow><mml:mtext>creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mtext>FA</mml:mtext></mml:mrow></mml:math></inline-formula>: <inline-formula><mml:math id="i293" display="inline" alttext="uppercase italic n equals 102"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>102</mml:mn></mml:mrow></mml:math></inline-formula>.</p>
                  </fn>
                  <fn id="TF6">
                    <label>
                      <sup>
                        <italic toggle="yes">e</italic>
                      </sup>
                    </label>
                    <p>400FA: <inline-formula><mml:math id="i294" display="inline" alttext="uppercase italic n equals 152"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>152</mml:mn></mml:mrow></mml:math></inline-formula>; creatine: <inline-formula><mml:math id="i295" display="inline" alttext="uppercase italic n equals 100"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:math></inline-formula>.</p>
                  </fn>
                  <fn id="TF7">
                    <label>
                      <sup>
                        <italic toggle="yes">f</italic>
                      </sup>
                    </label>
                    <p>PBO: <inline-formula><mml:math id="i296" display="inline" alttext="uppercase italic n equals 100"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:math></inline-formula>; 400FA: <inline-formula><mml:math id="i297" display="inline" alttext="uppercase italic n equals 148"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>148</mml:mn></mml:mrow></mml:math></inline-formula>; 800FA: <inline-formula><mml:math id="i298" display="inline" alttext="uppercase italic n equals 148"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>148</mml:mn></mml:mrow></mml:math></inline-formula>.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>Compliance with supplementation in FACT has been previously reported by Peters et al.<sup><xref rid="c17" ref-type="bibr">17</xref></sup> Pill counts were used to calculate the percentage of study pills taken by each participant throughout the trial. Median compliance was 99.5%, and compliance was similar across treatment groups and study phases (range: 79.1%–100%; IQR: 98.3%–100.0%).<sup><xref rid="c17" ref-type="bibr">17</xref></sup> Compliance, as assessed by plasma folate, was also high. Plasma folate concentrations at week 12 in the 400FA, 800FA, and <inline-formula><mml:math id="i299" display="inline" alttext="creatine plus 400 folic acid"><mml:mrow><mml:mtext>creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mtext>FA</mml:mtext></mml:mrow></mml:math></inline-formula> groups were significantly greater than baseline concentrations (paired Wilcoxon test <inline-formula><mml:math id="i300" display="inline" alttext="lowercase italic p less than 0.001"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.001</mml:mn></mml:mrow></mml:math></inline-formula>) and significantly greater than week 12 concentrations in the PBO group (Wilcoxon test <inline-formula><mml:math id="i301" display="inline" alttext="lowercase italic p less than 0.001"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.001</mml:mn></mml:mrow></mml:math></inline-formula>). The prevalence of folate deficiency did not considerably change in the PBO and creatine arms, whereas all groups receiving FA had a decrease in the prevalence of folate deficiency to <inline-formula><mml:math id="i302" display="inline" alttext="less than 1.5 percent"><mml:mrow><mml:mo>&lt;</mml:mo><mml:mn>1.5</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> at week 12 (from 17.9%–23.5% at baseline). Furthermore, participants who remained on FA for the second phase of the trial sustained their plasma folate concentrations, whereas plasma folate returned to near baseline levels among participants who switched to PBO for the second phase.<sup><xref rid="c17" ref-type="bibr">17</xref></sup></p>
              <sec id="s3.1">
                <title>Treatment Effects on bAs Methylation Indices</title>
                <p>GMs of PMI and SMI at baseline, week 1, and week 12 are provided in Table S1; individual-level data are provided in Excel File 1. Changes in bAs indices between baseline and week 12, ranked by change in PMI and SMI, are shown in Figure S1. The percentage change in the GM of bAs methylation indices between baseline and week 12 are shown in <xref rid="t2" ref-type="table">Table 2</xref>. As early as week 1, the increase in SMI, an indicator of the extent to which the second methylation reaction is completed, was higher in the <inline-formula><mml:math id="i303" display="inline" alttext="creatine plus 400 folic acid"><mml:mrow><mml:mtext>creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mtext>FA</mml:mtext></mml:mrow></mml:math></inline-formula> treatment group than the PBO group: within-person change increased by 6.3% (95% CI: 3.4, 9.3) compared with 2.1% (95% CI: <inline-formula><mml:math id="i304" display="inline" alttext="negative 0.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.8</mml:mn></mml:mrow></mml:math></inline-formula>, 5.2) for PBO (<inline-formula><mml:math id="i305" display="inline" alttext="lowercase italic p equals 0.05"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>).</p>
                <table-wrap position="float" id="t2">
                  <label>Table 2</label>
                  <caption>
                    <p><inline-formula><mml:math id="i306" display="inline" alttext="geometric mean plus or minus geometric standard deviation"><mml:mrow><mml:mtext>GM</mml:mtext><mml:mo>±</mml:mo><mml:mtext>GSD</mml:mtext></mml:mrow></mml:math></inline-formula> at baseline and percentage change in GM (95% CI) at interval (week) of blood arsenic methylation indices and metabolite concentrations from baseline by treatment group.</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="top" span="1"/>
                      <col align="left" valign="top" span="1"/>
                      <col align="left" valign="top" span="1"/>
                      <col align="left" valign="top" span="1"/>
                      <col align="left" valign="top" span="1"/>
                      <col align="left" valign="top" span="1"/>
                      <col align="left" valign="top" span="1"/>
                      <col align="left" valign="top" span="1"/>
                      <col align="left" valign="top" span="1"/>
                      <col align="left" valign="top" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="center" rowspan="2" id="t2c1" scope="col" colspan="1">Arsenic methylation measures by timepoint (week)</th>
                        <th align="center" id="t2c2" scope="col" colspan="1" rowspan="1">PBO</th>
                        <th colspan="2" align="center" id="t2c3" scope="colgroup" rowspan="1">400FA</th>
                        <th colspan="2" align="center" id="t2c4" scope="colgroup" rowspan="1">800FA</th>
                        <th colspan="2" align="center" id="t2c5" scope="colgroup" rowspan="1">Creatine</th>
                        <th colspan="2" align="center" id="t2c6" scope="colgroup" rowspan="1">
                          <inline-formula>
                            <mml:math id="i307" display="inline" alttext="creatine plus 400 folic acid">
                              <mml:mrow>
                                <mml:mtext>Creatine</mml:mtext>
                                <mml:mspace width="0.3em"/>
                                <mml:mo>+</mml:mo>
                                <mml:mspace width="0.3em"/>
                                <mml:mn>400</mml:mn>
                                <mml:mtext>FA</mml:mtext>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </th>
                      </tr>
                      <tr>
                        <th align="center" id="t2c7" scope="col" headers="t2c2" colspan="1" rowspan="1"><inline-formula><mml:math id="i308" display="inline" alttext="geometric mean plus or minus geometric standard deviation"><mml:mrow><mml:mtext>GM</mml:mtext><mml:mo>±</mml:mo><mml:mtext>GSD</mml:mtext></mml:mrow></mml:math></inline-formula> or % change from baseline (95% CI)</th>
                        <th align="center" id="t2c8" scope="col" headers="t2c3" colspan="1" rowspan="1"><inline-formula><mml:math id="i309" display="inline" alttext="geometric mean plus or minus geometric standard deviation"><mml:mrow><mml:mtext>GM</mml:mtext><mml:mo>±</mml:mo><mml:mtext>GSD</mml:mtext></mml:mrow></mml:math></inline-formula> or % change from baseline (95% CI)</th>
                        <th align="center" id="t2c9" scope="col" headers="t2c3" colspan="1" rowspan="1"><inline-formula><mml:math id="i310" display="inline" alttext="lowercase italic p"><mml:mi>p</mml:mi></mml:math></inline-formula>-Value<xref rid="TF9" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></th>
                        <th align="center" id="t2c10" scope="col" headers="t2c4" colspan="1" rowspan="1"><inline-formula><mml:math id="i311" display="inline" alttext="geometric mean plus or minus geometric standard deviation"><mml:mrow><mml:mtext>GM</mml:mtext><mml:mo>±</mml:mo><mml:mtext>GSD</mml:mtext></mml:mrow></mml:math></inline-formula> or % change from baseline (95% CI)</th>
                        <th align="center" id="t2c11" scope="col" headers="t2c4" colspan="1" rowspan="1"><inline-formula><mml:math id="i312" display="inline" alttext="lowercase italic p"><mml:mi>p</mml:mi></mml:math></inline-formula>-Value<xref rid="TF9" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></th>
                        <th align="center" id="t2c12" scope="col" headers="t2c5" colspan="1" rowspan="1"><inline-formula><mml:math id="i313" display="inline" alttext="geometric mean plus or minus geometric standard deviation"><mml:mrow><mml:mtext>GM</mml:mtext><mml:mo>±</mml:mo><mml:mtext>GSD</mml:mtext></mml:mrow></mml:math></inline-formula> or % change from baseline (95% CI)</th>
                        <th align="center" id="t2c13" scope="col" headers="t2c5" colspan="1" rowspan="1"><inline-formula><mml:math id="i312a" display="inline" alttext="lowercase italic p"><mml:mi>p</mml:mi></mml:math></inline-formula>-Value<xref rid="TF9" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></th>
                        <th align="center" id="t2c14" scope="col" headers="t2c6" colspan="1" rowspan="1"><inline-formula><mml:math id="i314" display="inline" alttext="geometric mean plus or minus geometric standard deviation"><mml:mrow><mml:mtext>GM</mml:mtext><mml:mo>±</mml:mo><mml:mtext>GSD</mml:mtext></mml:mrow></mml:math></inline-formula> or % change from baseline (95% CI)</th>
                        <th align="center" id="t2c15" scope="col" headers="t2c6" colspan="1" rowspan="1"><inline-formula><mml:math id="i315" display="inline" alttext="lowercase italic p"><mml:mi>p</mml:mi></mml:math></inline-formula>-Value<xref rid="TF9" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <th colspan="10" align="left" id="t2c16" scope="row" headers="t2c1" rowspan="1">Arsenic methylation indices</th>
                      </tr>
                      <tr>
                        <th colspan="10" align="left" id="t2c17" scope="row" headers="t2c1" rowspan="1"> PMI</th>
                      </tr>
                      <tr>
                        <td align="left" id="t2c18" scope="row" headers="t2c1 t2c17" colspan="1" rowspan="1">  Baseline</td>
                        <td align="char" char="plusmn" headers="t2c2 t2c7 t2c18" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i316" display="inline" alttext="1.61 plus or minus 1.27">
                              <mml:mrow>
                                <mml:mn>1.61</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.27</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="char" char="plusmn" headers="t2c3 t2c8 t2c18" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i317" display="inline" alttext="1.65 plus or minus 1.20">
                              <mml:mrow>
                                <mml:mn>1.65</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.20</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" headers="t2c3 t2c9 t2c18" colspan="1" rowspan="1">—</td>
                        <td align="char" char="plusmn" headers="t2c4 t2c10 t2c18" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i318" display="inline" alttext="1.63 plus or minus 1.20">
                              <mml:mrow>
                                <mml:mn>1.63</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.20</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" headers="t2c4 t2c11 t2c18" colspan="1" rowspan="1">—</td>
                        <td align="char" char="plusmn" headers="t2c5 t2c12 t2c18" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i319" display="inline" alttext="1.63 plus or minus 1.20">
                              <mml:mrow>
                                <mml:mn>1.63</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.20</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" headers="t2c5 t2c13 t2c18" colspan="1" rowspan="1">—</td>
                        <td align="char" char="plusmn" headers="t2c6 t2c14 t2c18" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i320" display="inline" alttext="1.70 plus or minus 1.19">
                              <mml:mrow>
                                <mml:mn>1.70</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.19</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" headers="t2c6 t2c15 t2c18" colspan="1" rowspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" id="t2c19" scope="row" headers="t2c1 t2c17" colspan="1" rowspan="1">  1</td>
                        <td align="char" char="(" headers="t2c2 t2c7 t2c19" colspan="1" rowspan="1"><inline-formula><mml:math id="i321" display="inline" alttext="negative 17.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>17.0</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i322" display="inline" alttext="negative 21.6"><mml:mrow><mml:mo>−</mml:mo><mml:mn>21.6</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i323" display="inline" alttext="negative 12.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>12.0</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="(" headers="t2c3 t2c8 t2c19" colspan="1" rowspan="1"><inline-formula><mml:math id="i324" display="inline" alttext="negative 18.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>18.1</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i325" display="inline" alttext="negative 21.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>21.1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i326" display="inline" alttext="negative 15.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>15.0</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="." headers="t2c3 t2c9 t2c19" colspan="1" rowspan="1">0.69</td>
                        <td align="char" char="(" headers="t2c4 t2c10 t2c19" colspan="1" rowspan="1"><inline-formula><mml:math id="i327" display="inline" alttext="negative 15.3"><mml:mrow><mml:mo>−</mml:mo><mml:mn>15.3</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i328" display="inline" alttext="negative 18.3"><mml:mrow><mml:mo>−</mml:mo><mml:mn>18.3</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i329" display="inline" alttext="negative 12.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>12.1</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="." headers="t2c4 t2c11 t2c19" colspan="1" rowspan="1">0.57</td>
                        <td align="char" char="(" headers="t2c5 t2c12 t2c19" colspan="1" rowspan="1"><inline-formula><mml:math id="i330" display="inline" alttext="negative 18.3"><mml:mrow><mml:mo>−</mml:mo><mml:mn>18.3</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i331" display="inline" alttext="negative 22.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>22.2</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i332" display="inline" alttext="negative 14.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>14.2</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="." headers="t2c5 t2c13 t2c19" colspan="1" rowspan="1">0.66</td>
                        <td align="char" char="(" headers="t2c6 t2c14 t2c19" colspan="1" rowspan="1"><inline-formula><mml:math id="i333" display="inline" alttext="negative 20.4"><mml:mrow><mml:mo>−</mml:mo><mml:mn>20.4</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i334" display="inline" alttext="negative 23.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>23.5</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i335" display="inline" alttext="negative 17.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>17.2</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="." headers="t2c6 t2c15 t2c19" colspan="1" rowspan="1">0.23</td>
                      </tr>
                      <tr>
                        <td align="left" id="t2c20" scope="row" headers="t2c1 t2c17" colspan="1" rowspan="1">  12</td>
                        <td align="char" char="(" headers="t2c2 t2c7 t2c20" colspan="1" rowspan="1"><inline-formula><mml:math id="i336" display="inline" alttext="negative 5.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>5.5</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i337" display="inline" alttext="negative 9.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>9.8</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i338" display="inline" alttext="negative 1.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>1.0</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="(" headers="t2c3 t2c8 t2c20" colspan="1" rowspan="1"><inline-formula><mml:math id="i339" display="inline" alttext="negative 12.6"><mml:mrow><mml:mo>−</mml:mo><mml:mn>12.6</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i340" display="inline" alttext="negative 15.7"><mml:mrow><mml:mo>−</mml:mo><mml:mn>15.7</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i341" display="inline" alttext="negative 9.4"><mml:mrow><mml:mo>−</mml:mo><mml:mn>9.4</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="." headers="t2c3 t2c9 t2c20" colspan="1" rowspan="1">0.01</td>
                        <td align="char" char="(" headers="t2c4 t2c10 t2c20" colspan="1" rowspan="1"><inline-formula><mml:math id="i342" display="inline" alttext="negative 10.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>10.8</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i343" display="inline" alttext="negative 13.9"><mml:mrow><mml:mo>−</mml:mo><mml:mn>13.9</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i344" display="inline" alttext="negative 7.7"><mml:mrow><mml:mo>−</mml:mo><mml:mn>7.7</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="." headers="t2c4 t2c11 t2c20" colspan="1" rowspan="1">0.05</td>
                        <td align="char" char="(" headers="t2c5 t2c12 t2c20" colspan="1" rowspan="1"><inline-formula><mml:math id="i345" display="inline" alttext="negative 9.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>9.8</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i346" display="inline" alttext="negative 14.9"><mml:mrow><mml:mo>−</mml:mo><mml:mn>14.9</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i347" display="inline" alttext="negative 4.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>4.5</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="." headers="t2c5 t2c13 t2c20" colspan="1" rowspan="1">0.22</td>
                        <td align="char" char="(" headers="t2c6 t2c14 t2c20" colspan="1" rowspan="1"><inline-formula><mml:math id="i348" display="inline" alttext="negative 12.7"><mml:mrow><mml:mo>−</mml:mo><mml:mn>12.7</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i349" display="inline" alttext="negative 16.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>16.1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i350" display="inline" alttext="negative 9.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>9.2</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="." headers="t2c6 t2c15 t2c20" colspan="1" rowspan="1">0.01</td>
                      </tr>
                      <tr>
                        <th colspan="10" align="left" id="t2c21" scope="row" headers="t2c1" rowspan="1"> SMI</th>
                      </tr>
                      <tr>
                        <td align="left" id="t2c22" scope="row" headers="t2c1 t2c21" colspan="1" rowspan="1">  Baseline</td>
                        <td align="center" headers="t2c2 t2c7 t2c22" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i351" display="inline" alttext="0.62 plus or minus 1.29">
                              <mml:mrow>
                                <mml:mn>0.62</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.29</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="char" char="plusmn" headers="t2c3 t2c8 t2c22" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i352" display="inline" alttext="0.63 plus or minus 1.29">
                              <mml:mrow>
                                <mml:mn>0.63</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.29</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" headers="t2c3 t2c9 t2c22" colspan="1" rowspan="1">—</td>
                        <td align="char" char="plusmn" headers="t2c4 t2c10 t2c22" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i353" display="inline" alttext="0.65 plus or minus 1.31">
                              <mml:mrow>
                                <mml:mn>0.65</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.31</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" headers="t2c4 t2c11 t2c22" colspan="1" rowspan="1">—</td>
                        <td align="char" char="plusmn" headers="t2c5 t2c12 t2c22" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i354" display="inline" alttext="0.63 plus or minus 1.29">
                              <mml:mrow>
                                <mml:mn>0.63</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.29</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" headers="t2c5 t2c13 t2c22" colspan="1" rowspan="1">—</td>
                        <td align="char" char="plusmn" headers="t2c6 t2c14 t2c22" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i355" display="inline" alttext="0.66 plus or minus 1.30">
                              <mml:mrow>
                                <mml:mn>0.66</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.30</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" headers="t2c6 t2c15 t2c22" colspan="1" rowspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" id="t2c23" scope="row" headers="t2c1 t2c21" colspan="1" rowspan="1">  1</td>
                        <td align="char" char="(" headers="t2c2 t2c7 t2c23" colspan="1" rowspan="1">2.1 (<inline-formula><mml:math id="i356" display="inline" alttext="negative 0.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.8</mml:mn></mml:mrow></mml:math></inline-formula>, 5.2)</td>
                        <td align="char" char="(" headers="t2c3 t2c8 t2c23" colspan="1" rowspan="1">5.4 (2.4, 8.5)</td>
                        <td align="char" char="." headers="t2c3 t2c9 t2c23" colspan="1" rowspan="1">0.12</td>
                        <td align="char" char="(" headers="t2c4 t2c10 t2c23" colspan="1" rowspan="1">3.0 (0.2, 6.3)</td>
                        <td align="char" char="." headers="t2c4 t2c11 t2c23" colspan="1" rowspan="1">0.69</td>
                        <td align="char" char="(" headers="t2c5 t2c12 t2c23" colspan="1" rowspan="1">3.9 (1.4, 6.5)</td>
                        <td align="char" char="." headers="t2c5 t2c13 t2c23" colspan="1" rowspan="1">0.37</td>
                        <td align="char" char="(" headers="t2c6 t2c14 t2c23" colspan="1" rowspan="1">6.3 (3.4, 9.3)</td>
                        <td align="char" char="." headers="t2c6 t2c15 t2c23" colspan="1" rowspan="1">0.05</td>
                      </tr>
                      <tr>
                        <td align="left" id="t2c24" scope="row" headers="t2c1 t2c21" colspan="1" rowspan="1">  12</td>
                        <td align="char" char="(" headers="t2c2 t2c7 t2c24" colspan="1" rowspan="1">2.2 (<inline-formula><mml:math id="i357" display="inline" alttext="negative 1.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>1.5</mml:mn></mml:mrow></mml:math></inline-formula>, 5.9)</td>
                        <td align="char" char="(" headers="t2c3 t2c8 t2c24" colspan="1" rowspan="1">26.3 (22.1, 30.5)</td>
                        <td align="char" char="." headers="t2c3 t2c9 t2c24" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i358" display="inline" alttext="less than 0.001">
                              <mml:mrow>
                                <mml:mo>&lt;</mml:mo>
                                <mml:mn>0.001</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="char" char="(" headers="t2c4 t2c10 t2c24" colspan="1" rowspan="1">23.8 (19.7, 27.9)</td>
                        <td align="char" char="." headers="t2c4 t2c11 t2c24" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i359" display="inline" alttext="less than 0.001">
                              <mml:mrow>
                                <mml:mo>&lt;</mml:mo>
                                <mml:mn>0.001</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="char" char="(" headers="t2c5 t2c12 t2c24" colspan="1" rowspan="1">8.9 (4.7, 13.2)</td>
                        <td align="char" char="." headers="t2c5 t2c13 t2c24" colspan="1" rowspan="1">0.02</td>
                        <td align="char" char="(" headers="t2c6 t2c14 t2c24" colspan="1" rowspan="1">17.9 (14.3, 21.6)</td>
                        <td align="char" char="." headers="t2c6 t2c15 t2c24" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i360" display="inline" alttext="less than 0.001">
                              <mml:mrow>
                                <mml:mo>&lt;</mml:mo>
                                <mml:mn>0.001</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                      </tr>
                      <tr>
                        <th colspan="10" align="left" id="t2c25" scope="row" headers="t2c1" rowspan="1">Arsenic metabolites (<inline-formula><mml:math id="i361" display="inline" alttext="micrograms per liter"><mml:mrow><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula>)</th>
                      </tr>
                      <tr>
                        <th colspan="10" align="left" id="t2c26" scope="row" headers="t2c1" rowspan="1"> InAs</th>
                      </tr>
                      <tr>
                        <td align="left" id="t2c27" scope="row" headers="t2c1 t2c26" colspan="1" rowspan="1">  Baseline</td>
                        <td align="char" char="plusmn" headers="t2c2 t2c7 t2c27" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i362" display="inline" alttext="2.20 plus or minus 1.75">
                              <mml:mrow>
                                <mml:mn>2.20</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.75</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="char" char="plusmn" headers="t2c3 t2c8 t2c27" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i363" display="inline" alttext="2.22 plus or minus 1.79">
                              <mml:mrow>
                                <mml:mn>2.22</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.79</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" headers="t2c3 t2c9 t2c27" colspan="1" rowspan="1">—</td>
                        <td align="char" char="plusmn" headers="t2c4 t2c10 t2c27" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i364" display="inline" alttext="2.25 plus or minus 1.65">
                              <mml:mrow>
                                <mml:mn>2.25</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.65</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" headers="t2c4 t2c11 t2c27" colspan="1" rowspan="1">—</td>
                        <td align="char" char="plusmn" headers="t2c5 t2c12 t2c27" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i365" display="inline" alttext="2.24 plus or minus 1.85">
                              <mml:mrow>
                                <mml:mn>2.24</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.85</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" headers="t2c5 t2c13 t2c27" colspan="1" rowspan="1">—</td>
                        <td align="char" char="plusmn" headers="t2c6 t2c14 t2c27" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i366" display="inline" alttext="2.27 plus or minus 1.65">
                              <mml:mrow>
                                <mml:mn>2.27</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.65</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" headers="t2c6 t2c15 t2c27" colspan="1" rowspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" id="t2c28" scope="row" headers="t2c1 t2c26" colspan="1" rowspan="1">  1</td>
                        <td align="char" char="(" headers="t2c2 t2c7 t2c28" colspan="1" rowspan="1">13.5 (9.7, 17.5)</td>
                        <td align="char" char="(" headers="t2c3 t2c8 t2c28" colspan="1" rowspan="1">13.7 (10.9, 16.5)</td>
                        <td align="char" char="." headers="t2c3 t2c9 t2c28" colspan="1" rowspan="1">0.96</td>
                        <td align="char" char="(" headers="t2c4 t2c10 t2c28" colspan="1" rowspan="1">11.6 (8.9, 14.4)</td>
                        <td align="char" char="." headers="t2c4 t2c11 t2c28" colspan="1" rowspan="1">0.42</td>
                        <td align="char" char="(" headers="t2c5 t2c12 t2c28" colspan="1" rowspan="1">14.3 (10.5, 18.1)</td>
                        <td align="char" char="." headers="t2c5 t2c13 t2c28" colspan="1" rowspan="1">0.80</td>
                        <td align="char" char="(" headers="t2c6 t2c14 t2c28" colspan="1" rowspan="1">15.9 (12.7, 19.1)</td>
                        <td align="char" char="." headers="t2c6 t2c15 t2c28" colspan="1" rowspan="1">0.36</td>
                      </tr>
                      <tr>
                        <td align="left" id="t2c29" scope="row" headers="t2c1 t2c26" colspan="1" rowspan="1">  12</td>
                        <td align="char" char="(" headers="t2c2 t2c7 t2c29" colspan="1" rowspan="1">4.0 (0.9, 7.2)</td>
                        <td align="char" char="(" headers="t2c3 t2c8 t2c29" colspan="1" rowspan="1">2.9 (0.5, 5.5)</td>
                        <td align="char" char="." headers="t2c3 t2c9 t2c29" colspan="1" rowspan="1">0.61</td>
                        <td align="char" char="(" headers="t2c4 t2c10 t2c29" colspan="1" rowspan="1">2.1 (0.3, 4.6)</td>
                        <td align="char" char="." headers="t2c4 t2c11 t2c29" colspan="1" rowspan="1">0.36</td>
                        <td align="char" char="(" headers="t2c5 t2c12 t2c29" colspan="1" rowspan="1">4.8 (1.5, 8.3)</td>
                        <td align="char" char="." headers="t2c5 t2c13 t2c29" colspan="1" rowspan="1">0.73</td>
                        <td align="char" char="(" headers="t2c6 t2c14 t2c29" colspan="1" rowspan="1">5.4 (2.6, 8.3)</td>
                        <td align="char" char="." headers="t2c6 t2c15 t2c29" colspan="1" rowspan="1">0.51</td>
                      </tr>
                      <tr>
                        <th colspan="10" align="left" id="t2c30" scope="row" headers="t2c1" rowspan="1"> MMAs</th>
                      </tr>
                      <tr>
                        <td align="left" id="t2c31" scope="row" headers="t2c1 t2c30" colspan="1" rowspan="1">  Baseline</td>
                        <td align="char" char="plusmn" headers="t2c2 t2c7 t2c31" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i367" display="inline" alttext="3.55 plus or minus 1.89">
                              <mml:mrow>
                                <mml:mn>3.55</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.89</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="char" char="plusmn" headers="t2c3 t2c8 t2c31" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i368" display="inline" alttext="3.67 plus or minus 1.97">
                              <mml:mrow>
                                <mml:mn>3.67</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.97</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" headers="t2c3 t2c9 t2c31" colspan="1" rowspan="1">—</td>
                        <td align="char" char="plusmn" headers="t2c4 t2c10 t2c31" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i369" display="inline" alttext="3.67 plus or minus 1.82">
                              <mml:mrow>
                                <mml:mn>3.67</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.82</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" headers="t2c4 t2c11 t2c31" colspan="1" rowspan="1">—</td>
                        <td align="char" char="plusmn" headers="t2c5 t2c12 t2c31" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i370" display="inline" alttext="3.64 plus or minus 1.93">
                              <mml:mrow>
                                <mml:mn>3.64</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.93</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" headers="t2c5 t2c13 t2c31" colspan="1" rowspan="1">—</td>
                        <td align="char" char="plusmn" headers="t2c6 t2c14 t2c31" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i371" display="inline" alttext="3.85 plus or minus 1.73">
                              <mml:mrow>
                                <mml:mn>3.85</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.73</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" headers="t2c6 t2c15 t2c31" colspan="1" rowspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" id="t2c32" scope="row" headers="t2c1 t2c30" colspan="1" rowspan="1">  1</td>
                        <td align="char" char="(" headers="t2c2 t2c7 t2c32" colspan="1" rowspan="1"><inline-formula><mml:math id="i372" display="inline" alttext="negative 6.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>6.1</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i373" display="inline" alttext="negative 8.4"><mml:mrow><mml:mo>−</mml:mo><mml:mn>8.4</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i374" display="inline" alttext="negative 3.7"><mml:mrow><mml:mo>−</mml:mo><mml:mn>3.7</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="(" headers="t2c3 t2c8 t2c32" colspan="1" rowspan="1"><inline-formula><mml:math id="i375" display="inline" alttext="negative 7.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>7.2</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i376" display="inline" alttext="negative 8.7"><mml:mrow><mml:mo>−</mml:mo><mml:mn>8.7</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i377" display="inline" alttext="negative 5.7"><mml:mrow><mml:mo>−</mml:mo><mml:mn>5.7</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="." headers="t2c3 t2c9 t2c32" colspan="1" rowspan="1">0.42</td>
                        <td align="char" char="(" headers="t2c4 t2c10 t2c32" colspan="1" rowspan="1"><inline-formula><mml:math id="i378" display="inline" alttext="negative 5.9"><mml:mrow><mml:mo>−</mml:mo><mml:mn>5.9</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i379" display="inline" alttext="negative 7.4"><mml:mrow><mml:mo>−</mml:mo><mml:mn>7.4</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i380" display="inline" alttext="negative 4.4"><mml:mrow><mml:mo>−</mml:mo><mml:mn>4.4</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="." headers="t2c4 t2c11 t2c32" colspan="1" rowspan="1">0.92</td>
                        <td align="char" char="(" headers="t2c5 t2c12 t2c32" colspan="1" rowspan="1"><inline-formula><mml:math id="i381" display="inline" alttext="negative 7.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>7.2</mml:mn></mml:mrow></mml:math></inline-formula> (8.8, 5.5)</td>
                        <td align="char" char="." headers="t2c5 t2c13 t2c32" colspan="1" rowspan="1">0.45</td>
                        <td align="char" char="(" headers="t2c6 t2c14 t2c32" colspan="1" rowspan="1"><inline-formula><mml:math id="i382" display="inline" alttext="negative 8.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>8.2</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i383" display="inline" alttext="negative 9.6"><mml:mrow><mml:mo>−</mml:mo><mml:mn>9.6</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i384" display="inline" alttext="negative 6.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>6.8</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="." headers="t2c6 t2c15 t2c32" colspan="1" rowspan="1">0.11</td>
                      </tr>
                      <tr>
                        <td align="left" id="t2c33" scope="row" headers="t2c1 t2c30" colspan="1" rowspan="1">  12</td>
                        <td align="char" char="(" headers="t2c2 t2c7 t2c33" colspan="1" rowspan="1"><inline-formula><mml:math id="i385" display="inline" alttext="negative 2.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>2.0</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i386" display="inline" alttext="negative 4.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>4.0</mml:mn></mml:mrow></mml:math></inline-formula>, 0.0)</td>
                        <td align="char" char="(" headers="t2c3 t2c8 t2c33" colspan="1" rowspan="1"><inline-formula><mml:math id="i387" display="inline" alttext="negative 10.3"><mml:mrow><mml:mo>−</mml:mo><mml:mn>10.3</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i388" display="inline" alttext="negative 11.9"><mml:mrow><mml:mo>−</mml:mo><mml:mn>11.9</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i389" display="inline" alttext="negative 8.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>8.8</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="." headers="t2c3 t2c9 t2c33" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i390" display="inline" alttext="less than 0.001">
                              <mml:mrow>
                                <mml:mo>&lt;</mml:mo>
                                <mml:mn>0.001</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="char" char="(" headers="t2c4 t2c10 t2c33" colspan="1" rowspan="1"><inline-formula><mml:math id="i391" display="inline" alttext="negative 9.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>9.5</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i392" display="inline" alttext="negative 11.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>11.1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i393" display="inline" alttext="negative 8.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>8.0</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="." headers="t2c4 t2c11 t2c33" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i394" display="inline" alttext="less than 0.001">
                              <mml:mrow>
                                <mml:mo>&lt;</mml:mo>
                                <mml:mn>0.001</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="char" char="(" headers="t2c5 t2c12 t2c33" colspan="1" rowspan="1"><inline-formula><mml:math id="i395" display="inline" alttext="negative 5.9"><mml:mrow><mml:mo>−</mml:mo><mml:mn>5.9</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i396" display="inline" alttext="negative 8.6"><mml:mrow><mml:mo>−</mml:mo><mml:mn>8.6</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i397" display="inline" alttext="negative 3.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>3.0</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="." headers="t2c5 t2c13 t2c33" colspan="1" rowspan="1">0.03</td>
                        <td align="char" char="(" headers="t2c6 t2c14 t2c33" colspan="1" rowspan="1"><inline-formula><mml:math id="i398" display="inline" alttext="negative 8.4"><mml:mrow><mml:mo>−</mml:mo><mml:mn>8.4</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i399" display="inline" alttext="negative 10.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>10.0</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i400" display="inline" alttext="negative 6.9"><mml:mrow><mml:mo>−</mml:mo><mml:mn>6.9</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="." headers="t2c6 t2c15 t2c33" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i401" display="inline" alttext="less than 0.001">
                              <mml:mrow>
                                <mml:mo>&lt;</mml:mo>
                                <mml:mn>0.001</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                      </tr>
                      <tr>
                        <th colspan="10" align="left" id="t2c34" scope="row" headers="t2c1" rowspan="1"> DMAs</th>
                      </tr>
                      <tr>
                        <td align="left" id="t2c35" scope="row" headers="t2c1 t2c34" colspan="1" rowspan="1">  Baseline</td>
                        <td align="char" char="plusmn" headers="t2c2 t2c7 t2c35" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i402" display="inline" alttext="2.19 plus or minus 1.83">
                              <mml:mrow>
                                <mml:mn>2.19</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.83</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="char" char="plusmn" headers="t2c3 t2c8 t2c35" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i403" display="inline" alttext="2.30 plus or minus 1.93">
                              <mml:mrow>
                                <mml:mn>2.30</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.93</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" headers="t2c3 t2c9 t2c35" colspan="1" rowspan="1">—</td>
                        <td align="char" char="plusmn" headers="t2c4 t2c10 t2c35" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i404" display="inline" alttext="2.38 plus or minus 1.75">
                              <mml:mrow>
                                <mml:mn>2.38</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.75</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" headers="t2c4 t2c11 t2c35" colspan="1" rowspan="1">—</td>
                        <td align="char" char="plusmn" headers="t2c5 t2c12 t2c35" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i405" display="inline" alttext="2.29 plus or minus 1.83">
                              <mml:mrow>
                                <mml:mn>2.29</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.83</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" headers="t2c5 t2c13 t2c35" colspan="1" rowspan="1">—</td>
                        <td align="char" char="plusmn" headers="t2c6 t2c14 t2c35" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i406" display="inline" alttext="2.56 plus or minus 1.73">
                              <mml:mrow>
                                <mml:mn>2.56</mml:mn>
                                <mml:mo>±</mml:mo>
                                <mml:mn>1.73</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" headers="t2c6 t2c15 t2c35" colspan="1" rowspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" id="t2c36" scope="row" headers="t2c1 t2c34" colspan="1" rowspan="1">  1</td>
                        <td align="char" char="(" headers="t2c2 t2c7 t2c36" colspan="1" rowspan="1"><inline-formula><mml:math id="i407" display="inline" alttext="negative 4.4"><mml:mrow><mml:mo>−</mml:mo><mml:mn>4.4</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i408" display="inline" alttext="negative 6.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>6.5</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i409" display="inline" alttext="negative 2.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>2.2</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="(" headers="t2c3 t2c8 t2c36" colspan="1" rowspan="1"><inline-formula><mml:math id="i410" display="inline" alttext="negative 2.4"><mml:mrow><mml:mo>−</mml:mo><mml:mn>2.4</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i411" display="inline" alttext="negative 4.4"><mml:mrow><mml:mo>−</mml:mo><mml:mn>4.4</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i412" display="inline" alttext="negative 0.4"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.4</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="." headers="t2c3 t2c9 t2c36" colspan="1" rowspan="1">0.20</td>
                        <td align="char" char="(" headers="t2c4 t2c10 t2c36" colspan="1" rowspan="1"><inline-formula><mml:math id="i413" display="inline" alttext="negative 3.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>3.5</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i414" display="inline" alttext="negative 5.7"><mml:mrow><mml:mo>−</mml:mo><mml:mn>5.7</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i415" display="inline" alttext="negative 1.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>1.2</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="." headers="t2c4 t2c11 t2c36" colspan="1" rowspan="1">0.57</td>
                        <td align="char" char="(" headers="t2c5 t2c12 t2c36" colspan="1" rowspan="1"><inline-formula><mml:math id="i416" display="inline" alttext="negative 3.9"><mml:mrow><mml:mo>−</mml:mo><mml:mn>3.9</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i417" display="inline" alttext="negative 5.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>5.8</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i418" display="inline" alttext="negative 1.9"><mml:mrow><mml:mo>−</mml:mo><mml:mn>1.9</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="." headers="t2c5 t2c13 t2c36" colspan="1" rowspan="1">0.74</td>
                        <td align="char" char="(" headers="t2c6 t2c14 t2c36" colspan="1" rowspan="1"><inline-formula><mml:math id="i419" display="inline" alttext="negative 2.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>2.8</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i420" display="inline" alttext="negative 4.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>4.8</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i421" display="inline" alttext="negative 0.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.8</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="." headers="t2c6 t2c15 t2c36" colspan="1" rowspan="1">0.30</td>
                      </tr>
                      <tr>
                        <td align="left" id="t2c37" scope="row" headers="t2c1 t2c34" colspan="1" rowspan="1">  12</td>
                        <td align="char" char="(" headers="t2c2 t2c7 t2c37" colspan="1" rowspan="1"><inline-formula><mml:math id="i422" display="inline" alttext="negative 0.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i423" display="inline" alttext="negative 2.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>2.8</mml:mn></mml:mrow></mml:math></inline-formula>, 2.6)</td>
                        <td align="char" char="(" headers="t2c3 t2c8 t2c37" colspan="1" rowspan="1">12.8 (10.5, 15.2)</td>
                        <td align="char" char="." headers="t2c3 t2c9 t2c37" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i424" display="inline" alttext="less than 0.001">
                              <mml:mrow>
                                <mml:mo>&lt;</mml:mo>
                                <mml:mn>0.001</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="char" char="(" headers="t2c4 t2c10 t2c37" colspan="1" rowspan="1">11.3 (8.9, 13.8)</td>
                        <td align="char" char="." headers="t2c4 t2c11 t2c37" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i425" display="inline" alttext="less than 0.001">
                              <mml:mrow>
                                <mml:mo>&lt;</mml:mo>
                                <mml:mn>0.001</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="char" char="(" headers="t2c5 t2c12 t2c37" colspan="1" rowspan="1">2.2 (0.5, 5.0)</td>
                        <td align="char" char="." headers="t2c5 t2c13 t2c37" colspan="1" rowspan="1">0.23</td>
                        <td align="char" char="(" headers="t2c6 t2c14 t2c37" colspan="1" rowspan="1">7.5 (5.2, 9.7)</td>
                        <td align="char" char="." headers="t2c6 t2c15 t2c37" colspan="1" rowspan="1">
                          <inline-formula>
                            <mml:math id="i426" display="inline" alttext="less than 0.001">
                              <mml:mrow>
                                <mml:mo>&lt;</mml:mo>
                                <mml:mn>0.001</mml:mn>
                              </mml:mrow>
                            </mml:math>
                          </inline-formula>
                        </td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="TF8">
                      <p>Note: Percentage change was estimated using linear models. GMs for each time point are included in Table S1; individual-level data are included in Excel File 1. —, not applicable; %, percentage; 400FA, <inline-formula><mml:math id="i427" display="inline" alttext="400 micrograms"><mml:mrow><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA/d; 800FA, <inline-formula><mml:math id="i428" display="inline" alttext="800 micrograms"><mml:mrow><mml:mn>800</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA/d; CI, confidence interval; creatine, <inline-formula><mml:math id="i429" display="inline" alttext="3 grams"><mml:mrow><mml:mn>3</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> creatine/d; <inline-formula><mml:math id="i430" display="inline" alttext="creatine plus 400 folic acid"><mml:mrow><mml:mtext>creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mtext>FA</mml:mtext></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i431" display="inline" alttext="3 grams"><mml:mrow><mml:mn>3</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> creatine and <inline-formula><mml:math id="i432" display="inline" alttext="400 micrograms"><mml:mrow><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA/d; DMAs, dimethyl-arsenical species; FA, folic acid; GM, geometric mean; GSD, geometric standard deviation; InAs, inorganic arsenic; MMAs, monomethyl-arsenical species; PBO, placebo; PMI, primary methylation index; SMI, secondary methylation index.</p>
                    </fn>
                    <fn id="TF9">
                      <label>
                        <sup>
                          <italic toggle="yes">a</italic>
                        </sup>
                      </label>
                      <p><inline-formula><mml:math id="i433" display="inline" alttext="lowercase italic p"><mml:mi>p</mml:mi></mml:math></inline-formula>-Values were derived from Wald test on coefficients of group-by-time interaction terms in the linear models with repeated measures for differences in changes from baseline between each treatment and PBO group.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>At week 1, the increase in SMI from baseline was greater among participants in the 400FA, 800FA, and creatine treatment arms, with respective within-person changes of 5.4% (95% CI: 2.4, 8.5), 3.0% (95% CI: 0.2, 6.3), and 3.9% (95% CI: 1.4, 6.5) compared with PBO, but it did not reach statistical significance (<inline-formula><mml:math id="i434" display="inline" alttext="lowercase italic p equals 0.12"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.12</mml:mn></mml:mrow></mml:math></inline-formula>, 0.69, and 0.37, respectively). For PMI, in the 400FA, creatine, and <inline-formula><mml:math id="i435" display="inline" alttext="creatine plus 400 folic acid"><mml:mrow><mml:mtext>creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mtext>FA</mml:mtext></mml:mrow></mml:math></inline-formula> treatment groups, the <inline-formula><mml:math id="i436" display="inline" alttext="negative 18.1 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>18.1</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i437" display="inline" alttext="negative 21.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>21.1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i438" display="inline" alttext="negative 15.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>15.0</mml:mn></mml:mrow></mml:math></inline-formula>), <inline-formula><mml:math id="i439" display="inline" alttext="negative 18.3 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>18.3</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i440" display="inline" alttext="negative 22.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>22.2</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i441" display="inline" alttext="negative 14.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>14.2</mml:mn></mml:mrow></mml:math></inline-formula>), and <inline-formula><mml:math id="i442" display="inline" alttext="negative 20.4 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>20.4</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i443" display="inline" alttext="negative 23.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>23.5</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i444" display="inline" alttext="negative 17.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>17.2</mml:mn></mml:mrow></mml:math></inline-formula>) decreases at week 1, respectively, were greater than the <inline-formula><mml:math id="i445" display="inline" alttext="negative 17.0 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>17.0</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i446" display="inline" alttext="negative 21.6"><mml:mrow><mml:mo>−</mml:mo><mml:mn>21.6</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i447" display="inline" alttext="negative 12.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>12.0</mml:mn></mml:mrow></mml:math></inline-formula>) decrease in PBO but did not reach statistical significance (<inline-formula><mml:math id="i448" display="inline" alttext="lowercase italic p equals 0.69"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.69</mml:mn></mml:mrow></mml:math></inline-formula>, 0.66, and 0.23, respectively). In the 800FA group, the decrease in PMI of <inline-formula><mml:math id="i449" display="inline" alttext="negative 15.3 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>15.3</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i450" display="inline" alttext="negative 18.3"><mml:mrow><mml:mo>−</mml:mo><mml:mn>18.3</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i451" display="inline" alttext="negative 12.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>12.1</mml:mn></mml:mrow></mml:math></inline-formula>) was less than that of PBO, although it did not reach statistical significance (<inline-formula><mml:math id="i452" display="inline" alttext="lowercase italic p equals 0.57"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.57</mml:mn></mml:mrow></mml:math></inline-formula>).</p>
                <p>At week 12, the mean within-person decreases from baseline in PMI among participants in the 400FA, 800FA, and <inline-formula><mml:math id="i453" display="inline" alttext="creatine plus folic acid"><mml:mrow><mml:mtext>creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mtext>FA</mml:mtext></mml:mrow></mml:math></inline-formula> treatment groups were <inline-formula><mml:math id="i454" display="inline" alttext="negative 12.6 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>12.6</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i455" display="inline" alttext="negative 15.7"><mml:mrow><mml:mo>−</mml:mo><mml:mn>15.7</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i456" display="inline" alttext="negative 9.4"><mml:mrow><mml:mo>−</mml:mo><mml:mn>9.4</mml:mn></mml:mrow></mml:math></inline-formula>), <inline-formula><mml:math id="i457" display="inline" alttext="negative 10.8 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>10.8</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i458" display="inline" alttext="negative 13.9"><mml:mrow><mml:mo>−</mml:mo><mml:mn>13.9</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i459" display="inline" alttext="negative 7.7"><mml:mrow><mml:mo>−</mml:mo><mml:mn>7.7</mml:mn></mml:mrow></mml:math></inline-formula>), and <inline-formula><mml:math id="i460" display="inline" alttext="negative 12.7 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>12.7</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i461" display="inline" alttext="negative 16.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>16.1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i462" display="inline" alttext="negative 9.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>9.2</mml:mn></mml:mrow></mml:math></inline-formula>), respectively; these were all significantly greater than the <inline-formula><mml:math id="i463" display="inline" alttext="negative 5.5 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>5.5</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i464" display="inline" alttext="negative 9.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>9.8</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i465" display="inline" alttext="negative 1.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>1.0</mml:mn></mml:mrow></mml:math></inline-formula>) decrease in the PBO group. Among participants in the creatine group, the mean within-person decrease in PMI of <inline-formula><mml:math id="i466" display="inline" alttext="negative 9.8 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>9.8</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i467" display="inline" alttext="negative 14.9"><mml:mrow><mml:mo>−</mml:mo><mml:mn>14.9</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i468" display="inline" alttext="negative 4.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>4.5</mml:mn></mml:mrow></mml:math></inline-formula>) was larger than the PBO group, but this did not reach statistical significance (<inline-formula><mml:math id="i469" display="inline" alttext="lowercase italic p equals 0.22"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.22</mml:mn></mml:mrow></mml:math></inline-formula>). In addition, among all treatment groups, the mean percentage changes in SMI at week 12 were significantly greater (<inline-formula><mml:math id="i470" display="inline" alttext="lowercase italic p less than 0.05"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>) than the 2.2% (95% CI: <inline-formula><mml:math id="i471" display="inline" alttext="negative 1.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>1.5</mml:mn></mml:mrow></mml:math></inline-formula>, 5.9) increase in the PBO group: 400FA: 26.3% (95% CI: 22.1, 30.5), 800FA: 23.8% (95% CI: 19.7, 27.9), creatine: 8.9% (95% CI: 4.7, 13.2), and <inline-formula><mml:math id="i472" display="inline" alttext="creatine plus 400 folic acid"><mml:mrow><mml:mtext>creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mtext>FA</mml:mtext></mml:mrow></mml:math></inline-formula>: 17.9% (95% CI: 14.3, 21.6).</p>
              </sec>
              <sec id="s3.2">
                <title>Treatment Effects on bAs Metabolite Concentrations</title>
                <p>GMs of bInAs, bMMAs, and bDMAs concentrations at baseline, week 1, and week 12 are provided in Table S1; individual-level data are provided in Excel File 1. The changes in participants’ bAs metabolite concentrations between baseline and week 12 by treatment group are shown in <xref rid="f3" ref-type="fig">Figure 3</xref>. Decreases in bAs metabolite concentrations between baseline and week 12 were observed across treatment groups, likely due to water filter use.<sup><xref rid="c22" ref-type="bibr">22</xref></sup> However, <xref rid="f3" ref-type="fig">Figure 3</xref> illustrates that all treatment groups who received FA showed an overall trend toward a decrease in InAs and MMAs concentrations between baseline and week 12 (i.e., a greater proportion of participants falling below the <italic toggle="yes">y</italic>-axis, representing a decrease in concentrations).</p>
                <fig position="float" id="f3">
                  <label>Figure 3.</label>
                  <caption>
                    <p>Change in participants’ blood arsenic metabolite concentrations between baseline and 12 wk by treatment group. The <italic toggle="yes">x</italic>-axes are ranked by participants with the largest decreases to the largest increases in blood arsenic metabolite concentrations. The PBO, <inline-formula><mml:math id="i473" display="inline" alttext="400 micrograms"><mml:mrow><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> of FA/d (400FA), <inline-formula><mml:math id="i474" display="inline" alttext="800 micrograms"><mml:mrow><mml:mn>800</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> of FA/d (800FA), <inline-formula><mml:math id="i475" display="inline" alttext="3 grams"><mml:mrow><mml:mn>3</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> creatine (creatine), and <inline-formula><mml:math id="i476" display="inline" alttext="3 grams creatine plus 400 micrograms of folic acid per day"><mml:mrow><mml:mn>3</mml:mn><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">g</mml:mi><mml:mtext> creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mtext> of FA</mml:mtext><mml:mo>/</mml:mo><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i477" display="inline" alttext="creatine plus 400 folic acid"><mml:mrow><mml:mtext>creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mtext>FA</mml:mtext></mml:mrow></mml:math></inline-formula>) are shown in brown, green, blue, orange, and purple, respectively. Individual-level blood arsenic metabolite concentration data are included in Excel File 1. Note: DMAs, dimethyl-arsenical species; FA, folic acid; InAs, inorganic arsenic; MMAs, monomethyl-arsenical species; PBO, placebo.</p>
                  </caption>
                  <alt-text>Figure 3 is a set of graphs plotting the change in the concentrations (micrograms per liter) of inorganic arsenic (panel A), monomethyl-arsenicals (panel B), and dimethyl-arsenicals (panel C) across treatment groups. The treatment groups are shown in the columns labeled: Placebo, 400 folic acid, 800 folic acid, creatine, and creatine plus 400 folic acid. Each plot shows the change in arsenic species concentrations between baseline and 12 weeks, ranging from negative 15 to 5 in increments of 5 (y-axis) across the rank of change in concentration (x-axis).</alt-text>
                  <graphic xlink:href="ehp11270_f3" position="float"/>
                </fig>
                <p>The percentage change in the GM of bAs metabolite concentrations over time in phase 1 are shown in <xref rid="t2" ref-type="table">Table 2</xref>. At week 1, compared with baseline, bMMAs decreased across all treatment groups, although these changes were not significantly different than that of the PBO group (<inline-formula><mml:math id="i478" display="inline" alttext="lowercase italic p greater than 0.05"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>). At week 12, the decreases in bMMAs were significantly greater (<inline-formula><mml:math id="i479" display="inline" alttext="lowercase italic p less than 0.05"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>) for all treatment groups receiving FA as compared with PBO: the mean within-person decrease was <inline-formula><mml:math id="i480" display="inline" alttext="negative 2.0 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>2.0</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i481" display="inline" alttext="negative 4.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>4.0</mml:mn></mml:mrow></mml:math></inline-formula>, 0.0) in the PBO group, vs. <inline-formula><mml:math id="i482" display="inline" alttext="negative 10.3 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>10.3</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i483" display="inline" alttext="negative 11.9"><mml:mrow><mml:mo>−</mml:mo><mml:mn>11.9</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i484" display="inline" alttext="negative 8.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>8.8</mml:mn></mml:mrow></mml:math></inline-formula>), <inline-formula><mml:math id="i485" display="inline" alttext="negative 9.5 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>9.5</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i486" display="inline" alttext="negative 11.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>11.1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i487" display="inline" alttext="negative 8.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>8.0</mml:mn></mml:mrow></mml:math></inline-formula>), and <inline-formula><mml:math id="i488" display="inline" alttext="negative 8.4 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>8.4</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i489" display="inline" alttext="negative 10.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>10.0</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i490" display="inline" alttext="negative 6.9"><mml:mrow><mml:mo>−</mml:mo><mml:mn>6.9</mml:mn></mml:mrow></mml:math></inline-formula>) for the 400FA, 800FA, and <inline-formula><mml:math id="i491" display="inline" alttext="creatine plus 400 folic acid"><mml:mrow><mml:mtext>creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mtext>FA</mml:mtext></mml:mrow></mml:math></inline-formula> groups, respectively. The mean within-person decrease in bMMAs in the 800FA group (<inline-formula><mml:math id="i492" display="inline" alttext="negative 9.5 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>9.5</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula>) was not significantly different from the decrease in the 400FA group (<inline-formula><mml:math id="i493" display="inline" alttext="negative 10.3 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>10.3</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula>) (Wald test <inline-formula><mml:math id="i494" display="inline" alttext="lowercase italic p greater than 0.05"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>), suggesting that there was not a dose–response effect of FA on bMMAs. The mean within-person change in bDMAs concentrations from baseline to week 12 was 12.8% (95% CI: 10.5, 15.2) for the 400FA group and 11.3% (95% CI: 8.9, 13.8) for the 800FA group vs. <inline-formula><mml:math id="i495" display="inline" alttext="negative 0.1 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.1</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i496" display="inline" alttext="negative 2.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>2.8</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i497" display="inline" alttext="negative 2.6"><mml:mrow><mml:mo>−</mml:mo><mml:mn>2.6</mml:mn></mml:mrow></mml:math></inline-formula>) for the PBO group (<inline-formula><mml:math id="i498" display="inline" alttext="lowercase italic p less than 0.001"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.001</mml:mn></mml:mrow></mml:math></inline-formula>). The changes in bInAs concentrations from baseline to weeks 1 and 12 in the FA and creatine treatment groups were not significantly different from changes in the PBO group (<inline-formula><mml:math id="i499" display="inline" alttext="lowercase italic p greater than 0.05"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>).</p>
                <p>Overall, models stratified by sex were consistent with the unstratified models. Results from sex-stratified linear models are presented in Tables S2 and S3; GMs of bAs methylation indices and metabolite concentrations are provided in Tables S4 and S5. There appear to be sex-specific changes in bAs indices and concentrations that were significantly different (<inline-formula><mml:math id="i500" display="inline" alttext="lowercase italic p less than 0.05"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>) in the creatine group compared with PBO among male participants that were not significant (<inline-formula><mml:math id="i501" display="inline" alttext="lowercase italic p greater than 0.05"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>) among female participants. This was reflected in decreases in bMMAs and increases in SMI in the creatine arm that were significantly different from PBO in male participants [creatine vs. PBO: bMMAs: <inline-formula><mml:math id="i502" display="inline" alttext="negative 6.6 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>6.6</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i503" display="inline" alttext="negative 9.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>9.5</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i504" display="inline" alttext="negative 3.7"><mml:mrow><mml:mo>−</mml:mo><mml:mn>3.7</mml:mn></mml:mrow></mml:math></inline-formula>) vs. <inline-formula><mml:math id="i505" display="inline" alttext="negative 2.7 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>2.7</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i506" display="inline" alttext="negative 4.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>4.8</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i507" display="inline" alttext="negative 0.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:math></inline-formula>), <inline-formula><mml:math id="i508" display="inline" alttext="lowercase italic p equals 0.03"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.03</mml:mn></mml:mrow></mml:math></inline-formula>; SMI: 12.3% (95% CI: 6.1, 18.8) vs. 3.1% (95% CI: <inline-formula><mml:math id="i509" display="inline" alttext="negative 0.9"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.9</mml:mn></mml:mrow></mml:math></inline-formula>, 7.3), <inline-formula><mml:math id="i510" display="inline" alttext="lowercase italic p equals 0.02"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.02</mml:mn></mml:mrow></mml:math></inline-formula>], but not female participants [bMMAs: <inline-formula><mml:math id="i511" display="inline" alttext="negative 5.0 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>5.0</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i512" display="inline" alttext="negative 9.6"><mml:mrow><mml:mo>−</mml:mo><mml:mn>9.6</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i513" display="inline" alttext="negative 0.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.2</mml:mn></mml:mrow></mml:math></inline-formula>) vs. <inline-formula><mml:math id="i514" display="inline" alttext="negative 1.4 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>1.4</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i515" display="inline" alttext="negative 4.7"><mml:mrow><mml:mo>−</mml:mo><mml:mn>4.7</mml:mn></mml:mrow></mml:math></inline-formula>, 2.1), <inline-formula><mml:math id="i516" display="inline" alttext="lowercase italic p equals 0.31"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.31</mml:mn></mml:mrow></mml:math></inline-formula>; SMI: 5.4% (95% CI: 0.2, 10.9) vs. 1.3% (95% CI: <inline-formula><mml:math id="i517" display="inline" alttext="negative 4.7"><mml:mrow><mml:mo>−</mml:mo><mml:mn>4.7</mml:mn></mml:mrow></mml:math></inline-formula>, 7.6), <inline-formula><mml:math id="i518" display="inline" alttext="lowercase italic p equals 0.21"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.21</mml:mn></mml:mrow></mml:math></inline-formula>]. However, effect modification of creatine treatment by sex was not statistically significant as measured by the inclusion of a group-by-time-by-sex interaction term in unstratified models (<inline-formula><mml:math id="i519" display="inline" alttext="lowercase italic p greater than 0.05"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>; Table S6).</p>
              </sec>
              <sec id="s3.3">
                <title>Treatment Effects during the Second Phase</title>
                <p>To evaluate the potential reversal of treatment effects on As metabolites after cessation of FA, we evaluated the percentage changes in bAs indices and metabolites from baseline to week 12, baseline to week 24, and from week 12 to week 24 (<xref rid="t3" ref-type="table">Table 3</xref>). The percentage increase in SMI between baseline and week 24 was significantly greater among the groups who continued FA treatment compared with groups who discontinued treatment [400FA/FA: 29.2% (95% CI: 23.1, 35.5), 400FA/PBO: 14.1% (95% CI: 9.13, 19.3), 800FA/FA: 23.7% (95% CI: 18.9, 28.6), 800FA/PBO: 13.4% (95% CI: 8.2, 18.9)] (<inline-formula><mml:math id="i520" display="inline" alttext="lowercase italic p less than 0.05"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>). In the 800FA/FA group, percentage changes in bInAs, bMMAs, bDMAs, and PMI over 24 wk were similar to those in the 800FA/PBO group (<inline-formula><mml:math id="i521" display="inline" alttext="lowercase italic p greater than 0.05"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>). Data from the second phase, comparing week 12 to week 24, showed evidence of the reversal of treatment effects on As metabolites following FA cessation, with significant decreases in SMI [<inline-formula><mml:math id="i522" display="inline" alttext="negative 9.0 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>9.0</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i523" display="inline" alttext="negative 14.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>14.8</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i524" display="inline" alttext="negative 3.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>3.5</mml:mn></mml:mrow></mml:math></inline-formula>)] and DMAs [<inline-formula><mml:math id="i525" display="inline" alttext="negative 5.9 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>5.9</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i526" display="inline" alttext="negative 10.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>10.2</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i527" display="inline" alttext="negative 1.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>1.8</mml:mn></mml:mrow></mml:math></inline-formula>)] in the 800FA/PBO group and similar trends in the 400FA/PBO group that were not statistically significant (<inline-formula><mml:math id="i528" display="inline" alttext="lowercase italic p greater than 0.05"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>). For those who continued <inline-formula><mml:math id="i529" display="inline" alttext="800 micrograms"><mml:mrow><mml:mn>800</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA supplementation, PMI and MMAs concentrations decreased between weeks 12 and 24 [PMI: <inline-formula><mml:math id="i530" display="inline" alttext="negative 7.2 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>7.2</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i531" display="inline" alttext="negative 14.3"><mml:mrow><mml:mo>−</mml:mo><mml:mn>14.3</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i532" display="inline" alttext="negative 0.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:math></inline-formula>); MMAs: <inline-formula><mml:math id="i533" display="inline" alttext="negative 3.1 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>3.1</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i534" display="inline" alttext="negative 6.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>6.2</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i535" display="inline" alttext="negative 0.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:math></inline-formula>)], whereas changes in the 800FA/PBO group were not significantly different than 0 [PMI: <inline-formula><mml:math id="i536" display="inline" alttext="negative 1.8 percent"><mml:mrow><mml:mo>−</mml:mo><mml:mn>1.8</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> (95% CI: <inline-formula><mml:math id="i537" display="inline" alttext="negative 10.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>10.0</mml:mn></mml:mrow></mml:math></inline-formula>, 5.7), MMAs: 2.8% (95% CI: <inline-formula><mml:math id="i538" display="inline" alttext="negative 0.3"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.3</mml:mn></mml:mrow></mml:math></inline-formula>, 5.8)]. Similar trends were observed in the 400FA/FA group but were not statistically significant (<inline-formula><mml:math id="i539" display="inline" alttext="lowercase italic p greater than 0.05"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>).</p>
                <table-wrap position="float" id="t3">
                  <label>Table 3</label>
                  <caption>
                    <p>Percentage change (95% CI) in blood arsenic methylation indices and metabolite concentrations between baseline and week 12, baseline and week 24, and week 12 and week 24 by folic acid supplementation groups.</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="top" span="1"/>
                      <col align="left" valign="top" span="1"/>
                      <col align="left" valign="top" span="1"/>
                      <col align="left" valign="top" span="1"/>
                      <col align="left" valign="top" span="1"/>
                      <col align="left" valign="top" span="1"/>
                      <col align="left" valign="top" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="center" rowspan="2" id="t3c1" scope="col" colspan="1">Arsenic methylation measures by treatment group</th>
                        <th colspan="3" align="center" id="t3c2" scope="colgroup" rowspan="1">400FA<xref rid="TF11" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></th>
                        <th colspan="3" align="center" id="t3c3" scope="colgroup" rowspan="1">800FA<xref rid="TF12" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></th>
                      </tr>
                      <tr>
                        <th align="center" id="t3c4" scope="col" headers="t3c2" colspan="1" rowspan="1">Baseline to week 12</th>
                        <th align="center" id="t3c5" scope="col" headers="t3c2" colspan="1" rowspan="1">Baseline to week 24</th>
                        <th align="center" id="t3c6" scope="col" headers="t3c2" colspan="1" rowspan="1">Week 12 to week 24</th>
                        <th align="center" id="t3c7" scope="col" headers="t3c3" colspan="1" rowspan="1">Baseline to week 12</th>
                        <th align="center" id="t3c8" scope="col" headers="t3c3" colspan="1" rowspan="1">Baseline to week 24</th>
                        <th align="center" id="t3c9" scope="col" headers="t3c3" colspan="1" rowspan="1">Week 12 to week 24</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <th colspan="7" align="left" id="t3c10" scope="row" headers="t3c1" rowspan="1">Arsenic methylation indices</th>
                      </tr>
                      <tr>
                        <th colspan="7" align="left" id="t3c11" scope="row" headers="t3c1" rowspan="1"> PMI</th>
                      </tr>
                      <tr>
                        <td align="left" id="t3c12" scope="row" headers="t3c1 t3c11" colspan="1" rowspan="1">  FA/FA</td>
                        <td align="char" char="(" headers="t3c2 t3c4 t3c12" colspan="1" rowspan="1"><inline-formula><mml:math id="i540" display="inline" alttext="negative 11.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>11.2</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i541" display="inline" alttext="negative 15.3"><mml:mrow><mml:mo>−</mml:mo><mml:mn>15.3</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i542" display="inline" alttext="negative 6.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>6.8</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="(" headers="t3c2 t3c5 t3c12" colspan="1" rowspan="1"><inline-formula><mml:math id="i543" display="inline" alttext="negative 11.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>11.1</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i544" display="inline" alttext="negative 14.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>14.8</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i545" display="inline" alttext="negative 7.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>7.2</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="(" headers="t3c2 t3c6 t3c12" colspan="1" rowspan="1"><inline-formula><mml:math id="i546" display="inline" alttext="negative 5.4"><mml:mrow><mml:mo>−</mml:mo><mml:mn>5.4</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i547" display="inline" alttext="negative 13.3"><mml:mrow><mml:mo>−</mml:mo><mml:mn>13.3</mml:mn></mml:mrow></mml:math></inline-formula>, 2.0)</td>
                        <td align="char" char="(" headers="t3c3 t3c7 t3c12" colspan="1" rowspan="1"><inline-formula><mml:math id="i548" display="inline" alttext="negative 8.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>8.1</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i549" display="inline" alttext="negative 12.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>12.1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i550" display="inline" alttext="negative 4.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>4.0</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="(" headers="t3c3 t3c8 t3c12" colspan="1" rowspan="1"><inline-formula><mml:math id="i551" display="inline" alttext="negative 9.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>9.5</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i552" display="inline" alttext="negative 13.3"><mml:mrow><mml:mo>−</mml:mo><mml:mn>13.3</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i553" display="inline" alttext="negative 5.6"><mml:mrow><mml:mo>−</mml:mo><mml:mn>5.6</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="(" headers="t3c3 t3c9 t3c12" colspan="1" rowspan="1"><inline-formula><mml:math id="i554" display="inline" alttext="negative 7.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>7.2</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i555" display="inline" alttext="negative 14.3"><mml:mrow><mml:mo>−</mml:mo><mml:mn>14.3</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i556" display="inline" alttext="negative 0.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                      </tr>
                      <tr>
                        <td align="left" id="t3c13" scope="row" headers="t3c1 t3c11" colspan="1" rowspan="1">  FA/PBO</td>
                        <td align="char" char="(" headers="t3c2 t3c4 t3c13" colspan="1" rowspan="1"><inline-formula><mml:math id="i557" display="inline" alttext="negative 13.3"><mml:mrow><mml:mo>−</mml:mo><mml:mn>13.3</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i558" display="inline" alttext="negative 18.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>18.0</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i559" display="inline" alttext="negative 8.4"><mml:mrow><mml:mo>−</mml:mo><mml:mn>8.4</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="(" headers="t3c2 t3c5 t3c13" colspan="1" rowspan="1"><inline-formula><mml:math id="i560" display="inline" alttext="negative 6.4"><mml:mrow><mml:mo>−</mml:mo><mml:mn>6.4</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i561" display="inline" alttext="negative 10.6"><mml:mrow><mml:mo>−</mml:mo><mml:mn>10.6</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i562" display="inline" alttext="negative 2.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>2.0</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="(" headers="t3c2 t3c6 t3c13" colspan="1" rowspan="1">2.3 (<inline-formula><mml:math id="i563" display="inline" alttext="negative 4.9"><mml:mrow><mml:mo>−</mml:mo><mml:mn>4.9</mml:mn></mml:mrow></mml:math></inline-formula>, 9.0)</td>
                        <td align="char" char="(" headers="t3c3 t3c7 t3c13" colspan="1" rowspan="1"><inline-formula><mml:math id="i564" display="inline" alttext="negative 12.4"><mml:mrow><mml:mo>−</mml:mo><mml:mn>12.4</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i565" display="inline" alttext="negative 17.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>17.1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i566" display="inline" alttext="negative 7.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>7.5</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="(" headers="t3c3 t3c8 t3c13" colspan="1" rowspan="1"><inline-formula><mml:math id="i567" display="inline" alttext="negative 9.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>9.2</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i568" display="inline" alttext="negative 13.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>13.0</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i569" display="inline" alttext="negative 5.3"><mml:mrow><mml:mo>−</mml:mo><mml:mn>5.3</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="(" headers="t3c3 t3c9 t3c13" colspan="1" rowspan="1"><inline-formula><mml:math id="i570" display="inline" alttext="negative 1.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>1.8</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i571" display="inline" alttext="negative 10.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>10.0</mml:mn></mml:mrow></mml:math></inline-formula>, 5.7)</td>
                      </tr>
                      <tr>
                        <th colspan="7" align="left" id="t3c14" scope="row" headers="t3c1" rowspan="1"> SMI</th>
                      </tr>
                      <tr>
                        <td align="left" id="t3c15" scope="row" headers="t3c1 t3c14" colspan="1" rowspan="1">  FA/FA</td>
                        <td align="char" char="(" headers="t3c2 t3c4 t3c15" colspan="1" rowspan="1">26.9 (21.1, 33.1)</td>
                        <td align="char" char="(" headers="t3c2 t3c5 t3c15" colspan="1" rowspan="1">29.2 (23.1, 35.5)</td>
                        <td align="char" char="(" headers="t3c2 t3c6 t3c15" colspan="1" rowspan="1">3.7 (<inline-formula><mml:math id="i572" display="inline" alttext="negative 2.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>2.1</mml:mn></mml:mrow></mml:math></inline-formula>, 9.1)</td>
                        <td align="char" char="(" headers="t3c3 t3c7 t3c15" colspan="1" rowspan="1">20.9 (16.0, 26.0)</td>
                        <td align="char" char="(" headers="t3c3 t3c8 t3c15" colspan="1" rowspan="1">23.7 (19.0, 28.6)</td>
                        <td align="char" char="(" headers="t3c3 t3c9 t3c15" colspan="1" rowspan="1">4.2 (<inline-formula><mml:math id="i573" display="inline" alttext="negative 1.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>1.0</mml:mn></mml:mrow></mml:math></inline-formula>, 9.1)</td>
                      </tr>
                      <tr>
                        <td align="left" id="t3c16" scope="row" headers="t3c1 t3c14" colspan="1" rowspan="1">  FA/PBO</td>
                        <td align="char" char="(" headers="t3c2 t3c4 t3c16" colspan="1" rowspan="1">25.2 (19.6, 31.1)</td>
                        <td align="char" char="(" headers="t3c2 t3c5 t3c16" colspan="1" rowspan="1">14.1 (9.1, 19.3)</td>
                        <td align="char" char="(" headers="t3c2 t3c6 t3c16" colspan="1" rowspan="1"><inline-formula><mml:math id="i574" display="inline" alttext="negative 7.6"><mml:mrow><mml:mo>−</mml:mo><mml:mn>7.6</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i575" display="inline" alttext="negative 14.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>14.5</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i576" display="inline" alttext="negative 1.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>1.1</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="(" headers="t3c3 t3c7 t3c16" colspan="1" rowspan="1">26.1 (19.8, 32.7)</td>
                        <td align="char" char="(" headers="t3c3 t3c8 t3c16" colspan="1" rowspan="1">13.4 (8.2, 18.9)</td>
                        <td align="char" char="(" headers="t3c3 t3c9 t3c16" colspan="1" rowspan="1"><inline-formula><mml:math id="i577" display="inline" alttext="negative 9.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>9.0</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i578" display="inline" alttext="negative 14.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>14.8</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i579" display="inline" alttext="negative 3.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>3.5</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                      </tr>
                      <tr>
                        <th colspan="7" align="left" id="t3c17" scope="row" headers="t3c1" rowspan="1">Arsenic metabolites</th>
                      </tr>
                      <tr>
                        <th colspan="7" align="left" id="t3c18" scope="row" headers="t3c1" rowspan="1"> InAs</th>
                      </tr>
                      <tr>
                        <td align="left" id="t3c19" scope="row" headers="t3c1 t3c18" colspan="1" rowspan="1">  FA/FA</td>
                        <td align="char" char="(" headers="t3c2 t3c4 t3c19" colspan="1" rowspan="1">1.6 (<inline-formula><mml:math id="i580" display="inline" alttext="negative 1.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>1.5</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i581" display="inline" alttext="negative 4.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>4.8</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="(" headers="t3c2 t3c5 t3c19" colspan="1" rowspan="1">0.9 (<inline-formula><mml:math id="i582" display="inline" alttext="negative 2.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>2.2</mml:mn></mml:mrow></mml:math></inline-formula>, 4.0)</td>
                        <td align="char" char="(" headers="t3c2 t3c6 t3c19" colspan="1" rowspan="1">3.0 (<inline-formula><mml:math id="i583" display="inline" alttext="negative 1.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>1.5</mml:mn></mml:mrow></mml:math></inline-formula>, 7.2)</td>
                        <td align="char" char="(" headers="t3c3 t3c7 t3c19" colspan="1" rowspan="1">0.7 (<inline-formula><mml:math id="i584" display="inline" alttext="negative 2.3"><mml:mrow><mml:mo>−</mml:mo><mml:mn>2.3</mml:mn></mml:mrow></mml:math></inline-formula>, 3.7)</td>
                        <td align="char" char="(" headers="t3c3 t3c8 t3c19" colspan="1" rowspan="1">0.9 (<inline-formula><mml:math id="i585" display="inline" alttext="negative 2.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>2.0</mml:mn></mml:mrow></mml:math></inline-formula>, 3.9)</td>
                        <td align="char" char="(" headers="t3c3 t3c9 t3c19" colspan="1" rowspan="1">3.9 (<inline-formula><mml:math id="i586" display="inline" alttext="negative 0.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.2</mml:mn></mml:mrow></mml:math></inline-formula>, 7.2)</td>
                      </tr>
                      <tr>
                        <td align="left" id="t3c20" scope="row" headers="t3c1 t3c18" colspan="1" rowspan="1">  FA/PBO</td>
                        <td align="char" char="(" headers="t3c2 t3c4 t3c20" colspan="1" rowspan="1">3.6 (<inline-formula><mml:math id="i587" display="inline" alttext="negative 0.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:math></inline-formula>, 7.6)</td>
                        <td align="char" char="(" headers="t3c2 t3c5 t3c20" colspan="1" rowspan="1">1.0 (<inline-formula><mml:math id="i588" display="inline" alttext="negative 2.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>2.1</mml:mn></mml:mrow></mml:math></inline-formula>, 4.2)</td>
                        <td align="char" char="(" headers="t3c2 t3c6 t3c20" colspan="1" rowspan="1">1.1 (<inline-formula><mml:math id="i589" display="inline" alttext="negative 3.6"><mml:mrow><mml:mo>−</mml:mo><mml:mn>3.6</mml:mn></mml:mrow></mml:math></inline-formula>, 5.5)</td>
                        <td align="char" char="(" headers="t3c3 t3c7 t3c20" colspan="1" rowspan="1">2.4 (<inline-formula><mml:math id="i590" display="inline" alttext="negative 1.4"><mml:mrow><mml:mo>−</mml:mo><mml:mn>1.4</mml:mn></mml:mrow></mml:math></inline-formula>, 6.4)</td>
                        <td align="char" char="(" headers="t3c3 t3c8 t3c20" colspan="1" rowspan="1">3.4 (0.2, 6.8)</td>
                        <td align="char" char="(" headers="t3c3 t3c9 t3c20" colspan="1" rowspan="1">4.5 (<inline-formula><mml:math id="i591" display="inline" alttext="negative 0.7"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.7</mml:mn></mml:mrow></mml:math></inline-formula>, 9.5)</td>
                      </tr>
                      <tr>
                        <th colspan="7" align="left" id="t3c21" scope="row" headers="t3c1" rowspan="1"> MMAs</th>
                      </tr>
                      <tr>
                        <td align="left" id="t3c22" scope="row" headers="t3c1 t3c21" colspan="1" rowspan="1">  FA/FA</td>
                        <td align="char" char="(" headers="t3c2 t3c4 t3c22" colspan="1" rowspan="1"><inline-formula><mml:math id="i592" display="inline" alttext="negative 10.0"><mml:mrow><mml:mo>−</mml:mo><mml:mn>10.0</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i593" display="inline" alttext="negative 12.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>12.2</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i594" display="inline" alttext="negative 7.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>7.8</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="(" headers="t3c2 t3c5 t3c22" colspan="1" rowspan="1"><inline-formula><mml:math id="i595" display="inline" alttext="negative 10.4"><mml:mrow><mml:mo>−</mml:mo><mml:mn>10.4</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i596" display="inline" alttext="negative 12.3"><mml:mrow><mml:mo>−</mml:mo><mml:mn>12.3</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i597" display="inline" alttext="negative 8.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>8.5</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="(" headers="t3c2 t3c6 t3c22" colspan="1" rowspan="1"><inline-formula><mml:math id="i598" display="inline" alttext="negative 2.4"><mml:mrow><mml:mo>−</mml:mo><mml:mn>2.4</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i599" display="inline" alttext="negative 5.9"><mml:mrow><mml:mo>−</mml:mo><mml:mn>5.9</mml:mn></mml:mrow></mml:math></inline-formula>, 1.1)</td>
                        <td align="char" char="(" headers="t3c3 t3c7 t3c22" colspan="1" rowspan="1"><inline-formula><mml:math id="i600" display="inline" alttext="negative 7.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>7.8</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i601" display="inline" alttext="negative 9.6"><mml:mrow><mml:mo>−</mml:mo><mml:mn>9.6</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i602" display="inline" alttext="negative 5.9"><mml:mrow><mml:mo>−</mml:mo><mml:mn>5.9</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="(" headers="t3c3 t3c8 t3c22" colspan="1" rowspan="1"><inline-formula><mml:math id="i603" display="inline" alttext="negative 8.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>8.8</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i604" display="inline" alttext="negative 10.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>10.5</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i605" display="inline" alttext="negative 7.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>7.1</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="(" headers="t3c3 t3c9 t3c22" colspan="1" rowspan="1"><inline-formula><mml:math id="i606" display="inline" alttext="negative 3.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>3.1</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i607" display="inline" alttext="negative 6.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>6.2</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i608" display="inline" alttext="negative 0.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                      </tr>
                      <tr>
                        <td align="left" id="t3c23" scope="row" headers="t3c1 t3c21" colspan="1" rowspan="1">  FA/PBO</td>
                        <td align="char" char="(" headers="t3c2 t3c4 t3c23" colspan="1" rowspan="1"><inline-formula><mml:math id="i609" display="inline" alttext="negative 10.3"><mml:mrow><mml:mo>−</mml:mo><mml:mn>10.3</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i610" display="inline" alttext="negative 12.6"><mml:mrow><mml:mo>−</mml:mo><mml:mn>12.6</mml:mn></mml:mrow></mml:math></inline-formula>, 8.0)</td>
                        <td align="char" char="(" headers="t3c2 t3c5 t3c23" colspan="1" rowspan="1"><inline-formula><mml:math id="i611" display="inline" alttext="negative 5.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>5.5</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i612" display="inline" alttext="negative 7.6"><mml:mrow><mml:mo>−</mml:mo><mml:mn>7.6</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i613" display="inline" alttext="negative 3.4"><mml:mrow><mml:mo>−</mml:mo><mml:mn>3.4</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="(" headers="t3c2 t3c6 t3c23" colspan="1" rowspan="1">3.3 (<inline-formula><mml:math id="i614" display="inline" alttext="negative 0.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:math></inline-formula>, 6.6)</td>
                        <td align="char" char="(" headers="t3c3 t3c7 t3c23" colspan="1" rowspan="1"><inline-formula><mml:math id="i615" display="inline" alttext="negative 10.7"><mml:mrow><mml:mo>−</mml:mo><mml:mn>10.7</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i616" display="inline" alttext="negative 13.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>13.1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i617" display="inline" alttext="negative 8.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>8.2</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="(" headers="t3c3 t3c8 t3c23" colspan="1" rowspan="1"><inline-formula><mml:math id="i618" display="inline" alttext="negative 6.3"><mml:mrow><mml:mo>−</mml:mo><mml:mn>6.3</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i619" display="inline" alttext="negative 8.3"><mml:mrow><mml:mo>−</mml:mo><mml:mn>8.3</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i620" display="inline" alttext="negative 4.3"><mml:mrow><mml:mo>−</mml:mo><mml:mn>4.3</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                        <td align="char" char="(" headers="t3c3 t3c9 t3c23" colspan="1" rowspan="1">2.82 (<inline-formula><mml:math id="i621" display="inline" alttext="negative 0.3"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.3</mml:mn></mml:mrow></mml:math></inline-formula>, 5.8)</td>
                      </tr>
                      <tr>
                        <th colspan="7" align="left" id="t3c24" scope="row" headers="t3c1" rowspan="1"> DMAs</th>
                      </tr>
                      <tr>
                        <td align="left" id="t3c25" scope="row" headers="t3c1 t3c24" colspan="1" rowspan="1">  FA/FA</td>
                        <td align="char" char="(" headers="t3c2 t3c4 t3c25" colspan="1" rowspan="1">14.1 (10.8, 17.5)</td>
                        <td align="char" char="(" headers="t3c2 t3c5 t3c25" colspan="1" rowspan="1">15.6 (11.8, 19.6)</td>
                        <td align="char" char="(" headers="t3c2 t3c6 t3c25" colspan="1" rowspan="1">1.3 (<inline-formula><mml:math id="i622" display="inline" alttext="negative 2.5"><mml:mrow><mml:mo>−</mml:mo><mml:mn>2.5</mml:mn></mml:mrow></mml:math></inline-formula>, 5.0)</td>
                        <td align="char" char="(" headers="t3c3 t3c7 t3c25" colspan="1" rowspan="1">11.4 (8.2, 14.6)</td>
                        <td align="char" char="(" headers="t3c3 t3c8 t3c25" colspan="1" rowspan="1">6.1 (2.7, 9.6)</td>
                        <td align="char" char="(" headers="t3c3 t3c9 t3c25" colspan="1" rowspan="1">1.2 (<inline-formula><mml:math id="i623" display="inline" alttext="negative 2.4"><mml:mrow><mml:mo>−</mml:mo><mml:mn>2.4</mml:mn></mml:mrow></mml:math></inline-formula>, 4.6)</td>
                      </tr>
                      <tr>
                        <td align="left" id="t3c26" scope="row" headers="t3c1 t3c24" colspan="1" rowspan="1">  FA/PBO</td>
                        <td align="char" char="(" headers="t3c2 t3c4 t3c26" colspan="1" rowspan="1">12.2 (9.0, 15.5)</td>
                        <td align="char" char="(" headers="t3c2 t3c5 t3c26" colspan="1" rowspan="1">7.8 (4.7, 10.9)</td>
                        <td align="char" char="(" headers="t3c2 t3c6 t3c26" colspan="1" rowspan="1"><inline-formula><mml:math id="i624" display="inline" alttext="negative 4.1"><mml:mrow><mml:mo>−</mml:mo><mml:mn>4.1</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i625" display="inline" alttext="negative 8.4"><mml:mrow><mml:mo>−</mml:mo><mml:mn>8.4</mml:mn></mml:mrow></mml:math></inline-formula>, 0.1)</td>
                        <td align="char" char="(" headers="t3c3 t3c7 t3c26" colspan="1" rowspan="1">12.4 (<inline-formula><mml:math id="i626" display="inline" alttext="negative 8.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>8.8</mml:mn></mml:mrow></mml:math></inline-formula>, 16.1)</td>
                        <td align="char" char="(" headers="t3c3 t3c8 t3c26" colspan="1" rowspan="1">6.1 (2.7, 9.6)</td>
                        <td align="char" char="(" headers="t3c3 t3c9 t3c26" colspan="1" rowspan="1"><inline-formula><mml:math id="i627" display="inline" alttext="negative 5.9"><mml:mrow><mml:mo>−</mml:mo><mml:mn>5.9</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="i628" display="inline" alttext="negative 10.2"><mml:mrow><mml:mo>−</mml:mo><mml:mn>10.2</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i629" display="inline" alttext="negative 1.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>1.8</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="TF10">
                      <p>Note: Percentage change was estimated using linear models. GMs for each time point are included in Table S7; individual-level data are included in Excel File 1. 400FA, <inline-formula><mml:math id="i630" display="inline" alttext="400 micrograms"><mml:mrow><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA/d; 800FA, <inline-formula><mml:math id="i631" display="inline" alttext="800 micrograms"><mml:mrow><mml:mn>800</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA/d; CI, confidence interval; DMAs, dimethyl-arsenical species; FA, folic acid; FA/FA, continued folic acid treatment; FA/PBO, discontinued folic acid treatment; InAs, inorganic arsenic; MMAs, monomethyl-arsenical species; PBO, placebo; PMI, primary methylation index; SMI, secondary methylation index.</p>
                    </fn>
                    <fn id="TF11">
                      <label>
                        <sup>
                          <italic toggle="yes">a</italic>
                        </sup>
                      </label>
                      <p>400FA/FA: <inline-formula><mml:math id="i632" display="inline" alttext="uppercase italic n equals 77"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>77</mml:mn></mml:mrow></mml:math></inline-formula>; 400FA/PBO:<inline-formula><mml:math id="i633" display="inline" alttext="uppercase italic n equals 76"><mml:mrow><mml:mtext> </mml:mtext><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>76</mml:mn></mml:mrow></mml:math></inline-formula>.</p>
                    </fn>
                    <fn id="TF12">
                      <label>
                        <sup>
                          <italic toggle="yes">b</italic>
                        </sup>
                      </label>
                      <p>800FA/FA: <inline-formula><mml:math id="i634" display="inline" alttext="uppercase italic n equals 76"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>76</mml:mn></mml:mrow></mml:math></inline-formula>; 800FA/PBO: <inline-formula><mml:math id="i635" display="inline" alttext="uppercase italic n equals 74"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>74</mml:mn></mml:mrow></mml:math></inline-formula>.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>In <xref rid="f4" ref-type="fig">Figure 4</xref> and Table S7, the GMs for As methylation indices and bAs metabolite concentrations are shown at baseline, week 12, and week 24 for the PBO, 400FA, and 800FA treated groups, with separate groups for those who continued and discontinued FA supplementation; individual-level data are provided in Excel File 1. Across treatment groups, there was a trend toward an increase in bAs metabolite concentrations during the second phase, a period with reduced compliance with water filter use, which has previously been reported by Sanchez et al.<sup><xref rid="c22" ref-type="bibr">22</xref></sup> The plots illustrate similar declines in PMI and increases in SMI for the 400FA and 800FA groups at week 12; these were maintained at week 24 in both FA/FA groups, whereas in the FA/PBO groups, week 24 values tended to revert toward baseline values.</p>
                <fig position="float" id="f4">
                  <label>Figure 4.</label>
                  <caption>
                    <p>Geometric mean of blood arsenic indices and metabolite concentrations by treatment group from baseline to week 24. The <italic toggle="yes">y</italic>-axes are the (A) primary methylation index (PMI), (B) secondary methylation index (SMI), (C) inorganic arsenic (InAs), (D) monomethyl-arsenical species (MMAs), and (E) dimethyl-arsenical species (DMAs) levels and the <italic toggle="yes">x</italic>-axes are weeks. Participants that received PBO, continuous <inline-formula><mml:math id="i636" display="inline" alttext="400 micrograms"><mml:mrow><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> of FA/d (400FA/FA), continuous <inline-formula><mml:math id="i637" display="inline" alttext="800 micrograms"><mml:mrow><mml:mn>800</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> of FA/d (800FA/FA), cessation of <inline-formula><mml:math id="i638" display="inline"><mml:mrow><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA/d at 12 wk (400FA/PBO), or cessation of <inline-formula><mml:math id="i639" display="inline" alttext="800 micrograms"><mml:mrow><mml:mn>800</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> of FA/d at 12 wk (800FA/PBO) are shown in brown solid lines (triangle points), green solid lines (circle points), blue solid lines (square points), light green dashed lines (circle points), and light blue dotted lines (square points), respectively. The bAs PMI and SMI were calculated as bMMAs/bInAs and bDMAs/bMMAs concentrations, respectively. Percentage change was estimated using linear models. Individual-level data are included in Excel File 1. Note: bDMAs, blood dimethyl-arsenical species; bInAs, blood inorganic arsenic metabolites; bMMAs, blood monomethyl-arsenical species; FA, folic acid; PBO, placebo.</p>
                  </caption>
                  <alt-text>Figures 4A to 4E are line graphs, plotting primary methylation index, ranging from 1.3 to 1.6 in increments of 0.1; secondary methylation index, ranging from 0.6 to 0.9 in increments of 0.1; inorganic arsenic concentrations (micrograms per liter), ranging from 1.0 to 3.0 in increments of 0.5; monomethyl-arsenical species concentrations (micrograms per liter), ranging from 2.0 to 4.0 in increments of 0.5; and dimethyl-arsenical species concentrations (micro grams per liter), ranging from 1.5 to 3.0 in increments of 0.5 (y-axis) across week, ranging from 0 to 24.</alt-text>
                  <graphic xlink:href="ehp11270_f4" position="float"/>
                </fig>
              </sec>
            </sec>
            <sec id="s4">
              <title>Discussion</title>
              <p>Reduced As methylation capacity has been linked to increased risk for a number of As-related health outcomes, including cancers of the bladder,<sup><xref rid="c28" ref-type="bibr">28</xref>,<xref rid="c29" ref-type="bibr">29</xref></sup> lung,<sup><xref rid="c12" ref-type="bibr">12</xref>,<xref rid="c30" ref-type="bibr">30</xref></sup> and skin,<sup><xref rid="c31" ref-type="bibr">31</xref>,<xref rid="c32" ref-type="bibr">32</xref></sup> and noncancer outcomes, such as arsenical skin lesions<sup><xref rid="c33" ref-type="bibr">33</xref>,<xref rid="c34" ref-type="bibr">34</xref></sup> and atherosclerosis.<sup><xref rid="c35" ref-type="bibr">35</xref></sup> FACT was designed to investigate the efficacy of FA, creatine, and a combination of FA and creatine supplementation on increasing As methylation capacity among a population of mixed folate-deficient and -sufficient individuals in Bangladesh, a country that does not currently have food folate fortification. Our outcomes of interest included changes in bAs methylation indices, PMI and SMI, and bAs metabolite concentrations.</p>
              <p>We previously reported findings on total bAs and urinary As metabolites.<sup><xref rid="c8" ref-type="bibr">8</xref>,<xref rid="c17" ref-type="bibr">17</xref>,<xref rid="c18" ref-type="bibr">18</xref></sup> In short, groups receiving FA supplementation had significantly greater decreases in %MMAs and increases %DMAs in urine compared with PBO (<inline-formula><mml:math id="i640" display="inline" alttext="lowercase italic p less than 0.05"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>).<sup><xref rid="c18" ref-type="bibr">18</xref></sup> In our earlier RCT of <inline-formula><mml:math id="i641" display="inline" alttext="400 micrograms"><mml:mrow><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA supplementation in only folate-deficient individuals,<sup><xref rid="c8" ref-type="bibr">8</xref></sup> the group receiving <inline-formula><mml:math id="i642" display="inline" alttext="400 micrograms"><mml:mrow><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA had a significantly greater decrease in total bAs compared with PBO (<inline-formula><mml:math id="i643" display="inline" alttext="lowercase italic p greater than 0.05"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>). In contrast, in the present study of a mixed folate-deficient/replete population, <inline-formula><mml:math id="i644" display="inline" alttext="400 micrograms"><mml:mrow><mml:mn>400</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA was not effective in lowering total bAs to a significantly greater extent than PBO over the course of the trial, indicating that a higher dose of FA (<inline-formula><mml:math id="i645" display="inline" alttext="800 micrograms"><mml:mrow><mml:mn>800</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> FA) or a longer duration of supplementation may be required to lower total bAs.<sup><xref rid="c17" ref-type="bibr">17</xref></sup></p>
              <p>Here we report new data on As metabolite concentrations in blood, where the distribution of As metabolites differs considerably from that previously reported for urine.<sup><xref rid="c18" ref-type="bibr">18</xref></sup> Although the distribution of As metabolites in urine at baseline ranged from 13.2% to 14.7% InAs, 12.5% to 13.4% MMAs, and 72.0% to 74.4% DMAs across treatment groups,<sup><xref rid="c18" ref-type="bibr">18</xref></sup> the GMs in blood ranged from 25.9% to 27.5% InAs, 44.0% to 44.3% MMAs, and 27.2% to 29.2% DMAs (<xref rid="t1" ref-type="table">Table 1</xref>). These differences between blood and urine are similar to those observed in our earlier study of folate-deficient participants<sup><xref rid="c8" ref-type="bibr">8</xref></sup> and are related to the more rapid renal excretion of DMAs in urine. The measurement of As, As indices, and As metabolite concentrations in blood has the added advantage that the overall concentration of blood is relatively constant<sup><xref rid="c36" ref-type="bibr">36</xref></sup> as compared with urine, which requires adjustment for hydration status with urinary creatinine or specific gravity<sup><xref rid="c37" ref-type="bibr">37</xref>–<xref rid="c40" ref-type="bibr">40</xref></sup> and expression of As metabolites as percentages rather than concentrations. Furthermore, intuitively, As metabolite concentrations in blood should more closely reflect As metabolite exposures to tissues as compared with urine where concentrations of As metabolites are much higher. The bAs methylation indices, PMI and SMI, have the advantage that they are less impacted by As exposure levels and water filter compliance, as observed in the present study, than are bAs metabolite concentrations.</p>
              <p>In the first phase of FACT, we observed significant increases in As methylation capacity as reflected by greater decreases in bMMAs and PMI and increases in bDMAs and SMI in all treatment groups receiving FA relative to PBO. In addition, treatment effects on increasing SMI were seen as early as the first week of intervention for the <inline-formula><mml:math id="i646" display="inline" alttext="creatine plus 400 folic acid"><mml:mrow><mml:mtext>creatine</mml:mtext><mml:mspace width="0.3em"/><mml:mo>+</mml:mo><mml:mspace width="0.3em"/><mml:mn>400</mml:mn><mml:mtext>FA</mml:mtext></mml:mrow></mml:math></inline-formula> treatment group. The nonsignificant increase in SMI from baseline to week 1 in the PBO group [2.1% (95% CI: <inline-formula><mml:math id="i647" display="inline" alttext="negative 0.8"><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.8</mml:mn></mml:mrow></mml:math></inline-formula>, 5.2)] was likely due to water filter use,<sup><xref rid="c22" ref-type="bibr">22</xref></sup> given that water As concentrations have been negatively associated with SMI in urine<sup><xref rid="c33" ref-type="bibr">33</xref></sup> and that there is experimental evidence showing that arsenic methylation capacity is saturable.<sup><xref rid="c41" ref-type="bibr">41</xref></sup> Although no significant changes in bInAs concentrations were observed for any treatment groups compared with PBO over time, this was likely due to its methylation to MMAs and continued InAs exposure owing to poor compliance with As-removal filters.<sup><xref rid="c22" ref-type="bibr">22</xref></sup> In exploratory sex-stratified analyses, FA supplementation results were similar among male and female participants, whereas creatine supplementation alone resulted in significantly greater decreases in bMMAs and increases in SMI compared with PBO only among male participants. Although the changes in bMMAs and SMI with creatine treatment compared with PBO were not significant in female participants, they were in the same direction as those in male participants. Thus, given that our study was not powered to detect effect modification, this could be an issue of small sample size, or it could possibly be related to differences in creatine metabolism due to higher muscle mass among male participants. The finding that FA supplementation was effective in increasing As methylation capacity in this population that was predominantly folate sufficient (plasma folate was <inline-formula><mml:math id="i648" display="inline" alttext="greater than or equal to 9.0 nanomoles per liter"><mml:mrow><mml:mo>≥</mml:mo><mml:mn>9.0</mml:mn><mml:mtext> nmol</mml:mtext><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula> in 80.3% of the study participants) has important implications. For example, if FA supplementation was only effective in folate-deficient individuals, then targeted approaches would be more appropriate than widespread food FA fortification programs. The latter can influence entire populations and overcome problems associated with FA supplementation, such as poor long-term compliance and difficulties in reaching vulnerable subsets of the population.</p>
              <p>In the second phase of FACT, the data showed evidence of the reversal of treatment effects on As methylation following FA cessation from weeks 12 to 24, with significant decreases in SMI and bDMAs in those who switched from 800FA to PBO, whereas for those who remained on 800FA, PMI and bMMAs concentrations continued to decline, showing added benefit to a longer intervention. In addition, as compared with baseline, there was a significantly greater increase in SMI at week 24 among participants who continued supplementation as compared with those who switched to PBO. Data on bDMAs concentrations also suggest the reversal of treatment effects on As methylation after FA cessation: the 7.77% increase in bDMAs concentrations between baseline and week 24 among participants who discontinued 400FA supplementation was roughly half that of those who continued FA supplementation (15.6%). These data indicate that sustainable improvement in As methylation capacity may require long-term interventions, such as food fortification programs, which are generally low-cost, effective approaches that can achieve broad coverage.</p>
              <p>The mechanisms of As toxicity are multifactorial; for example, chromosomal instability and altered methylation of DNA and histones are two mechanisms involved in As toxicity, as reviewed in Abuawad et al.<sup><xref rid="c42" ref-type="bibr">42</xref></sup> These mechanisms can be exacerbated by impairments in OCM and may also be improved by folate supplementation. There is some evidence to suggest that folate and/or other OCM-related micronutrients may also be beneficial in reducing As-related toxicity through these mechanisms, in addition to our observed effects of increasing As methylation and lowering bAs, although additional data are needed.<sup><xref rid="c43" ref-type="bibr">43</xref>,<xref rid="c44" ref-type="bibr">44</xref></sup></p>
              <p>The creatine treatment arms were designed to test our <italic toggle="yes">a priori</italic> hypothesis that creatine supplementation would reduce the high demand for SAM needed to support endogenous creatine biosynthesis, thereby sparing SAM for the methylation of As. This hypothesis is supported by positive associations between urinary creatinine levels and As methylation capacity in observational studies.<sup><xref rid="c17" ref-type="bibr">17</xref>,<xref rid="c19" ref-type="bibr">19</xref>,<xref rid="c45" ref-type="bibr">45</xref>–<xref rid="c47" ref-type="bibr">47</xref></sup> In FACT, <inline-formula><mml:math id="i649" display="inline" alttext="3 grams"><mml:mrow><mml:mn>3</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:math></inline-formula> creatine supplementation decreased creatine biosynthesis as indicated by significant decreases in plasma GAA, the precursor to creatine.<sup><xref rid="c48" ref-type="bibr">48</xref></sup> In our previous FACT report on urinary As metabolites, the group receiving creatine supplementation had a significantly greater decrease in %MMAs in urine compared with PBO following treatment, but no significant creatine treatment effects were observed for %InAs or %DMAs.<sup><xref rid="c18" ref-type="bibr">18</xref></sup> In the present analyses, the group receiving creatine supplementation alone had a significantly greater decrease in bMMAs concentrations and increase in SMI from baseline to week 12 compared with PBO. However, the creatine treatment effect was small compared with that of FA supplementation, and there were no significant differences observed in changes of bInAs, bDMAs, or PMI. Potential explanations for limited creatine treatment effects include long-range allosteric regulation of OCM that regulate intracellular SAM concentrations, for example, by changes in activity of glycine-<inline-formula><mml:math id="i650" display="inline" alttext="uppercase italic n"><mml:mi>N</mml:mi></mml:math></inline-formula>-methyltransferase (GNMT), a major regulator of SAM concentrations, and in flux through the transsulfuration pathway, which is stimulated by SAM.<sup><xref rid="c49" ref-type="bibr">49</xref>–<xref rid="c51" ref-type="bibr">51</xref></sup> The strong cross-sectional associations previously reported between urinary creatinine and As methylation patterns may partially be related to dietary creatine intake, but they could also potentially be influenced by dietary protein/methionine content associated with meat intake or other factors, such as renal function, which could differentially influence excretion/reabsorption of As metabolites in urine.</p>
              <p>A limitation of this study includes decreased compliance with water filter use over time, as reported by Sanchez et al. in a study of total urine As and water As levels in FACT,<sup><xref rid="c22" ref-type="bibr">22</xref></sup> which complicates interpretation of changes in bAs metabolite concentrations given that there was a strong decline in bAs for all groups at week 1 owing to initial compliance that reverted afterward. However, owing to the randomized study design, there is no evidence to suggest that compliance differed between treatment groups, which is supported by our data on total urinary As concentrations. Thus, this is not expected to change the conclusions of the study. Furthermore, the use of the As methylation indices, PMI and SMI, circumvents this issue that more directly affects bAs metabolite concentrations. Strengths of this study include the double-blind, randomized, PBO-controlled study design, including evaluation of the potential reversal of treatment effects on As metabolites following cessation of FA treatment and the high participant compliance with treatment. In addition, the use of blood, rather than urinary, measures of As metabolites may better reflect concentrations in tissues and be less affected by hydration levels. That a large proportion of the study population were folate replete increases generalizability to other As-exposed populations.</p>
            </sec>
            <sec id="s5">
              <title>Conclusion</title>
              <p>Our results indicate that FA supplementation increased As methylation capacity, as reflected by larger decreases in PMI and MMAs and increases in SMI and DMAs in blood within FA-treated groups compared with PBO. These findings are consistent with our previous report of the effects of FA supplementation on urinary As methylation profiles in this trial.<sup><xref rid="c18" ref-type="bibr">18</xref></sup> In recent years, the evidence supporting the critical role of nutritional factors in As methylation and corresponding toxicity has grown substantially.<sup><xref rid="c42" ref-type="bibr">42</xref>,<xref rid="c52" ref-type="bibr">52</xref></sup> Although As-remediation programs aimed at reducing exposure to As through contaminated drinking water should always remain the top priority, additional approaches to decrease the chronic health effects of As exposure through increasing As methylation capacity and lowering bAs concentrations are needed.</p>
              <p>Food fortification programs are one option. Approximately 85 countries mandate grain fortification with FA, but 28 European countries and most Asian countries do not or have only voluntary programs.<sup><xref rid="c53" ref-type="bibr">53</xref></sup> A major goal of FA fortification is to reduce neural tube defects, a lifelong debilitating condition due to failure of the neural folds to fuse during embryonic development. Fortification circumvents issues associated with FA supplementation or other dietary public health interventions, such as unplanned pregnancies, poor supplementation compliance, and difficulties reaching segments of the population.<sup><xref rid="c54" ref-type="bibr">54</xref></sup> However, despite the many known benefits of FA fortification, there are knowledge gaps regarding the potential risks of excessive folate intake and/or high FA levels, particularly in populations where use of folate supplements is common. These are summarized in the proceedings of a National Institutes of Health (NIH) workshop and include the masking of <inline-formula><mml:math id="i651" display="inline" alttext="uppercase b begin subscript 12 end subscript"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> deficiency, metabolic interactions with <inline-formula><mml:math id="i652" display="inline" alttext="uppercase b begin subscript 12 end subscript"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> that may influence neurocognitive outcomes among the elderly, and potential adverse effects on cancer risk, birth outcomes, and other diseases.<sup><xref rid="c55" ref-type="bibr">55</xref></sup> In addition, FA is a synthetic form of folate used in food fortification because it is chemically more stable than 5-mTHF, which is easily degraded by prolonged cooking. Individuals vary in their ability to fully metabolize FA to 5-mTHF. As a result, detectable levels of circulating unmetabolized FA are nearly ubiquitous in populations with FA fortification programs, such as in the United States.<sup><xref rid="c56" ref-type="bibr">56</xref></sup> Evidence of potential unanticipated effects of unmetabolized FA is controversial and is described by the NIH workshop proceedings as inconclusive.<sup><xref rid="c55" ref-type="bibr">55</xref></sup></p>
              <p>Many parts of the world affected by high levels of As contamination of drinking water, such as Bangladesh, do not currently have voluntary, let alone mandatory, FA fortification programs, and folate deficiency is common.<sup><xref rid="c57" ref-type="bibr">57</xref></sup> Carefully executed FA fortification programs or other public health interventions are needed to eradicate folate deficiency and its associated adverse health outcomes and could also facilitate a partial reduction in the extensive public health burden of As exposure.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material position="float" content-type="local-data">
                <media xlink:href="ehp11270.smcontents.508.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <media xlink:href="ehp11270.s001.acco.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <media xlink:href="ehp11270.s002.codeanddata.acco.zip">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <title>Acknowledgments</title>
              <p>We thank all of the Folic Acid and Creatine Trial participants and staff who made this work possible. This study was supported by U.S. National Institutes of Health grants, including R01 CA133595, P42 ES010349, R01ES030945, P30 ES0090089, R25 GM062454, and F31 ES032321.</p>
              <p>This trial was registered at <ext-link xlink:href="https://clinicaltrials.gov" ext-link-type="uri">https://clinicaltrials.gov</ext-link> as NCT01050556.</p>
            </ack>
            <ref-list>
              <title>References</title>
              <ref id="c1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Podgorski</surname><given-names>J</given-names></string-name>, <string-name><surname>Berg</surname><given-names>M</given-names></string-name></person-group>. <year>2020</year>. <article-title>Global threat of arsenic in groundwater</article-title>. <source>Science</source><volume>368</volume>(<issue>6493</issue>):<fpage>845</fpage>–<lpage>850</lpage>, PMID: , <pub-id pub-id-type="doi">10.1126/science.aba1510</pub-id>.<?supplied-pmid 32439786?><pub-id pub-id-type="pmid">32439786</pub-id></mixed-citation>
              </ref>
              <ref id="c2">
                <label>2.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Ravenscroft</surname><given-names>P</given-names></string-name>, <string-name><surname>Brammer</surname><given-names>H</given-names></string-name>, <string-name><surname>Richards</surname><given-names>K</given-names></string-name></person-group>. <year>2009</year>. <source>Arsenic Pollution: A Global Synthesis</source>. <publisher-loc>Chichester, UK</publisher-loc>: <publisher-name>Wiley-Blackwell</publisher-name>.</mixed-citation>
              </ref>
              <ref id="c3">
                <label>3.</label>
                <mixed-citation publication-type="webpage"><collab>WHO (World Health Organization)</collab>. <year>2012</year>. <article-title>Arsenic. WHO fact sheets</article-title>, <ext-link xlink:href="http://www.who.int/mediacentre/factsheets/fs372/en/" ext-link-type="uri">http://www.who.int/mediacentre/factsheets/fs372/en/</ext-link> [accessed <date-in-citation content-type="access-date">20 March 2023</date-in-citation>].</mixed-citation>
              </ref>
              <ref id="c4">
                <label>4.</label>
                <mixed-citation publication-type="book"><collab>BBS (Bangladesh Bureau of Statistics)</collab>. <year>2019</year>. <article-title>Progotir Pathey, Bangladesh: Multiple Indicator Cluster Survey 2019, Key Findings</article-title>. <publisher-loc>Dhaka, Bangladesh</publisher-loc>: <publisher-name>Government of the Peoples’ Republic of Bangladesh, Bangladeshi Bureau of Statistics, United Nations Children’s Fund</publisher-name>. <ext-link xlink:href="https://bbs.portal.gov.bd/sites/default/files/files/bbs.portal.gov.bd/page/b343a8b4_956b_45ca_872f_4cf9b2f1a6e0/37817b8e25d0d6c1f442e294921ff85e.pdf" ext-link-type="uri">https://bbs.portal.gov.bd/sites/default/files/files/bbs.portal.gov.bd/page/b343a8b4_956b_45ca_872f_4cf9b2f1a6e0/37817b8e25d0d6c1f442e294921ff85e.pdf</ext-link> [accessed <date-in-citation content-type="access-date">15 February 2022</date-in-citation>].</mixed-citation>
              </ref>
              <ref id="c5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Naujokas</surname><given-names>MF</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>B</given-names></string-name>, <string-name><surname>Ahsan</surname><given-names>H</given-names></string-name>, <string-name><surname>Aposhian</surname><given-names>HV</given-names></string-name>, <string-name><surname>Graziano</surname><given-names>JH</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>C</given-names></string-name>, <etal>et al.</etal></person-group><year>2013</year>. <article-title>The broad scope of health effects from chronic arsenic exposure: update on a worldwide public health problem</article-title>. <source>Environ Health Perspect</source><volume>121</volume>(<issue>3</issue>):<fpage>295</fpage>–<lpage>302</lpage>, PMID: , <pub-id pub-id-type="doi">10.1289/ehp.1205875</pub-id>.<?supplied-pmid 23458756?><pub-id pub-id-type="pmid">23458756</pub-id></mixed-citation>
              </ref>
              <ref id="c6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saba</surname><given-names>S</given-names></string-name>, <string-name><surname>Akash</surname><given-names>MSH</given-names></string-name>, <string-name><surname>Rehman</surname><given-names>K</given-names></string-name>, <string-name><surname>Saleem</surname><given-names>U</given-names></string-name>, <string-name><surname>Fiayyaz</surname><given-names>F</given-names></string-name>, <string-name><surname>Ahmad</surname><given-names>T</given-names></string-name></person-group>. <year>2020</year>. <article-title>Assessment of heavy metals by ICP-OES and their impact on insulin stimulating hormone and carbohydrate metabolizing enzymes</article-title>. <source>Clin Exp Pharmacol Physiol</source><volume>47</volume>(<issue>10</issue>):<fpage>1682</fpage>–<lpage>1691</lpage>, PMID: , <pub-id pub-id-type="doi">10.1111/1440-1681.13353</pub-id>.<?supplied-pmid 32434266?><pub-id pub-id-type="pmid">32434266</pub-id></mixed-citation>
              </ref>
              <ref id="c7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kazemifar</surname><given-names>AM</given-names></string-name>, <string-name><surname>Shafikhani</surname><given-names>AA</given-names></string-name>, <string-name><surname>Mozhdehipanah</surname><given-names>H</given-names></string-name>, <string-name><surname>Khamesi</surname><given-names>S</given-names></string-name>, <string-name><surname>Arami</surname><given-names>M</given-names></string-name></person-group>. <year>2020</year>. <article-title>Evaluation of different types of arsenic methylation and its relationship with metabolic syndrome in an area chronically exposed to arsenic</article-title>. <source>Environ Anal Health Toxicol</source><volume>35</volume>(<issue>2</issue>):<elocation-id>e2020006</elocation-id>, PMID: , <pub-id pub-id-type="doi">10.5620/eaht.e2020006</pub-id>.<?supplied-pmid 32693558?><pub-id pub-id-type="pmid">32693558</pub-id></mixed-citation>
              </ref>
              <ref id="c8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gamble</surname><given-names>MV</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name><surname>Slavkovich</surname><given-names>V</given-names></string-name>, <string-name><surname>Pilsner</surname><given-names>JR</given-names></string-name>, <string-name><surname>Ilievski</surname><given-names>V</given-names></string-name>, <string-name><surname>Factor-Litvak</surname><given-names>P</given-names></string-name>, <etal>et al.</etal></person-group><year>2007</year>. <article-title>Folic acid supplementation lowers blood arsenic</article-title>. <source>Am J Clin Nutr</source><volume>86</volume>(<issue>4</issue>):<fpage>1202</fpage>–<lpage>1209</lpage>, PMID: , <pub-id pub-id-type="doi">10.1093/ajcn/86.4.1202</pub-id>.<?supplied-pmid 17921403?><pub-id pub-id-type="pmid">17921403</pub-id></mixed-citation>
              </ref>
              <ref id="c9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Challenger</surname><given-names>F</given-names></string-name></person-group>. <year>1945</year>. <article-title>Biological methylation</article-title>. <source>Chem Rev</source><volume>36</volume>(<issue>3</issue>):<fpage>315</fpage>–<lpage>361</lpage>, <pub-id pub-id-type="doi">10.1021/cr60115a003</pub-id>.</mixed-citation>
              </ref>
              <ref id="c10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moe</surname><given-names>B</given-names></string-name>, <string-name><surname>Peng</surname><given-names>H</given-names></string-name>, <string-name><surname>Lu</surname><given-names>X</given-names></string-name>, <string-name><surname>Chen</surname><given-names>B</given-names></string-name>, <string-name><surname>Chen</surname><given-names>LWL</given-names></string-name>, <string-name><surname>Gabos</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><year>2016</year>. <article-title>Comparative cytotoxicity of fourteen trivalent and pentavalent arsenic species determined using real-time cell sensing</article-title>. <source>J Environ Sci (China)</source><volume>49</volume>:<fpage>113</fpage>–<lpage>124</lpage>, PMID: , <pub-id pub-id-type="doi">10.1016/j.jes.2016.10.004</pub-id>.<?supplied-pmid 28007166?><pub-id pub-id-type="pmid">28007166</pub-id></mixed-citation>
              </ref>
              <ref id="c11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Petrick</surname><given-names>JS</given-names></string-name>, <string-name><surname>Ayala-Fierro</surname><given-names>F</given-names></string-name>, <string-name><surname>Cullen</surname><given-names>WR</given-names></string-name>, <string-name><surname>Carter</surname><given-names>DE</given-names></string-name>, <string-name><surname>Vasken Aposhian</surname><given-names>H</given-names></string-name></person-group>. <year>2000</year>. <article-title>Monomethylarsonous acid (MMA<sup>III</sup>) is more toxic than arsenite in Chang human hepatocytes</article-title>. <source>Toxicol Appl Pharmacol</source><volume>163</volume>(<issue>2</issue>):<fpage>203</fpage>–<lpage>207</lpage>, PMID: , <pub-id pub-id-type="doi">10.1006/taap.1999.8872</pub-id>.<?supplied-pmid 10698679?><pub-id pub-id-type="pmid">10698679</pub-id></mixed-citation>
              </ref>
              <ref id="c12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Steinmaus</surname><given-names>C</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Kalman</surname><given-names>D</given-names></string-name>, <string-name><surname>Rey</surname><given-names>OA</given-names></string-name>, <string-name><surname>Skibola</surname><given-names>CF</given-names></string-name>, <string-name><surname>Dauphine</surname><given-names>D</given-names></string-name>, <etal>et al.</etal></person-group><year>2010</year>. <article-title>Individual differences in arsenic metabolism and lung cancer in a case-control study in Cordoba, Argentina</article-title>. <source>Toxicol Appl Pharmacol</source><volume>247</volume>(<issue>2</issue>):<fpage>138</fpage>–<lpage>145</lpage>, PMID: , <pub-id pub-id-type="doi">10.1016/j.taap.2010.06.006</pub-id>.<?supplied-pmid 20600216?><pub-id pub-id-type="pmid">20600216</pub-id></mixed-citation>
              </ref>
              <ref id="c13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kuo</surname><given-names>CC</given-names></string-name>, <string-name><surname>Moon</surname><given-names>KA</given-names></string-name>, <string-name><surname>Wang</surname><given-names>SL</given-names></string-name>, <string-name><surname>Silbergeld</surname><given-names>E</given-names></string-name>, <string-name><surname>Navas-Acien</surname><given-names>A</given-names></string-name></person-group>. <year>2017</year>. <article-title>The association of arsenic metabolism with cancer, cardiovascular disease, and diabetes: a systematic review of the epidemiological evidence</article-title>. <source>Environ Health Perspect</source><volume>125</volume>(<issue>8</issue>):<elocation-id>087001</elocation-id>, PMID: , <pub-id pub-id-type="doi">10.1289/EHP577</pub-id>.<?supplied-pmid 28796632?><pub-id pub-id-type="pmid">28796632</pub-id></mixed-citation>
              </ref>
              <ref id="c14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brosnan</surname><given-names>JT</given-names></string-name>, <string-name><surname>da Silva</surname><given-names>RP</given-names></string-name>, <string-name><surname>Brosnan</surname><given-names>ME</given-names></string-name></person-group>. <year>2011</year>. <article-title>The metabolic burden of creatine synthesis</article-title>. <source>Amino Acids</source><volume>40</volume>(<issue>5</issue>):<fpage>1325</fpage>–<lpage>1331</lpage>, PMID: , <pub-id pub-id-type="doi">10.1007/s00726-011-0853-y</pub-id>.<?supplied-pmid 21387089?><pub-id pub-id-type="pmid">21387089</pub-id></mixed-citation>
              </ref>
              <ref id="c15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stead</surname><given-names>LM</given-names></string-name>, <string-name><surname>Au</surname><given-names>KP</given-names></string-name>, <string-name><surname>Jacobs</surname><given-names>RL</given-names></string-name>, <string-name><surname>Brosnan</surname><given-names>ME</given-names></string-name>, <string-name><surname>Brosnan</surname><given-names>JT</given-names></string-name></person-group>. <year>2001</year>. <article-title>Methylation demand and homocysteine metabolism: effects of dietary provision of creatine and guanidinoacetate</article-title>. <source>Am J Physiol Endocrinol Metab</source><volume>281</volume>(<issue>5</issue>):<elocation-id>E1095</elocation-id>–<lpage>E1100</lpage>, PMID: , <pub-id pub-id-type="doi">10.1152/ajpendo.2001.281.5.E1095</pub-id>.<?supplied-pmid 11595668?><pub-id pub-id-type="pmid">11595668</pub-id></mixed-citation>
              </ref>
              <ref id="c16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gamble</surname><given-names>MV</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name><surname>Ahsan</surname><given-names>H</given-names></string-name>, <string-name><surname>Pilsner</surname><given-names>JR</given-names></string-name>, <string-name><surname>Ilievski</surname><given-names>V</given-names></string-name>, <string-name><surname>Slavkovich</surname><given-names>V</given-names></string-name>, <etal>et al.</etal></person-group><year>2006</year>. <article-title>Folate and arsenic metabolism: a double-blind, placebo-controlled folic acid-supplementation trial in Bangladesh</article-title>. <source>Am J Clin Nutr</source><volume>84</volume>(<issue>5</issue>):<fpage>1093</fpage>–<lpage>1101</lpage>, PMID: , <pub-id pub-id-type="doi">10.1093/ajcn/84.5.1093</pub-id>.<?supplied-pmid 17093162?><pub-id pub-id-type="pmid">17093162</pub-id></mixed-citation>
              </ref>
              <ref id="c17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peters</surname><given-names>BA</given-names></string-name>, <string-name><surname>Hall</surname><given-names>MN</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name><surname>Parvez</surname><given-names>F</given-names></string-name>, <string-name><surname>Sanchez</surname><given-names>TR</given-names></string-name>, <string-name><surname>van Geen</surname><given-names>A</given-names></string-name>, <etal>et al.</etal></person-group><year>2015</year>. <article-title>Folic acid and creatine as therapeutic approaches to lower blood arsenic: a randomized controlled trial</article-title>. <source>Environ Health Perspect</source><volume>123</volume>(<issue>12</issue>):<fpage>1294</fpage>–<lpage>1301</lpage>, PMID: , <pub-id pub-id-type="doi">10.1289/ehp.1409396</pub-id>.<?supplied-pmid 25978852?><pub-id pub-id-type="pmid">25978852</pub-id></mixed-citation>
              </ref>
              <ref id="c18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bozack</surname><given-names>AK</given-names></string-name>, <string-name><surname>Hall</surname><given-names>MN</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name><surname>Ilievski</surname><given-names>V</given-names></string-name>, <string-name><surname>Lomax-Luu</surname><given-names>AM</given-names></string-name>, <string-name><surname>Parvez</surname><given-names>F</given-names></string-name>, <etal>et al.</etal></person-group><year>2019</year>. <article-title>Folic acid supplementation enhances arsenic methylation: results from a folic acid and creatine supplementation randomized controlled trial in Bangladesh</article-title>. <source>Am J Clin Nutr</source><volume>109</volume>(<issue>2</issue>):<fpage>380</fpage>–<lpage>391</lpage>, PMID: , <pub-id pub-id-type="doi">10.1093/ajcn/nqy148</pub-id>.<?supplied-pmid 30590411?><pub-id pub-id-type="pmid">30590411</pub-id></mixed-citation>
              </ref>
              <ref id="c19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ahsan</surname><given-names>H</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name><surname>Parvez</surname><given-names>F</given-names></string-name>, <string-name><surname>Argos</surname><given-names>M</given-names></string-name>, <string-name><surname>Hussain</surname><given-names>AI</given-names></string-name>, <string-name><surname>Momotaj</surname><given-names>H</given-names></string-name>, <etal>et al.</etal></person-group><year>2006</year>. <article-title>Health Effects of Arsenic Longitudinal Study (HEALS): description of a multidisciplinary epidemiologic investigation</article-title>. <source>J Expo Sci Environ Epidemiol</source><volume>16</volume>(<issue>2</issue>):<fpage>191</fpage>–<lpage>205</lpage>, PMID: , <pub-id pub-id-type="doi">10.1038/sj.jea.7500449</pub-id>.<?supplied-pmid 16160703?><pub-id pub-id-type="pmid">16160703</pub-id></mixed-citation>
              </ref>
              <ref id="c20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shih</surname><given-names>YH</given-names></string-name>, <string-name><surname>Scannell Bryan</surname><given-names>M</given-names></string-name>, <string-name><surname>Parvez</surname><given-names>F</given-names></string-name>, <string-name><surname>Uesugi</surname><given-names>KH</given-names></string-name>, <string-name><surname>Shahriar</surname><given-names>M</given-names></string-name>, <string-name><surname>Ahmed</surname><given-names>A</given-names></string-name>, <etal>et al.</etal></person-group><year>2020</year>. <article-title>Gravidity, parity, blood pressure and mortality among women in Bangladesh from the HEALS cohort</article-title>. <source>BMJ Open</source><volume>10</volume>(<issue>8</issue>):<elocation-id>e037244</elocation-id>, PMID: , <pub-id pub-id-type="doi">10.1136/bmjopen-2020-037244</pub-id>.<?supplied-pmid 32847913?><pub-id pub-id-type="pmid">32847913</pub-id></mixed-citation>
              </ref>
              <ref id="c21">
                <label>21.</label>
                <mixed-citation publication-type="book"><collab>Institute of Medicine Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline</collab>. <year>2000</year>. <source>Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>National Academies Press</publisher-name>.</mixed-citation>
              </ref>
              <ref id="c22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sanchez</surname><given-names>TR</given-names></string-name>, <string-name><surname>Levy</surname><given-names>D</given-names></string-name>, <string-name><surname>Shahriar</surname><given-names>MH</given-names></string-name>, <string-name><surname>Uddin</surname><given-names>MN</given-names></string-name>, <string-name><surname>Siddique</surname><given-names>AB</given-names></string-name>, <string-name><surname>Graziano</surname><given-names>JH</given-names></string-name>, <etal>et al.</etal></person-group><year>2016</year>. <article-title>Provision of well-water treatment units to 600 households in Bangladesh: a longitudinal analysis of urinary arsenic indicates fading utility</article-title>. <source>Sci Total Environ</source><volume>563–564</volume>:<fpage>131</fpage>–<lpage>137</lpage>, PMID: , <pub-id pub-id-type="doi">10.1016/j.scitotenv.2016.04.112</pub-id>.<?supplied-pmid 27135575?><pub-id pub-id-type="pmid">27135575</pub-id></mixed-citation>
              </ref>
              <ref id="c23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Csanaky</surname><given-names>I</given-names></string-name>, <string-name><surname>Gregus</surname><given-names>Z</given-names></string-name></person-group>. <year>2003</year>. <article-title>Effect of selenite on the disposition of arsenate and arsenite in rats</article-title>. <source>Toxicology</source><volume>186</volume>(<issue>1–2</issue>):<fpage>33</fpage>–<lpage>50</lpage>, PMID: , <pub-id pub-id-type="doi">10.1016/s0300-483x(02)00604-2</pub-id>.<?supplied-pmid 12604169?><pub-id pub-id-type="pmid">12604169</pub-id></mixed-citation>
              </ref>
              <ref id="c24">
                <label>24.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Reuter</surname><given-names>W</given-names></string-name>, <string-name><surname>Davidowski</surname><given-names>L</given-names></string-name>, <string-name><surname>Neubauer</surname><given-names>K</given-names></string-name>, <string-name><surname>Di Bussolo</surname><given-names>J</given-names></string-name></person-group>. <year>2003</year>. <article-title>Speciation of five arsenic compounds in urine by HPLC/ICP-MS</article-title>. <publisher-loc>Shelton, CT</publisher-loc>: <publisher-name>PerkinElmer SciEx</publisher-name>. <ext-link xlink:href="https://www.perkinelmer.com/PDFs/Downloads/app_speciationfivearseniccompounds.pdf" ext-link-type="uri">https://www.perkinelmer.com/PDFs/Downloads/app_speciationfivearseniccompounds.pdf</ext-link> [accessed <date-in-citation content-type="access-date">20 March 2023</date-in-citation>].</mixed-citation>
              </ref>
              <ref id="c25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pfeiffer</surname><given-names>CM</given-names></string-name>, <string-name><surname>Huff</surname><given-names>DL</given-names></string-name>, <string-name><surname>Gunter</surname><given-names>EW</given-names></string-name></person-group>. <year>1999</year>. <article-title>Rapid and accurate HPLC assay for plasma total homocysteine and cysteine in a clinical laboratory setting</article-title>. <source>Clin Chem</source><volume>45</volume>(<issue>2</issue>):<fpage>290</fpage>–<lpage>292</lpage>, PMID: , <pub-id pub-id-type="doi">10.1093/clinchem/45.2.290</pub-id>.<?supplied-pmid 9931056?><pub-id pub-id-type="pmid">9931056</pub-id></mixed-citation>
              </ref>
              <ref id="c26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cheng</surname><given-names>Z</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>Y</given-names></string-name>, <string-name><surname>Mortlock</surname><given-names>R</given-names></string-name>, <string-name><surname>Van Geen</surname><given-names>A</given-names></string-name></person-group>. <year>2004</year>. <article-title>Rapid multi-element analysis of groundwater by high-resolution inductively coupled plasma mass spectrometry</article-title>. <source>Anal Bioanal Chem</source><volume>379</volume>(<issue>3</issue>):<fpage>512</fpage>–<lpage>518</lpage>, PMID: , <pub-id pub-id-type="doi">10.1007/s00216-004-2618-x</pub-id>.<?supplied-pmid 15098084?><pub-id pub-id-type="pmid">15098084</pub-id></mixed-citation>
              </ref>
              <ref id="c27">
                <label>27.</label>
                <mixed-citation publication-type="webpage"><collab>CDC (Centers for Disease Control and Prevention)</collab>. <year>2017</year>. <article-title>Data sources and data analysis. Blood, serum, and urine samples from NHANES</article-title>. <ext-link xlink:href="https://www.cdc.gov/exposurereport/data_sources_analysis.html" ext-link-type="uri">https://www.cdc.gov/exposurereport/data_sources_analysis.html</ext-link> [accessed <date-in-citation content-type="access-date">2 February 2022</date-in-citation>].</mixed-citation>
              </ref>
              <ref id="c28">
                <label>28.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Steinmaus</surname><given-names>C</given-names></string-name>, <string-name><surname>Bates</surname><given-names>MN</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Kalman</surname><given-names>D</given-names></string-name>, <string-name><surname>Atallah</surname><given-names>R</given-names></string-name>, <string-name><surname>Rey</surname><given-names>OA</given-names></string-name>, <etal>et al.</etal></person-group><year>2006</year>. <article-title>Arsenic methylation and bladder cancer risk in case–control studies in Argentina and the United States</article-title>. <source>J Occup Environ Med</source><volume>48</volume>(<issue>5</issue>):<fpage>478</fpage>–<lpage>488</lpage>, PMID: , <pub-id pub-id-type="doi">10.1097/01.jom.0000200982.28276.70</pub-id>.<?supplied-pmid 16688004?><pub-id pub-id-type="pmid">16688004</pub-id></mixed-citation>
              </ref>
              <ref id="c29">
                <label>29.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pu</surname><given-names>YS</given-names></string-name>, <string-name><surname>Yang</surname><given-names>SM</given-names></string-name>, <string-name><surname>Huang</surname><given-names>YK</given-names></string-name>, <string-name><surname>Chung</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Huang</surname><given-names>SK</given-names></string-name>, <string-name><surname>Chiu</surname><given-names>AWH</given-names></string-name>, <etal>et al.</etal></person-group><year>2007</year>. <article-title>Urinary arsenic profile affects the risk of urothelial carcinoma even at low arsenic exposure</article-title>. <source>Toxicol Appl Pharmacol</source><volume>218</volume>(<issue>2</issue>):<fpage>99</fpage>–<lpage>106</lpage>, PMID: , <pub-id pub-id-type="doi">10.1016/j.taap.2006.09.021</pub-id>.<?supplied-pmid 17196235?><pub-id pub-id-type="pmid">17196235</pub-id></mixed-citation>
              </ref>
              <ref id="c30">
                <label>30.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Melak</surname><given-names>D</given-names></string-name>, <string-name><surname>Ferreccio</surname><given-names>C</given-names></string-name>, <string-name><surname>Kalman</surname><given-names>D</given-names></string-name>, <string-name><surname>Parra</surname><given-names>R</given-names></string-name>, <string-name><surname>Acevedo</surname><given-names>J</given-names></string-name>, <string-name><surname>Pérez</surname><given-names>L</given-names></string-name>, <etal>et al.</etal></person-group><year>2014</year>. <article-title>Arsenic methylation and lung and bladder cancer in a case-control study in northern Chile</article-title>. <source>Toxicol Appl Pharmacol</source><volume>274</volume>(<issue>2</issue>):<fpage>225</fpage>–<lpage>231</lpage>, PMID: , <pub-id pub-id-type="doi">10.1016/j.taap.2013.11.014</pub-id>.<?supplied-pmid 24296302?><pub-id pub-id-type="pmid">24296302</pub-id></mixed-citation>
              </ref>
              <ref id="c31">
                <label>31.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yu</surname><given-names>RC</given-names></string-name>, <string-name><surname>Hsu</surname><given-names>KH</given-names></string-name>, <string-name><surname>Chen</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Froines</surname><given-names>JR</given-names></string-name></person-group>. <year>2000</year>. <article-title>Arsenic methylation capacity and skin cancer</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source><volume>9</volume>:<fpage>1259</fpage>–<lpage>1262</lpage>, PMID: .<?supplied-pmid 11097236?><pub-id pub-id-type="pmid">11097236</pub-id></mixed-citation>
              </ref>
              <ref id="c32">
                <label>32.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gilbert-Diamond</surname><given-names>D</given-names></string-name>, <string-name><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name><surname>Perry</surname><given-names>AE</given-names></string-name>, <string-name><surname>Spencer</surname><given-names>SK</given-names></string-name>, <string-name><surname>Gandolfi</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Karagas</surname><given-names>MR</given-names></string-name>, <etal>et al.</etal></person-group><year>2013</year>. <article-title>A population-based case–control study of urinary arsenic species and squamous cell carcinoma in New Hampshire, USA</article-title>. <source>Environ Health Perspect</source><volume>121</volume>(<issue>10</issue>):<fpage>1154</fpage>–<lpage>1160</lpage>, PMID: , <pub-id pub-id-type="doi">10.1289/ehp.1206178</pub-id>.<?supplied-pmid 23872349?><pub-id pub-id-type="pmid">23872349</pub-id></mixed-citation>
              </ref>
              <ref id="c33">
                <label>33.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ahsan</surname><given-names>H</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name><surname>Kibriya</surname><given-names>MG</given-names></string-name>, <string-name><surname>Slavkovich</surname><given-names>V</given-names></string-name>, <string-name><surname>Parvez</surname><given-names>F</given-names></string-name>, <string-name><surname>Jasmine</surname><given-names>F</given-names></string-name>, <etal>et al.</etal></person-group><year>2007</year>. <article-title>Arsenic metabolism, genetic susceptibility, and risk of premalignant skin lesions in Bangladesh</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source><volume>16</volume>(<issue>6</issue>):<fpage>1270</fpage>–<lpage>1278</lpage>, PMID: , <pub-id pub-id-type="doi">10.1158/1055-9965.EPI-06-0676</pub-id>.<?supplied-pmid 17548696?><pub-id pub-id-type="pmid">17548696</pub-id></mixed-citation>
              </ref>
              <ref id="c34">
                <label>34.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lindberg</surname><given-names>AL</given-names></string-name>, <string-name><surname>Rahman</surname><given-names>M</given-names></string-name>, <string-name><surname>Persson</surname><given-names>LÅ</given-names></string-name>, <string-name><surname>Vahter</surname><given-names>M</given-names></string-name></person-group>. <year>2008</year>. <article-title>The risk of arsenic induced skin lesions in Bangladeshi men and women is affected by arsenic metabolism and the age at first exposure</article-title>. <source>Toxicol Appl Pharmacol</source><volume>230</volume>(<issue>1</issue>):<fpage>9</fpage>–<lpage>16</lpage>, PMID: , <pub-id pub-id-type="doi">10.1016/j.taap.2008.02.001</pub-id>.<?supplied-pmid 18336856?><pub-id pub-id-type="pmid">18336856</pub-id></mixed-citation>
              </ref>
              <ref id="c35">
                <label>35.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname><given-names>MM</given-names></string-name>, <string-name><surname>Chiou</surname><given-names>HY</given-names></string-name>, <string-name><surname>Hsueh</surname><given-names>YM</given-names></string-name>, <string-name><surname>Hong</surname><given-names>CT</given-names></string-name>, <string-name><surname>Su</surname><given-names>CL</given-names></string-name>, <string-name><surname>Chang</surname><given-names>SF</given-names></string-name>, <etal>et al.</etal></person-group><year>2006</year>. <article-title>Effect of plasma homocysteine level and urinary monomethylarsonic acid on the risk of arsenic-associated carotid atherosclerosis</article-title>. <source>Toxicol Appl Pharmacol</source><volume>216</volume>(<issue>1</issue>):<fpage>168</fpage>–<lpage>175</lpage>, PMID: , <pub-id pub-id-type="doi">10.1016/j.taap.2006.05.005</pub-id>.<?supplied-pmid 16806340?><pub-id pub-id-type="pmid">16806340</pub-id></mixed-citation>
              </ref>
              <ref id="c36">
                <label>36.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hall</surname><given-names>M</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ahsan</surname><given-names>H</given-names></string-name>, <string-name><surname>Slavkovich</surname><given-names>V</given-names></string-name>, <string-name><surname>van Geen</surname><given-names>A</given-names></string-name>, <string-name><surname>Parvez</surname><given-names>F</given-names></string-name>, <etal>et al.</etal></person-group><year>2006</year>. <article-title>Blood arsenic as a biomarker of arsenic exposure: results from a prospective study</article-title>. <source>Toxicology</source><volume>225</volume>(<issue>2–3</issue>):<fpage>225</fpage>–<lpage>233</lpage>, PMID: , <pub-id pub-id-type="doi">10.1016/j.tox.2006.06.010</pub-id>.<?supplied-pmid 16860454?><pub-id pub-id-type="pmid">16860454</pub-id></mixed-citation>
              </ref>
              <ref id="c37">
                <label>37.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoet</surname><given-names>P</given-names></string-name>, <string-name><surname>Deumer</surname><given-names>G</given-names></string-name>, <string-name><surname>Bernard</surname><given-names>A</given-names></string-name>, <string-name><surname>Lison</surname><given-names>D</given-names></string-name>, <string-name><surname>Haufroid</surname><given-names>V</given-names></string-name></person-group>. <year>2016</year>. <article-title>Urinary trace element concentrations in environmental settings: is there a value for systematic creatinine adjustment or do we introduce a bias?</article-title><source>J Expo Sci Environ Epidemiol</source><volume>26</volume>(<issue>3</issue>):<fpage>296</fpage>–<lpage>302</lpage>, PMID: , <pub-id pub-id-type="doi">10.1038/jes.2015.23</pub-id>.<?supplied-pmid 25827313?><pub-id pub-id-type="pmid">25827313</pub-id></mixed-citation>
              </ref>
              <ref id="c38">
                <label>38.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nermell</surname><given-names>B</given-names></string-name>, <string-name><surname>Lindberg</surname><given-names>AL</given-names></string-name>, <string-name><surname>Rahman</surname><given-names>M</given-names></string-name>, <string-name><surname>Berglund</surname><given-names>M</given-names></string-name>, <string-name><surname>Persson</surname><given-names>LA</given-names></string-name>, <string-name><surname>El Arifeen</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><year>2008</year>. <article-title>Urinary arsenic concentration adjustment factors and malnutrition</article-title>. <source>Environ Res</source><volume>106</volume>(<issue>2</issue>):<fpage>212</fpage>–<lpage>218</lpage>, PMID: , <pub-id pub-id-type="doi">10.1016/j.envres.2007.08.005</pub-id>.<?supplied-pmid 17900556?><pub-id pub-id-type="pmid">17900556</pub-id></mixed-citation>
              </ref>
              <ref id="c39">
                <label>39.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>DK</given-names></string-name>, <string-name><surname>Song</surname><given-names>JW</given-names></string-name>, <string-name><surname>Park</surname><given-names>JD</given-names></string-name>, <string-name><surname>Choi</surname><given-names>BS</given-names></string-name></person-group>. <year>2011</year>. <article-title>A comparison of the adjustment methods for assessing urinary concentrations of cadmium and arsenic: creatinine vs. specific gravity</article-title>. <source>Korean J Environ Health Sci</source><volume>37</volume>(<issue>6</issue>):<fpage>450</fpage>–<lpage>459</lpage>, <pub-id pub-id-type="doi">10.5668/JEHS.2011.37.6.450</pub-id>.</mixed-citation>
              </ref>
              <ref id="c40">
                <label>40.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abuawad</surname><given-names>A</given-names></string-name>, <string-name><surname>Goldsmith</surname><given-names>J</given-names></string-name>, <string-name><surname>Herbstman</surname><given-names>JB</given-names></string-name>, <string-name><surname>Parvez</surname><given-names>F</given-names></string-name>, <string-name><surname>Islam</surname><given-names>T</given-names></string-name>, <string-name><surname>LoIacono</surname><given-names>N</given-names></string-name>, <etal>et al.</etal></person-group><year>2022</year>. <article-title>Urine dilution correction methods utilizing urine creatinine or specific gravity in arsenic analyses: comparisons to blood and water arsenic in the FACT and FOX studies in Bangladesh</article-title>. <source>Water</source><volume>14</volume>(<issue>9</issue>):<fpage>1477</fpage>, <pub-id pub-id-type="doi">10.3390/w14091477</pub-id>.</mixed-citation>
              </ref>
              <ref id="c41">
                <label>41.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Styblo</surname><given-names>M</given-names></string-name>, <string-name><surname>Delnomdedieu</surname><given-names>M</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>DJ</given-names></string-name></person-group>. <year>1996</year>. <article-title>Mono- and dimethylation of arsenic in rat liver cytosol in vitro</article-title>. <source>Chem Biol Interact</source><volume>99</volume>(<issue>1–3</issue>):<fpage>147</fpage>–<lpage>164</lpage>, PMID: , <pub-id pub-id-type="doi">10.1016/0009-2797(95)03666-0</pub-id>.<?supplied-pmid 8620564?><pub-id pub-id-type="pmid">8620564</pub-id></mixed-citation>
              </ref>
              <ref id="c42">
                <label>42.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abuawad</surname><given-names>A</given-names></string-name>, <string-name><surname>Bozack</surname><given-names>AK</given-names></string-name>, <string-name><surname>Saxena</surname><given-names>R</given-names></string-name>, <string-name><surname>Gamble</surname><given-names>MV</given-names></string-name></person-group>. <year>2021</year>. <article-title>Nutrition, one-carbon metabolism and arsenic methylation</article-title>. <source>Toxicology</source><volume>457</volume>:<elocation-id>152803</elocation-id>, PMID: , <pub-id pub-id-type="doi">10.1016/j.tox.2021.152803</pub-id>.<?supplied-pmid 33905762?><pub-id pub-id-type="pmid">33905762</pub-id></mixed-citation>
              </ref>
              <ref id="c43">
                <label>43.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pilsner</surname><given-names>JR</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name><surname>Ahsan</surname><given-names>H</given-names></string-name>, <string-name><surname>Ilievski</surname><given-names>V</given-names></string-name>, <string-name><surname>Slavkovich</surname><given-names>V</given-names></string-name>, <string-name><surname>Levy</surname><given-names>D</given-names></string-name>, <etal>et al.</etal></person-group><year>2007</year>. <article-title>Genomic methylation of peripheral blood leukocyte DNA: influences of arsenic and folate in Bangladeshi adults</article-title>. <source>Am J Clin Nutr</source><volume>86</volume>(<issue>4</issue>):<fpage>1179</fpage>–<lpage>1186</lpage>, PMID: , <pub-id pub-id-type="doi">10.1093/ajcn/86.4.1179</pub-id>.<?supplied-pmid 17921400?><pub-id pub-id-type="pmid">17921400</pub-id></mixed-citation>
              </ref>
              <ref id="c44">
                <label>44.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Howe</surname><given-names>CG</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name><surname>Hall</surname><given-names>MN</given-names></string-name>, <string-name><surname>Ilievski</surname><given-names>V</given-names></string-name>, <string-name><surname>Caudill</surname><given-names>MA</given-names></string-name>, <string-name><surname>Malysheva</surname><given-names>O</given-names></string-name>, <etal>et al.</etal></person-group><year>2017</year>. <article-title>Sex-specific associations between one-carbon metabolism indices and posttranslational histone modifications in arsenic-exposed Bangladeshi adults</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source><volume>26</volume>(<issue>2</issue>):<fpage>261</fpage>–<lpage>269</lpage>, PMID: , <pub-id pub-id-type="doi">10.1158/1055-9965.EPI-16-0202</pub-id>.<?supplied-pmid 27765800?><pub-id pub-id-type="pmid">27765800</pub-id></mixed-citation>
              </ref>
              <ref id="c45">
                <label>45.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Basu</surname><given-names>A</given-names></string-name>, <string-name><surname>Mitra</surname><given-names>S</given-names></string-name>, <string-name><surname>Chung</surname><given-names>J</given-names></string-name>, <string-name><surname>Guha Mazumder</surname><given-names>DN</given-names></string-name>, <string-name><surname>Ghosh</surname><given-names>N</given-names></string-name>, <string-name><surname>Kalman</surname><given-names>D</given-names></string-name>, <etal>et al.</etal></person-group><year>2011</year>. <article-title>Creatinine, diet, micronutrients, and arsenic methylation in West Bengal, India</article-title>. <source>Environ Health Perspect</source><volume>119</volume>(<issue>9</issue>):<fpage>1308</fpage>–<lpage>1313</lpage>, PMID: , <pub-id pub-id-type="doi">10.1289/ehp.1003393</pub-id>.<?supplied-pmid 21652291?><pub-id pub-id-type="pmid">21652291</pub-id></mixed-citation>
              </ref>
              <ref id="c46">
                <label>46.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gamble</surname><given-names>MV</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name><surname>Ahsan</surname><given-names>H</given-names></string-name>, <string-name><surname>Pilsner</surname><given-names>R</given-names></string-name>, <string-name><surname>Ilievski</surname><given-names>V</given-names></string-name>, <string-name><surname>Slavkovich</surname><given-names>V</given-names></string-name>, <etal>et al.</etal></person-group><year>2005</year>. <article-title>Folate, homocysteine, and arsenic metabolism in arsenic-exposed individuals in Bangladesh</article-title>. <source>Environ Health Perspect</source><volume>113</volume>(<issue>12</issue>):<fpage>1683</fpage>–<lpage>1688</lpage>, PMID: , <pub-id pub-id-type="doi">10.1289/ehp.8084</pub-id>.<?supplied-pmid 16330347?><pub-id pub-id-type="pmid">16330347</pub-id></mixed-citation>
              </ref>
              <ref id="c47">
                <label>47.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peters</surname><given-names>BA</given-names></string-name>, <string-name><surname>Hall</surname><given-names>MN</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name><surname>Neugut</surname><given-names>YD</given-names></string-name>, <string-name><surname>Pilsner</surname><given-names>JR</given-names></string-name>, <string-name><surname>Levy</surname><given-names>D</given-names></string-name>, <etal>et al.</etal></person-group><year>2014</year>. <article-title>Creatinine, arsenic metabolism, and renal function in an arsenic-exposed population in Bangladesh</article-title>. <source>PLoS One</source><volume>9</volume>(<issue>12</issue>):<elocation-id>e113760</elocation-id>, PMID: , <pub-id pub-id-type="doi">10.1371/journal.pone.0113760</pub-id>.<?supplied-pmid 25438247?><pub-id pub-id-type="pmid">25438247</pub-id></mixed-citation>
              </ref>
              <ref id="c48">
                <label>48.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peters</surname><given-names>BA</given-names></string-name>, <string-name><surname>Hall</surname><given-names>MN</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name><surname>Parvez</surname><given-names>F</given-names></string-name>, <string-name><surname>Siddique</surname><given-names>AB</given-names></string-name>, <string-name><surname>Shahriar</surname><given-names>H</given-names></string-name>, <etal>et al.</etal></person-group><year>2015</year>. <article-title>Low-dose creatine supplementation lowers plasma guanidinoacetate, but not plasma homocysteine, in a double-blind, randomized, placebo-controlled trial</article-title>. <source>J Nutr</source><volume>145</volume>(<issue>10</issue>):<fpage>2245</fpage>–<lpage>2252</lpage>, PMID: , <pub-id pub-id-type="doi">10.3945/jn.115.216739</pub-id>.<?supplied-pmid 26311810?><pub-id pub-id-type="pmid">26311810</pub-id></mixed-citation>
              </ref>
              <ref id="c49">
                <label>49.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jencks</surname><given-names>DA</given-names></string-name>, <string-name><surname>Mathews</surname><given-names>RG</given-names></string-name></person-group>. <year>1987</year>. <article-title>Allosteric inhibition of methylenetetrahydrofolate reductase by adenosylmethionine. Effects of adenosylmethionine and NADPH on the equilibrium between active and inactive forms of the enzyme and on the kinetics of approach to equilibrium</article-title>. <source>J Biol Chem</source><volume>262</volume>(<issue>6</issue>):<fpage>2485</fpage>–<lpage>2493</lpage>, PMID: , <pub-id pub-id-type="doi">10.1016/S0021-9258(18)61530-3</pub-id>.<?supplied-pmid 3818603?><pub-id pub-id-type="pmid">3818603</pub-id></mixed-citation>
              </ref>
              <ref id="c50">
                <label>50.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wagner</surname><given-names>C</given-names></string-name>, <string-name><surname>Briggs</surname><given-names>WT</given-names></string-name>, <string-name><surname>Cook</surname><given-names>RJ</given-names></string-name></person-group>. <year>1985</year>. <article-title>Inhibition of glycine n-methyltransferase activity by folate derivatives: implications for regulation of methyl group metabolism</article-title>. <source>Biochem Biophys Res Commun</source><volume>127</volume>(<issue>3</issue>):<fpage>746</fpage>–<lpage>752</lpage>, PMID: , <pub-id pub-id-type="doi">10.1016/s0006-291x(85)80006-1</pub-id>.<?supplied-pmid 3838667?><pub-id pub-id-type="pmid">3838667</pub-id></mixed-citation>
              </ref>
              <ref id="c51">
                <label>51.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Luka</surname><given-names>Z</given-names></string-name>, <string-name><surname>Mudd</surname><given-names>SH</given-names></string-name>, <string-name><surname>Wagner</surname><given-names>C</given-names></string-name></person-group>. <year>2009</year>. <article-title>Glycine <italic toggle="yes">N</italic>-methyltransferase and regulation of <italic toggle="yes">S</italic>-adenosylmethionine levels</article-title>. <source>J Biol Chem</source><volume>284</volume>(<issue>34</issue>):<fpage>22507</fpage>–<lpage>22511</lpage>, PMID: , <pub-id pub-id-type="doi">10.1074/jbc.R109.019273</pub-id>.<?supplied-pmid 19483083?><pub-id pub-id-type="pmid">19483083</pub-id></mixed-citation>
              </ref>
              <ref id="c52">
                <label>52.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bozack</surname><given-names>AK</given-names></string-name>, <string-name><surname>Saxena</surname><given-names>R</given-names></string-name>, <string-name><surname>Gamble</surname><given-names>MV</given-names></string-name></person-group>. <year>2018</year>. <article-title>Nutritional influences on one-carbon metabolism: effects on arsenic methylation and toxicity</article-title>. <source>Annu Rev Nutr</source><volume>38</volume>:<fpage>401</fpage>–<lpage>429</lpage>, PMID: , <pub-id pub-id-type="doi">10.1146/annurev-nutr-082117-051757</pub-id>.<?supplied-pmid 29799766?><pub-id pub-id-type="pmid">29799766</pub-id></mixed-citation>
              </ref>
              <ref id="c53">
                <label>53.</label>
                <mixed-citation publication-type="webpage"><collab>Food Fortification Initiative</collab>. <year>2017</year>. <article-title>Global progress</article-title>. <ext-link xlink:href="https://www.ffinetwork.org/globalprogress" ext-link-type="uri">https://www.ffinetwork.org/globalprogress</ext-link> [accessed <date-in-citation content-type="access-date">2 February 2022</date-in-citation>].</mixed-citation>
              </ref>
              <ref id="c54">
                <label>54.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Finer</surname><given-names>LB</given-names></string-name>, <string-name><surname>Henshaw</surname><given-names>SK</given-names></string-name></person-group>. <year>2006</year>. <article-title>Disparities in rates of unintended pregnancy in the United States, 1994 and 2001</article-title>. <source>Perspect Sex Reprod Health</source><volume>38</volume>(<issue>2</issue>):<fpage>90</fpage>–<lpage>96</lpage>, PMID: , <pub-id pub-id-type="doi">10.1363/3809006</pub-id>.<?supplied-pmid 16772190?><pub-id pub-id-type="pmid">16772190</pub-id></mixed-citation>
              </ref>
              <ref id="c55">
                <label>55.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maruvada</surname><given-names>P</given-names></string-name>, <string-name><surname>Stover</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Mason</surname><given-names>JB</given-names></string-name>, <string-name><surname>Bailey</surname><given-names>RL</given-names></string-name>, <string-name><surname>Davis</surname><given-names>CD</given-names></string-name>, <string-name><surname>Field</surname><given-names>MS</given-names></string-name>, <etal>et al.</etal></person-group><year>2020</year>. <article-title>Knowledge gaps in understanding the metabolic and clinical effects of excess folates/folic acid: a summary, and perspectives, from an NIH workshop</article-title>. <source>Am J Clin Nutr</source><volume>112</volume>(<issue>5</issue>):<fpage>1390</fpage>–<lpage>1403</lpage>, PMID: , <pub-id pub-id-type="doi">10.1093/ajcn/nqaa259</pub-id>.<?supplied-pmid 33022704?><pub-id pub-id-type="pmid">33022704</pub-id></mixed-citation>
              </ref>
              <ref id="c56">
                <label>56.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pfeiffer</surname><given-names>CM</given-names></string-name>, <string-name><surname>Sternberg</surname><given-names>MR</given-names></string-name>, <string-name><surname>Fazili</surname><given-names>Z</given-names></string-name>, <string-name><surname>Yetley</surname><given-names>EA</given-names></string-name>, <string-name><surname>Lacher</surname><given-names>DA</given-names></string-name>, <string-name><surname>Bailey</surname><given-names>RL</given-names></string-name>, <etal>et al.</etal></person-group><year>2015</year>. <article-title>Unmetabolized folic acid is detected in nearly all serum samples from US children, adolescents, and adults</article-title>. <source>J Nutr</source><volume>145</volume>(<issue>3</issue>):<fpage>520</fpage>–<lpage>531</lpage>, PMID: , <pub-id pub-id-type="doi">10.3945/jn.114.201210</pub-id>.<?supplied-pmid 25733468?><pub-id pub-id-type="pmid">25733468</pub-id></mixed-citation>
              </ref>
              <ref id="c57">
                <label>57.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gamble</surname><given-names>MV</given-names></string-name>, <string-name><surname>Ahsan</surname><given-names>H</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name><surname>Factor-Litvak</surname><given-names>P</given-names></string-name>, <string-name><surname>Ilievski</surname><given-names>V</given-names></string-name>, <string-name><surname>Slavkovich</surname><given-names>V</given-names></string-name>, <etal>et al.</etal></person-group><year>2005</year>. <article-title>Folate and cobalamin deficiencies and hyperhomocysteinemia in Bangladesh</article-title>. <source>Am J Clin Nutr</source><volume>81</volume>(<issue>6</issue>):<fpage>1372</fpage>–<lpage>1377</lpage>, PMID: , <pub-id pub-id-type="doi">10.1093/ajcn/81.6.1372</pub-id>.<?supplied-pmid 15941889?><pub-id pub-id-type="pmid">15941889</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
